Method and device for cosmetic treatment of biological structures by radio frequency and magnetic energy

Through the combination of segmented RF electrodes and magnetic field generation devices, the synergistic effect of radio frequency and magnetic therapy is used to solve the problems of unevenness and discomfort of cosmetic treatment in the prior art, and the precise stimulation and heating of muscles and adipose tissues are achieved. , improves the effectiveness and safety of treatment.

CN119015609APending Publication Date: 2024-11-26BTL HEALTHCARE TECH AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410950210.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-11-07
Filing Date
2020-04-09
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing non-invasive cosmetic technologies such as mechanical wave and thermal treatment have problems with lipoinflammatory risks, non-target tissue damage, uneven results and patient discomfort. The application of time-varying magnetic fields in thick adipose tissue is inefficient, making it difficult to achieve precise muscle stimulation.

Method used

Using a combination of segmented RF electrodes and magnetic field generation devices, the synergistic effect of time-varying magnetic field and radio frequency therapy is used to reduce energy loss and the impact of magnetic therapy, so as to achieve precise stimulation and heating of muscles and adipose tissues, combining energy The storage device generates a strong magnetic field to induce muscle contraction.

Benefits of technology

It improves the targeting and safety of the treatment, reduces side effects, achieves more uniform biostructure heating and muscle stimulation, enhances the comfort and effect of the treatment, and promotes selective reduction of fat tissue and muscle fiber proliferation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015609A_ABST
    Figure CN119015609A_ABST
Patent Text Reader

Abstract

An apparatus is provided that excites muscle contraction by a time-varying magnetic field to provide magnetic therapy and provides radiofrequency therapy by heating a biological structure. The device includes an applicator having a radio frequency electrode and a magnetic field generating device. The device further comprises a main unit, a human-computer interface and a control unit. The control unit regulates the signal provided to the radio frequency electrode and forms a radio frequency circuit, and also regulates the signal provided to the magnetic field generating device and forms a magnetic circuit that is electrically insulated from the radio frequency circuit. The radio frequency circuit may include a power source and a power amplifier, and the magnetic circuit may include an energy storage device to power the magnetic field generating device with the circuit.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Aesthetic medicine includes all treatments that result in an enhanced visual appearance according to the patient's criteria. Patients wish to minimize all imperfections (including, for example, unwanted body fat in specific body areas), improve body shape, and counteract the effects of natural aging. Patients want fast, non-invasive procedures that provide satisfactory results with minimal health risks.

[0002] The most common methods for non-invasive cosmetic applications are based on the application of mechanical waves (such as ultrasound or shock wave therapy) or electromagnetic waves (such as radiofrequency therapy or light therapy including laser therapy). The effect of mechanical waves on the tissue is based on cavitation, vibration and / or heat-induced effects. The effect of the application of electromagnetic waves is based on the heating of biological structures.

[0003] Mechanical treatment using mechanical waves and / or pressure can be used for the treatment of cellulite or fat cells. However, such mechanical treatment has some disadvantages, such as the risk of panniculitis, destruction of non-target tissues, and / or non-uniform results.

[0004] Thermal treatments involving heating are applied to patients for visual enhancement of the skin and body, for example by increasing the production of collagen and / or elastin, smoothing the skin, reducing cellulite, and / or eliminating fat cells. However, thermal treatments have some disadvantages, such as the risk of overheating the patient, or even causing thermal damage to undesirable biological structures. The risk of fat inflammation and / or uneven results can be very common side effects of existing thermal treatments. In addition, insufficient blood flow and / or lymph flow during and / or after treatment can lead to fat inflammation and other health complications after treatment. In addition, treatment can be uncomfortable and accompanied by a sense of pain.

[0005] Muscle stimulation with a time-varying magnetic field provides multiple benefits compared to known methods for treating biological structures, and allows non-invasive stimulation of muscles located below other muscles. In addition, a time-varying magnetic field can be used to provide muscle stimulation to cause muscle contraction through electrical stimulation of a thick layer of fat tissue, to provide muscle contraction for delivering current from an electrode through the fat tissue to nerves and / or the neuromuscular plate connected to the muscle. Adipose tissue has a higher resistivity than muscle tissue, and the efficiency of delivering current from the electrode through insulating fat tissue to muscle tissue is low. Targeting of current to exact muscle can be imprecise, and muscle stimulation is very difficult, almost impossible. In addition, for thicker fat tissue, the current delivered by electrotherapy must be higher, and such a high amount of current that propagates and dissipates over long distances is very uncomfortable for the patient. On the other hand, the time-varying magnetic field induces current in the muscle, neuromuscular plate and / or nerve, so targeting and muscle stimulation by a time-varying magnetic field are easier, more precise, more comfortable and more effective. The time-varying magnetic field also allows for comfortable stimulation, or a greater number of muscles and / or muscle groups and the applicator can be in direct contact with the patient's body, which indirect contact can also improve the hygiene of the treatment and other treatment parameters.

[0006] The combination of radiofrequency (RF) therapy (which provides heating of the patient's soft tissue) and magnetic therapy (which provides stimulation of the patient's muscle tissue) can have a significant synergistic effect. The combined treatment can provide improved treatment effects, which can shorten the treatment period, increase patient comfort during treatment; can allow different treatment effects to be combined with synergistic effects, improve patient safety, etc. as described in depth later in this article.

[0007] To achieve the best synergistic effect, it is preferred to target the magnetic therapy and RF therapy providing muscle stimulation to one body part (e.g., the same body part), wherein at least one RF electrode providing RF therapy should be flat and / or should correspond to the patient's skin to ensure uniform heating of the patient's soft tissue. To target RF therapy and magnetic therapy to the same body part, it is necessary to position the magnetic field generating device and the RF electrode near each other, for example, the magnetic field generating device and the RF electrode at least partially overlap. However, arranging the RF electrode and the magnetic field generating device in close proximity is problematic because the time-varying magnetic field generated by the magnetic field generating device can induce undesirable physical effects, such as eddy currents, skin effects, and / or other physical effects in the RF electrode. Undesirable physical effects can cause significant energy losses, inefficiencies in such device arrangements and heating of the RF electrodes, impacts on device function, such as incorrect tuning of the device, inaccurate targeting of the generated energy, degradation of the generated magnetic field, electromagnetic field, etc. The RF electrode can be affected by the magnetic field generating device and vice versa.

[0008] The devices and methods described herein present a solution for providing RF and magnetic therapy with maximum synergistic effects, while also preserving the safety and efficiency of the delivered magnetic and RF (electromagnetic) fields. Summary of the invention

[0009] The present invention provides a therapeutic device and method for providing one or more therapeutic effects to at least one biological structure of at least one body part. The therapeutic device provides a unique opportunity to shape the human or animal body, improve visual appearance, restore muscle function, increase muscle strength, change (e.g., increase) muscle volume, change (e.g., increase) muscle tension, cause muscle fiber hypertrophy, cause muscle fiber hyperplasia, reduce the number and volume of fat cells and adipose tissue, eliminate cellulite, etc. The therapeutic device and method can use the use of radio frequency (RF) therapy and magnetic therapy to cause heating of at least one target biological structure in a body part and cause muscle stimulation, including muscle contraction, in a nearby or same body part. The therapeutic device can use RF electrodes as a therapeutic energy source to generate RF energy (which can be called an RF field) to provide RF therapy, and use a magnetic field generating device as a therapeutic energy source for generating a time-varying magnetic field to provide magnetic therapy.

[0010] To enhance the efficiency and safety of treatment, to minimize the energy loss and unwanted physical effects induced in at least one RF electrode and / or magnetic field generating device, the device may utilize one or more segmented RF electrodes, wherein the segmented RF electrode means an RF electrode having, for example, one or more apertures, cutouts and / or protrusions to minimize the effect of the nearby time-varying magnetic field generated by the magnetic field generating device. The aperture may be an opening in the body of the RF electrode. The cutout may be an opening in the body of the RF electrode along the boundary of the RF electrode. The opening in the body of the RF electrode may be defined by a view projected from the ground, which shows a view of the RF electrode from above. The outer area of ​​the aperture, cutout and / or protrusion may be filled with air, dielectric and / or other electrically insulating materials. The aperture, cutout and / or protrusion of the RF electrode may minimize the eddy current induction in the RF electrode, minimize energy loss, and inhibit overheating of the treatment device. In addition, the aperture, cutout and / or protrusion may minimize the effect of magnetic therapy on the generated RF therapy. The designed RF electrodes allow the same applicator to include a magnetic field generating device and an RF electrode that at least partially overlaps based on the topographical projection of the applicator, allowing both RF therapy and magnetic therapy to be targeted to the same part of the patient's body with the parameters described herein. The combination of the RF electrode and the magnetic field generating device in one applicator can enhance therapy targeting and achieve positive therapy results with minimal negative effects as described above.

[0011] Additionally, mutual insulation of the at least one RF circuit and the at least one magnetic circuit prevents interaction between electrical and / or electromagnetic signals.

[0012] The combination of the magnetic field generating device and the energy storage device allows the generation of a magnetic field having a certain strength (which may be a magnetic flux density) that induces muscle contraction. The energy storage device can be used to store electrical energy, thereby allowing the accumulation of an electric field with a voltage in the range of 500V to 15kV. The energy storage device can provide the stored electrical energy to the magnetic field generating device in pulses of a few microseconds to a few milliseconds.

[0013] The treatment method allows heating of at least one body part, which also induces muscle contraction, which minimizes muscle and / or ligament damage (such as tears or inflammation). When the patient finds the treatment uncomfortable, the heating of the skin, contracted muscles, contracting muscles, relaxed muscles, adipose tissue, fat tissue and / or adjacent biological structures of the treated body part can be offset.

[0014] Thus, heating can allow a higher amount of electromagnetic energy (e.g., RF and / or magnetic field) to be delivered to the patient's body to provide more muscle work through muscle contraction and subsequent relaxation. Another benefit of using RF therapy and magnetic therapy at the same site is that muscle work (e.g., provided by repeated muscle contraction and relaxation) accelerates blood and lymph flow at the targeted site, and thus improves the dissipation of thermal energy formed by the RF therapy. The application of RF therapy and magnetic therapy also improves the uniformity of heating of biological structures, which prevents the formation of hot spots, edge effects, and / or other adverse effects. Treatment methods that cause muscle stimulation and heating of the same body part can lead to over-acidification of the extracellular matrix, which over-acidification leads to apoptosis or necrosis of adipose tissue. RF therapy can provide selective heating of adipose tissue, which leads to at least one of the following: apoptosis, necrosis, volume reduction of adipocytes, and elimination of cellulite. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The accompanying drawings, which are incorporated herein and form a part of the specification, illustrate the present disclosure and, together with the description, also serve to explain the principles of the present disclosure and enable one skilled in the relevant art to make and use the present disclosure.

[0016] Figures 1a to 1e An exemplary schematic diagram of a treatment device is shown.

[0017] Figure 1f Exemplary individual parts of the therapeutic device are shown.

[0018] Figure 2 An exemplary communication diagram between parts of a device, such as an applicator, a remote control, additional treatment devices, and a communication device, is shown.

[0019] Figure 3 An exemplary communication diagram between a server and device components, such as an applicator, a remote control, and additional treatment devices, is shown.

[0020] Figure 4 An exemplary communication diagram between the communication medium of a treatment device, a therapy generator, and a host unit is shown.

[0021] Figure 5 Communications between a communication medium of a treatment device and a therapy generator are shown.

[0022] Figure 6 Different views of exemplary main units of a treatment device are shown.

[0023] Figure 7 An exemplary human machine interface (HMI) is shown.

[0024] Figures 8a to 8d The parts of an exemplary applicator are shown from an exterior view.

[0025] Figure 9a An exemplary magnetic field generating device is shown in a ground projection from the applicator.

[0026] Figure 9b The thickness of an exemplary magnetic field generating device is shown.

[0027] Figure 10a to Figure 10g Possible positions of exemplary RF electrodes relative to exemplary magnetic field generating means are shown.

[0028] Fig.11 A ground projection of the position of exemplary RF electrodes relative to an exemplary magnetic field generating device is shown.

[0029] Fig.12 A topographical projection of an applicator is shown, the applicator comprising RF electrodes and a magnetic field generating device partially overlapping according to the topographical projection of the applicator.

[0030] Figure 13a to Figure 13b An exemplary RF electrode having an aperture is shown.

[0031] Fig.13c An exemplary RF electrode having apertures, protrusions and cutouts is shown.

[0032] Fig.13d Another exemplary RF electrode having an aperture and a cutout is shown.

[0033] Fig.13e An exemplary RF electrode having protrusions is shown.

[0034] Figures 14a to 14e A bipolar RF electrode with parallel pairs of projections is shown.

[0035] Figures 15a to 15c A bipolar RF electrode pair with a protrusion is shown, wherein a first RF electrode at least partially surrounds a second RF electrode of the RF electrode pair.

[0036] Fig.16 An exemplary bump intersecting the magnetic field lines is shown, where the difference is above 0.1 T.

[0037] Fig.17 An exemplary schematic diagram of a magnet circuit is shown.

[0038] Fig.18a An exemplary schematic diagram of electrical components of a therapeutic device is shown.

[0039] Fig.18b An exemplary schematic diagram of an RF circuit is shown.

[0040] Fig.19 Exemplary compositions of magnetic fields are shown, including pulses or pulse rates.

[0041] Fig. 20 A trapezoidal envelope is shown.

[0042] Fig.21 Different types of muscle stimulation are shown.

[0043] Fig. 22 A support matrix is ​​shown for attaching an applicator and / or additional therapeutic devices to the patient's body.

[0044] Fig.23 A cross-section of a first side portion of an exemplary bend applicator is shown.

[0045] Fig.24 An exemplary symmetry element SYM is shown.

[0046] Fig.25 An exploded view of the applicator element is shown.

[0047] Fig.26 An exemplary spatial arrangement of components within the main unit of a treatment device is shown.

[0048] Figures 27a to 27d An example of synchronous application of magnetic fields is shown.

[0049] Fig.27e An example of independent application of magnetic fields is shown.

[0050] Fig.28 An exemplary increasing envelope of the magnetic field is shown.

[0051] Fig.29 An exemplary reduced envelope of the magnetic field is shown.

[0052] Fig.30 An exemplary rectangular envelope of the magnetic field is shown.

[0053] Fig.31 An exemplary combined envelope of the magnetic field is shown.

[0054] Fig.32 Another exemplary combined envelope of the magnetic field is shown.

[0055] Fig.33 An exemplary triangular envelope of the magnetic field is shown.

[0056] Fig.34 An exemplary trapezoidal envelope of the magnetic field is shown.

[0057] Fig.35 Another exemplary trapezoidal envelope of the magnetic field is shown.

[0058] Fig.36 Another exemplary trapezoidal envelope of the magnetic field is shown.

[0059] Fig.37 An exemplary step envelope of the magnetic field is shown.

[0060] Fig.38 Another exemplary step envelope of the magnetic field is shown.

[0061] Fig.39 Another exemplary trapezoidal envelope of the magnetic field is shown.

[0062] Fig.40 An example of the envelope of the magnetic field is shown, including modulation in the repetition rate domain.

[0063] Fig.41 An exemplary trapezoidal envelope formed by the sequence of magnetic fields is shown.

[0064] Fig.42 Another exemplary combined envelope of the magnetic field is shown.

[0065] Fig.43 Another exemplary combined envelope of the magnetic field is shown.

[0066] Fig.44 Two exemplary envelopes are shown with an example of an inter-envelope period. DETAILED DESCRIPTION

[0067] The present treatment devices and methods of use provide a novel physical therapy and / or cosmetic treatment through a combination of RF treatment and treatment providing muscle stimulation that is intended to achieve various therapeutic effects (such as rejuvenation, healing) and / or reshape at least a portion of at least one biological structure of a patient's tissue in at least one body part.

[0068] A biological structure may be any tissue in a human and / or animal body, which may have an equivalent function, structure, and / or composition. A biological structure may include or may be at least a portion of any type of tissue, for example: connective tissue (e.g., tendons, ligaments, collagen, elastic fibers), adipose tissue (e.g., adipocytes of subcutaneous adipose tissue and / or visceral adipocytes), bone, dermis, and / or other tissues, such as at least one neuron, a neuromuscular plate (neuromuscular junction), a muscle cell, one or more independent muscles, a muscle group, at least a portion of a muscle fiber, a volume of an extracellular matrix, an endocrine gland, a nervous tissue (e.g., peripheral nervous tissue, neurons, glial cells, neuromuscular plates), and / or a joint or a portion of a joint. For the purposes of this application, a biological structure may be referred to as a target biological structure.

[0069] The therapeutic effect provided to at least a portion of at least one target biological structure may include muscle contraction (including hypercontraction and / or tonic contraction, muscle twitching, muscle relaxation, and heating of the biological structure). In addition, the therapeutic effect may include, for example, remodeling of the biological structure, reduction of the number and / or volume of fat cells by apoptosis and / or necrosis, muscle strengthening, increase in muscle volume, induction of muscle fiber hypertrophy, muscle fiber hyperplasia, restoration of muscle function, proliferation and / or differentiation of somatic cells into muscle cells, improvement of muscle shape, improvement of muscle endurance, muscle definition, muscle relaxation, reduction in muscle volume, reorganization of collagen fibers, new collagen production, elastic tissue production, collagen therapy, improvement of blood and lymphatic flow, acceleration of at least a portion of at least one target biological structure, and / or other functions or benefits. During treatment of a body part by a therapeutic device, more than one therapeutic effect may be provided, and various therapeutic effects may be combined.

[0070] The therapeutic effects provided to the target biological structure may result in body shaping, improved body contours, body toning, muscle toning, muscle shaping, body shaping, breast lift, buttocks lift, buttocks rounding, and / or buttocks firming. In addition, providing a therapeutic effect may result in body rejuvenation, such as wrinkle reduction, skin rejuvenation, skin tightening, uniformity of skin color, reduction of sagging flesh, lip enhancement, cellulite elimination, stretch mark reduction, and / or scar elimination. The therapeutic effect may also result in acceleration of the healing process, anti-rheumatic effects, and / or other physical therapy and therapeutic effects.

[0071] The treatment device may provide one or more types of treatment energy, wherein the treatment energy may include a magnetic field (also referred to as magnetic energy) and an RF field (also referred to as RF energy) and / or a magnetic field (also referred to as magnetic energy). The magnetic field is provided during magnetic treatment. The RF field provided during RF treatment may include an electrical component of the RF field and a magnetic component of the RF field. The electrical component of the RF field may be referred to as one or more RF waves. The RF electrodes may generate the RF field, the RF waves, and / or other components of the RF field.

[0072] The magnetic field and / or RF field may be characterized by strength. In the case of a magnetic field, the strength may include the magnetic flux density or the magnitude of the magnetic flux density. In the case of an RF field, the strength may include the energy flux density of the RF field or RF wave.

[0073] A body part may include at least a portion of a patient's body that includes at least a muscle or muscle group covered by other soft tissue structures (e.g., adipose tissue, skin, etc.). A body part may be treated by a treatment device. A body part may be a body part such as a buttocks, saddle, love handles, abdomen, hip, leg, calf, thigh, arm, torso, shoulder, knee, neck, limb, breast fat, face or jaw, and / or any other tissue. For descriptive purposes, the term "body part" may be interchangeable with the term "body region."

[0074] Skin tissue consists of three basic elements: epidermis, dermis and hypodermis (so-called subcutaneous tissue). The outer layer of the skin and also the thinnest layer is the epidermis. The dermis is composed of collagen, elastic tissue and reticular fibers. The hypodermis is the lowest layer of the skin and includes the roots of hair follicles, lymphatic vessels, collagen tissue, nerves and fat, which forms subcutaneous white adipose tissue (SWAT). Adipose tissue can refer to at least one lipid-rich cell, such as adipocytes, such as lipoblasts. Adipocytes form lobules, which are bounded by connective tissue, fibrous septa (capsules).

[0075] Another part of the adipose tissue, the so-called visceral adipose tissue, is located in the abdominal cavity and forms the visceral white adipose tissue (VWAT) which is located between the apical peritoneum and the visceral peritoneum, immediately below the muscle fibers of the subcutaneous layer.

[0076] A muscle may include muscle fibers, a whole muscle, a muscle group, a neuromuscular plate, a peripheral nerve, and / or at least a portion of a nerve that innervates at least one muscle.

[0077] Deep muscle may refer to muscle at least partially covered by superficial muscle and / or muscle covered by a thick layer of other tissue, such as adipose tissue, wherein the thickness of the covering layer may be at least 4 cm, 5 cm, 7 cm, 10 cm or more, up to 15 cm thick.

[0078] The independent muscle can be an abdominal muscle, including the rectus abdominis, oblique abdominal muscles, transverse abdominal muscles and / or lumbar quadriceps. The independent muscle can be a muscle of the buttocks, including the gluteus maximus, gluteus medius and / or gluteus minimus. The independent muscle can be a muscle of the lower limb, including the quadriceps femoris, sartorius, gracilis, biceps femoris, adductor longus / brevis, tibialis anterior, extensor longus, extensor thumb longus, triceps femoris, lateralis / medial muscles, soleus, flexor thumb longus, flexor thumb longus, extensor thumb brevis, abductor thumb, adductor thumb, abductor thumb, adductor digiti minimi, abductor digiti minimi and / or interplanar muscles. The ligament can be Cooper's ligament of the breast.

[0079] An example may be the application of a treatment device and method to the abdomen of a patient, which can provide (or in which treatment can ultimately result in) treatment effects such as reduction in the number and volume of fat cells, muscle strengthening, fat elimination, reorganization of collagen fibers, acceleration of new collagen production and elastic tissue production, muscle strengthening, improvement of muscle function and muscle endurance, and muscle shape. These treatment effects can result in a reduction in the circumference of the abdominal area, elimination of abdominal sagging and / or firming of the abdominal area, reduction of cellulite, reduction of scars, and improvement of body posture (through strengthening of the abdominal muscles, body contours, body appearance, and patient health can also be improved).

[0080] One other example may be the application of a therapeutic device and method to a body part including the buttocks, which may provide (or where treatment may ultimately result in) therapeutic effects such as reduction in the number and volume of fat cells, reorganization of collagen fibers, acceleration of new collagen production and elastic tissue production, muscle strengthening, muscle toning, and muscle shaping. These therapeutic effects may result in reduction in waist or buttock circumference, buttock lifting, buttock rounding, buttock firming, and / or cellulite reduction.

[0081] Another example may be application of a treatment device and method to a body part including the thighs, which may provide (or wherein treatment may ultimately result in) a reduction in the number and volume of fat cells, muscle strengthening, muscle shaping, and muscle toning. Application of a treatment device and method to a body part including the thighs may result in a reduction in the circumference of the thighs, elimination of abdominal sagging, and reduction in cellulite.

[0082] Yet another example may be application of the treatment device and method to a body part including the arms, which may provide (or wherein the treatment may ultimately result in) a reduction in the number and volume of fat cells, muscle strengthening, muscle shaping, and muscle toning. Application of the treatment device and method to a body part including the arms may result in a reduction in the circumference of the abdomen, elimination of abdominal sagging, and reduction of cellulite.

[0083] One or more therapeutic effects provided to one or more target biological structures may be based on selectively targeting the RF field to one or more biological structures and providing heating and applying a magnetic field, which causes muscle stimulation (including muscle contraction). RF treatment may cause selective heating of one or more biological structures, polarization of the extracellular matrix and / or changes in the cell membrane potential of the patient's body. The magnetic field may be a time-varying magnetic field or a static magnetic field. When a time-varying magnetic field is used, magnetic therapy may be referred to as time-varying magnetic therapy. Magnetic therapy may cause muscle contraction, muscle relaxation, cell membrane polarization, eddy current induction, and / or other therapeutic effects, which are caused by generating a time-varying magnetic field in at least a portion of one or more target biological structures. The time-varying magnetic field may induce electric currents in the biological structure. The induced current may cause muscle contraction. Muscle contraction may be repetitive. The muscle contraction provided by the magnetic field may include excessive contraction, tonic contraction and / or incomplete tonic contraction. In addition, the magnetic field may provide muscle twitching.

[0084] The therapeutic effects provided by utilizing the therapeutic device and by applying magnetic therapy and RF therapy can be combined. For example, a reduction in the number and volume of fat cells can be achieved together with muscle strengthening, muscle shaping, and / or muscle conditioning during the actual treatment or during a period of time (e.g., three months or six months) after the treatment. In addition, the effects provided by utilizing the therapeutic device and by applying magnetic therapy and RF therapy can be cumulative. For example, muscle conditioning can be achieved by a combined reduction in the number and volume of fat cells, which can be achieved together with muscle strengthening.

[0085] The therapeutic method can provide a therapeutic effect to at least one of the target biological structures by heat therapy provided by the RF field in combination with the applied magnetic therapy. The therapeutic effect to the target biological structure can be provided by heating at least one biological structure and inducing at least partial muscle contraction or muscle contraction of a muscle by magnetic therapy.

[0086] The treatment method may allow heating of a body part, wherein muscle contraction is induced by a magnetic field. Heating may minimize muscle damage and / or ligament damage (including tearing or inflammation). Heating of contracting muscles and / or adjacent biological structures may also shift the threshold of uncomfortable treatment. Therefore, the heating caused by the RF field may allow a higher amount of magnetic energy to be delivered to the patient's biological structure to perform more muscle work. The heating of muscles and / or adjacent biological structures may also improve the quality and / or level of muscle contraction. Due to the heating provided by the RF field, more muscle fibers and / or longer portions of muscle fibers may be able to contract during magnetic treatment. Heating may also improve the permeability of muscle stimulation generated by magnetic treatment. In addition, when at least partial muscle contraction or muscle contraction is repeatedly induced, the patient's uncomfortable heating threshold may also shift higher. Such a shift in the threshold may allow more RF energy to be delivered to the patient's body.

[0087] Combined with heating, repeated muscle contraction and subsequent muscle relaxation can inhibit the uncomfortable sensation caused by muscle stimulation (e.g., muscle contraction). Muscle stimulation combined with heating can provide better regeneration after treatment and / or better prevention of panniculitis and other tissue damage.

[0088] Combined with RF heating, repeated muscle contraction and subsequent muscle relaxation (according to preliminary tests) may have a positive effect on treating and / or suppressing diabetic symptoms. Repeated muscle contraction induced by the provided magnetic field and heating of biological structures by the RF field may also improve the effects of diabetic symptoms or may also positively affect the results of diabetic symptom drug treatment. Successful treatment of diabetic symptoms may be caused by deep penetration of high amounts of radio frequency energy into the patient's abdominal area. Such penetration may be caused by simultaneously applying magnetic therapy, which may cause suppression of the patient's discomfort associated with high amounts of RF energy flux density and increased temperature in the tissue. In addition, magnetic therapy may cause polarization and depolarization of the patient's tissue, which may also increase RF energy penetration into the patient's body. RF therapy and / or magnetic therapy may affect glucose metabolism or may contribute to weight loss, which may suppress diabetic symptoms. It is believed that weight loss and exercise in patients with diabetic symptoms may contribute to suppressing diabetic symptoms.

[0089] The application of RF therapy through the RF field and magnetic therapy through the magnetic field can also positively affect the proliferation and differentiation of body cells into muscle cells. Tests have shown that magnetic therapy including time periods with different durations, repetition rates and magnetic flux densities (e.g., pulse rates or sequences as defined below) can provide the stimulation required to initiate the proliferation and differentiation of body cells.

[0090] Tests have also shown that a treatment method that provides a magnetic field that includes at least two or at least three consecutive periods (e.g., pulse rates, bursts, or sequences as defined below) of varying duration, repetition rate, and flux density can provide a muscle shock. Thus, the regenerative process leading to proliferation and differentiation of somatic cells can be initiated and further accelerated by the delivered RF field. Proliferation and differentiation of somatic cells can result in muscle enhancement, restoration of muscle function, increased muscle volume, and improvements in muscle shape, posture, or muscle tone.

[0091] The method of applying at least part of muscle stimulation or muscle contraction and heating to the same body part can obtain the hyperacidification of extracellular matrix. Hyperacidification can lead to the apoptosis of adipose tissue, and the acceleration of weight loss and body volume loss. Hyperacidification can be caused by the release of fatty acids to the extracellular matrix, wherein the release of fatty acids can be caused by the contracted high-intensity muscle work. The contracted high-intensity muscle work can be provided by a large amount of repeated muscle contraction, which is caused by applying the time-varying magnetic field generated by the described magnetic field generating device and the therapeutic device.

[0092] The therapeutic effect of RF treatment can be enhanced by magnetic treatment, such as by reducing or eliminating the risk of fat inflammation or local skin inflammation, because any accumulation of treated adipocytes can be prevented by the improved metabolism. The improved blood and / or lymphatic flow can help eliminate adipocytes. The elimination of adipocytes can also be promoted by a larger number of cells that phagocytize adipocytes. The synergistic effect of magnetic treatment and radio frequency (RF) treatment significantly improves metabolism. Therefore, the possibility of adverse events is limited, and the therapeutic results induced by the present invention are achieved in a shorter period of time.

[0093] The therapeutic device and treatment method can provide treatment of the same patient body part, wherein magnetic treatment and RF treatment can target at least a portion of one or more biological structures. One or more volumes of patient body tissue affected by the targeted RF and / or magnetic treatment can be in the vicinity. The volume of at least a portion of at least one or more affected biological structures of the patient's body tissue can be defined as the affected tissue volume, wherein the therapeutic effect provided by the therapeutic device and / or treatment method described above occurs. The therapeutic effect can be caused by repeated muscle contraction (e.g., provided by magnetic treatment), changes in tissue temperature (e.g., provided by RF treatment), and / or by at least partial polarization and acceleration of molecules in the patient's tissue. The change in tissue temperature can include, for example, an increase in tissue temperature of at least 3°C ​​or 4°C or 5°C or 6°C or 7°C or 10°C with reference to normal tissue temperature. In addition, the change in tissue temperature can include an increase or decrease in tissue temperature within the range of 1°C to 50°C or 2°C to 30°C or 2°C to 25°C compared to untreated tissue located in the same or different body part. The changed tissue temperature can be interpreted as a temperature change in any volume or any part of the biological tissue.

[0094] The proximity of tissue volumes affected by at least one RF treatment and / or at least one magnetic treatment has the meaning of the distance between two affected tissue volumes. At least two adjacent affected tissue volumes may have at least a partial overlap, wherein a smaller affected tissue volume of 2% to 15% or 5% to 30% or 2% to 100% or 30% to 60% or 80% to 100% or 40% to 85% may overlap with a larger affected tissue volume. Additionally, the distance between the affected tissue volumes may be in the range of 0.01 cm to 10 cm, or in the range of 0.01 cm to 5 cm, 0.01 cm to 3 cm or 0.01 cm to 1 cm. Alternatively, the overlap of the ranges described above may apply to two or more affected tissue volumes that have equivalent volumes without any distinction between smaller or larger tissue volumes.

[0095] Figures 1a to 1e Exemplary schematic diagrams of a treatment device are shown. These schematic diagrams may only apply to the main unit and applicator. The treatment device may include an input interface 103, a control system 104, a power source 105, a power network 106, one or more treatment clusters 107, and one or more treatment energy sources 108.

[0096] A plurality of therapeutic energy sources 108 may be coupled to or in communication with at least one therapeutic cluster 107. A control system 104 may be coupled to and in communication with each therapeutic cluster.

[0097] Figures 1a to 1e The parts of the therapeutic device may be electrical components of a circuit. Figures 1a to 1e One or more of the illustrated parts of the schematic diagram of may include multiple independent electrical components. The electrical components may generate, transfer, modify, receive or transmit electromagnetic signals (e.g., electrical signals) between individual electrical components. The electromagnetic signals may be characterized by current, voltage, phase, frequency, envelope, current value, signal amplitude and / or combinations thereof. When the electromagnetic signal reaches the therapeutic energy source, the corresponding therapeutic energy source may generate therapeutic energy and / or field.

[0098] The input interface 103 can receive input from a user. The input interface can include a human-machine interface (HMI). The HMI can include one or more displays, such as a liquid crystal display (LCD), a light emitting diode (LED) display, an organic LED (OLED) display, which can also include a touch screen display. The HMI can include one or more control elements for adjusting or controlling the treatment device. The control element can be at least one button, lever, dial, switch, knob, sliding control, pointer, touch pad and / or keyboard. The input interface can communicate or be connected to a control system, a power network.

[0099] The user may be an operator (e.g., a doctor, technician, nurse) or the patient himself; however, the treatment device may only be operated by the patient. In most cases, the treatment device may be operated by a user with appropriate training. In most cases, the user may be any individual, other than the patient, who influences the treatment parameters before or during treatment.

[0100] The control system 104 may include a host unit or one or more control units. The control system may be an integrated part of the input interface 103. The control system 104 may be controlled through the input interface 103. The control system may include one or more control elements for adjusting or controlling any part or electrical element of the treatment device. The host unit is a part of the treatment device (e.g., an applicator and / or a main unit) or an electrical element of a circuit that can be selected by a user and / or a treatment device to provide a master-slave communication including a high priority instruction to other parts of the treatment device. For example, the host unit may be a control unit or part of an input interface that provides high priority instructions to other parts of the treatment device. The treatment device may include a series of master-slave communications. For example, the treatment cluster 107 may include a control unit that provides instructions to the electrical elements of the treatment device 107; and the control unit of the treatment cluster 107 is subordinate to the host unit. The control system 104 may be connected to or communicate with the input interface 103, one or all power sources 105, the power network 106, and / or one or all treatment clusters where the treatment device exists. The control system 104 may include one or more processors (eg, microprocessors) or process control blocks (PCBs).

[0101] The power source 105 may provide electrical energy including electrical signals to one or more instruction clusters. The power source may include a module that converts AC voltage into DC voltage.

[0102] The power network 106 may represent a plug. The power network may represent a connection to an electrical grid. However, the power network may represent a battery for operation of the treatment device without an electrical grid. The power network may provide the electrical energy required for operation to the entire treatment device and / or its parts. Figures 1a to 1e As shown in the exemplary schematic diagram of , the power network provides electrical energy to the input interface 103 , the control system 104 and the power source 105 .

[0103] The treatment cluster 107 may include one or more electrical components associated with the generation of the corresponding treatment energy. For example, a treatment cluster for magnetic treatment (referred to as HIFEM) may include, for example, energy storage elements and switching devices. For another example, a treatment cluster for RF treatment (referred to as RF cluster) may include, for example, a power amplifier and / or a filter.

[0104] The therapeutic energy source 108 may include a specific source of therapeutic energy. In the case of magnetic therapy, the therapeutic energy source of the magnetic field may be a magnetic field generating device, such as a magnetic coil. In the case of RF therapy, the therapeutic energy source of RF energy (including RF waves) may be an RF electrode.

[0105] The treatment device may include one or more treatment circuits. A treatment circuit may include a power source, electrical components of a treatment cluster, and a corresponding treatment energy source. In the case of magnetic treatment, the magnetic circuit may include a power source, a HIFEM cluster, and a magnetic field generating device. In the case of RF treatment, the RF circuit may include a power source, an RF cluster, and a magnetic field generating device. The electromagnetic signals generated and / or emitted within a treatment circuit for RF treatment may be referred to as RF signals. Wiring connecting the corresponding electrical components of a treatment cluster may also be included in the corresponding cluster. The following detailed description Figures 1a to 1e Each of the treatment clusters can be either HIFEM, RF, or a combination.

[0106] One or more therapy circuits and / or parts thereof may be individually controlled or adjusted by any portion of the control system 104. For example, the speed of operation of a HIFEM cluster of one therapy circuit may be individually adjusted while operating a HIFEM cluster of another therapy circuit. In another example, the amount of energy flux density delivered by operating an RF electrode of one therapy circuit may be set independently of the operation of an RF electrode of another therapy circuit.

[0107] Figure 1a An exemplary schematic diagram of a treatment device is shown, which includes an input interface 103, a control system 104, a power source 105, a power network 106, two treatment clusters (including treatment cluster A 107a, treatment cluster B 107b), treatment energy source A 108a, and treatment energy source B 108b. In such cases, the treatment device may include two treatment circuits. One treatment circuit may include power source 105, treatment cluster A 107a, and treatment energy source A 108a. Another treatment circuit may include power source 105, treatment cluster B 107b, and / or treatment energy source B 108b. Treatment clusters 107a and 107b may communicate with each other.

[0108] Figure 1bAn exemplary schematic diagram of a treatment device is shown, which includes an input interface 103, a control system 104, two power sources (including power source A 105a and power source B 105b), a power network 106, two treatment clusters (including treatment cluster A 107a and treatment cluster B 107b), treatment energy source A 108a and treatment energy source B 108b. In such cases, the treatment device may include two treatment circuits. One treatment circuit may include power source 105a, treatment cluster A 107a and / or treatment energy source A 108a. Another treatment circuit may include power source B 105b, treatment cluster B 107b and / or treatment energy source B 108b. Treatment clusters 107a and 107b may communicate with each other.

[0109] Figure 1c An exemplary schematic diagram of a treatment device is shown, which includes an input interface 103, a control system 104, a power source 105, a power network 106, two treatment clusters (including treatment cluster A 107a and treatment cluster B 107b), and a treatment energy source 108. In such cases, the treatment device may include two treatment circuits. One treatment circuit may include the power source 105, the treatment cluster A 107a, and / or the treatment energy source 108. The other treatment circuit may include the power source 105, the treatment cluster B 107b, and / or the treatment energy source 108. The treatment clusters 107a and 107b may communicate with each other. The schematic diagram shown may include a magnetic field generating device that provides both RF treatment and magnetic treatment.

[0110] Figure 1d An exemplary schematic diagram of a treatment device is shown, which includes an input interface 103, a control system 104, a power source 105, a power network 106, four treatment clusters (including treatment cluster A1107a, treatment cluster A2107aa, treatment cluster B1107b, treatment cluster B2107bb) and four treatment energy sources (including treatment energy source A1108a, treatment energy source A2108aa, treatment energy source B1108b and treatment energy source B2108bb). In such a case, the treatment device may include four treatment circuits. The first treatment circuit may include power source 105, treatment cluster A1107a and / or treatment energy source 108a. The second treatment circuit may include power source 105, treatment cluster A2107aa and / or treatment energy source A2108aa. The third treatment circuit may include power source 105, treatment cluster B1107b and / or treatment energy source B1108b. The fourth therapy circuit may include power source 105, therapy cluster B2107bb and / or therapy energy source B2108bb. The therapy energy sources of the first therapy circuit and the second therapy circuit may be located in one applicator, while the therapy energy sources of the third therapy circuit and the fourth therapy circuit may be located in another applicator.

[0111] Figure 1e Another schematic diagram of a treatment device is shown, which includes an input interface 103, a control system 104, two power sources (including power source A 105a and power source B 105b), a power network 106, four treatment clusters (treatment cluster A1107a, treatment cluster A2107aa, treatment cluster B1107b, treatment cluster B2107bb) and four treatment energy sources (including treatment energy source A1108a, treatment energy source A2108aa, treatment energy source B1108b and treatment energy source B2108bb). In such a case, the treatment device may include four treatment circuits. The first treatment circuit may include power source A 105a, treatment cluster A1107a and / or treatment energy source 108a. The second treatment circuit may include power source A 105a, treatment cluster A2107aa and / or treatment energy source A2108aa. The third therapy circuit may include power source B 105b, therapy cluster B1 107b, and / or therapy energy source B1 108b. The fourth therapy circuit may include power source B 105b, therapy cluster B2 107bb, and / or therapy energy source B2 108bb. The therapy energy sources of the first therapy circuit and the second therapy circuit may be located in one applicator, while the therapy energy sources of the third therapy circuit and the fourth therapy circuit may be located in another applicator.

[0112] Figure 1f The separate parts of the treatment device are shown, including a main unit 11 connected or coupled to at least one applicator 12, a remote control 13, additional or additional treatment devices 14 and / or communication devices 15. The additional treatment devices may be at the same level of independence as the entire treatment device.

[0113] The treatment device may include a remote control 13. The remote control 13 may include a discomfort button for safety purposes, so that the user can press the discomfort button when the patient feels any discomfort during treatment. When the discomfort button is pressed, the remote control 13 may send a signal to the main unit and stop the treatment. In addition, the remote control 13 may notify the user through a human-machine interface (HMI). To stop the treatment during discomfort, the operation of the discomfort button may overrule the command of the main unit. Alternatively, the discomfort button may be connected to the main unit 11 or may be part of it.

[0114] The main unit 11 can be coupled or connected to one or more additional therapeutic devices 14, which can be powered by the main unit 11. However, the therapeutic device including the main unit 11 can be paired with one or more additional therapeutic devices 14 through software. In addition, one or more additional therapeutic devices 14 can also be powered by one or more energy sources of their own. The communication device 15, the additional therapeutic device 14, the remote control 13 and at least one applicator 12 can each communicate with the main unit 11. Communication can include sending and / or receiving information. Communication can be provided by wire and / or wireless, such as through an Internet network, a local network, RF waves, sound waves, light waves, 3G, 4G, 5G, GSM, a HUB switch, an LTE network, a GSM network, Bluetooth and / or other communication methods or protocols.

[0115] The additional therapeutic device 14 may be any device that is capable of providing at least one type of therapeutic energy (e.g., RF field, magnetic field, ultrasound, light, time-varying mechanical pressure, shock wave, or electric current) to the patient's body to cause a therapeutic effect on at least one target biological structure. The additional therapeutic device 14 may include at least one electrical component that generates therapeutic energy for at least one treatment, such as magnet, radio frequency, light, ultrasound, heating, cooling, massage, plasma, and / or electrotherapy. The additional therapeutic device 14 may be capable of providing at least one treatment without the instruction of the main unit 11. The additional therapeutic device 14 may communicate with the main unit 11, the communication device 15, and / or other additional therapeutic devices 14. The additional therapeutic device 14 may be any other device of the same or other company, wherein the device may be capable of providing a specific one or more types of therapeutic energy. The additional therapeutic device 14 may be an extension of the therapeutic device, wherein the additional therapeutic device 14 may provide therapeutic energy through parameters defined by the HMI of the main unit 11.

[0116] The communication device 15 can be connected to the main unit 11 by wire and / or wirelessly. The communication device 15 can be a computer (such as a laptop or desktop computer) or a mobile electronic device (such as a smart phone) or an electronic tablet. The communication device can send and / or receive information related to the treatment function of the treatment device and / or other information. The additional treatment device 14 and / or the communication device 15 can communicate directly with the main unit 11, or indirectly communicate with the main unit 11 through one or more additional parts or communication devices. To provide communication, the communication device may include a receiver, a transmitter and a control unit to process the sent and / or received information.

[0117] The information sent to and / or received from the independent parts of the treatment device may include communication data between the communication device 15 and the main unit 11, communication data between the applicator 12 and the main unit 11, communication data between the additional treatment device 14 and the main unit 11, and / or communication data between the remote control 13 and the main unit 11. The sent and / or received information may be stored in a black box, a cloud storage space, and / or other storage devices. The black box may be a part of the main unit 11 or any other part of the treatment device. Other storage devices may be USB, other memory devices, and / or communication devices with internal memory. At least a portion of the sent and / or received information may also be displayed through the HMI. The sent and / or received information may be displayed, evaluated, and / or changed automatically by the user through the HMI and / or by the control system. One type of sent and / or received information may be a predetermined value or current value or selection of one or more treatment parameters or patient information. Patient information may include, for example, the patient's gender, the patient's age, and / or body type.

[0118] The information sent and / or received may also notify external agencies, such as a support center, e.g., a service department and / or a sales department, which are also a subset of the communication device. The information sent and / or received to the external agency may include information about the status of the treatment device, a history of one or more treatments provided, an operating history of the treatment device, software update information, wear information, durability of the RF electrodes, durability of the magnetic field generating device, treatment warnings, treatment credit / billing information, such as information about the number of paid treatments or credits, and / or other operation and usage information.

[0119] One possible type of information sent and / or received may be identification of a connection of one or more applicators 12, remote control 13, additional therapeutic device 14, and / or communication device 15. Based on this information, the treatment device may manually or automatically identify the type of the connected additional therapeutic device 14 and / or applicator 12. Automatic identification may be provided by the control system. Based on information about the connection of one or more applicators 12, the connection of the additional therapeutic device 14, and / or the communication device 15, the treatment device may provide an implementation of an HMI that may show a notification about the connection of the applicator and / or a possible optimization of a new treatment option. The possible optimization of the new treatment option may include, for example, adjustment of at least one treatment parameter, implementation of an additional treatment energy source, parameter changes of a new treatment energy source, and the like. The treatment device (e.g., a control system) may automatically adjust or provide for adjustment of treatment parameters based on the newly connected applicator 12 and / or additional therapeutic device 14. The identification of the connected applicator 12, additional therapeutic device 14, and / or communication device 15 may be based on a specific connector (e.g., a specific pin connector). In addition, connection identification can be provided by specific physical characteristics (e.g., impedance of the connected parts) or by specific signals provided by the applicator or its connected parts to the main unit 11. The connection between the independent parts of the treatment device (such as the main unit 11, the applicator 12, the remote control 13, the additional treatment device 14 and / or the communication device 15) can be provided by wire and / or wireless (e.g., by RFID tags, RF, Bluetooth and / or optical electromagnetic pulses). The applicator 12 can be connected to the main unit 11 by wire to effectively supply energy. Alternatively, the applicator can be connected wirelessly to communicate with the main unit 11 and / or the communication device 15. The connected applicator 12, the additional treatment device 14 and / or the communication device 15 can be identified by software identification, a specific binary ID, manual identification of parts selected from a list implemented in the treatment device and / or by pairing application.

[0120] The connector side in the main unit 11 may include a unit capable of reading and / or identifying information included in the connector side of the applicator and / or the connector side of the additional treatment device. Based on the read and / or identified information, the applicator and / or the additional treatment device can identify the main unit 11. The connector side of the main unit 11 can be used as a first side connector for connection, wherein the connection of the applicator or the additional treatment device can be used as a second side connector for the connection. The sending of information, the receiving of information and / or the identification of the second side connector by the first side connector can be based on binary information received by conductive contact between the two connector sides, by optical reading and / or by the identification provided by the first side connector. Optical identification can be based on the reading of a specific QR code, bar code, etc. of a specific applicator 12, for example.

[0121] The first side connector in the main unit 11 may include a unit capable of reading / identifying binary information implemented by the second side connector of the applicator 12 and / or the cable of the additional treatment device 14. The implemented information in the second side connector may be stored in an SD card. Based on such implemented information, any part of the treatment device can be identified by the main unit 11.

[0122] The communication between the independent parts of the treatment device (including, for example, the main unit 11, the remote control, one or more applicators, one or more additional treatment devices and / or the communication device) can be based on peer-to-peer (referred to as P2P) and / or master-slave communication. During P2P communication, the independent parts of the treatment device have the same priority of their commands and / or can communicate directly between each other. During the initial identification of the connected independent parts of the treatment device, P2P communication can be used. Between some parts of the treatment device during treatment, such as between the communication devices, P2P communication can be used.

[0123] Master-slave communication may be used between independent parts of the treatment device at least for a short time before and / or after each treatment of an individual patient. During the master-slave communication, one part of the treatment device may provide commands with the highest priority. An independent part of the treatment device (e.g., the main unit 11) may provide commands with the highest priority and is referred to as the master unit. The treatment device may include at least one master-slave communication between independent electrical components (such as a power source and / or one or more control voltages), where one or more control components act as a master.

[0124] The host unit may be selected by the user before, after and / or during treatment. The user may select the host unit based on the available independent parts or electrical components of the treatment device. Thus, the user may select the main unit 11, the applicator 12, the remote control 13, the additional treatment device 14 or the communication device 15 as the host unit. The host unit may be a control unit selected to be present in the independent parts of the treatment device, for example, the control unit in the main unit 11. The user may select the host unit to facilitate the adjustment of the treatment parameters. The user may also select the communication device 15 as the host unit, wherein the communication device selected as the host device may provide control of more than one treatment device. The host unit 11 may include a control unit as the host unit, which monitors and evaluates at least one parameter of the treatment, such as the patient's temperature, the voltage on the independent components of the treatment device, etc.; the at least one parameter allows safe treatment to be provided even in the case of connection therebetween. In addition, the host unit may be a separate electrical component outside the human-machine interface. The host unit may be controlled by the user through the human-machine interface.

[0125] Alternatively, the host unit may be automatically selected based on a predetermined priority value of the connected parts of the treatment device. The selected host unit may remain unchanged, and the selected part of the treatment device may act as the host unit throughout the treatment. However, the selection of the host unit may change during the treatment based on the command priority and / or selection of the user. The host unit may also be determined according to the manufacturing configuration, or depend on the factory reset. For example, the remote control 13 may provide a command with the highest priority to stop the treatment when the patient feels uncomfortable, and the treatment will stop, regardless of the independent part of the treatment device set as the host unit and the set parameters of the treatment.

[0126] Figures 2 to 5 Some possible master-slave communication schemes are shown that may be used for communication between the main unit 11 and one or more applicators 12, remote controls 13, additional treatment devices 14, and / or communication devices 15. Figure 2 , one or more therapy generators 201 generate modified electrical signals to provide signals to a source of therapeutic energy, such as an RF electrode and / or a magnetic field generating device. The therapy generator 201 may include a group of electrical components of the therapeutic device and / or a circuit present in the main unit or at least two components of the group of electrical components. The group of electrical components may include a control unit, a power source, a coaxial cable system, one or more switches, one or more energy storage devices, one or more pin diodes, one or more LC circuits, one or more LRC circuits, one or more power amplifiers and / or other parts of the therapeutic device that actively modify the electrical signal in a controlled manner. The therapy generator can provide modification of the electrical signal in a controlled manner.

[0127] Modifying the electrical signal in a controlled manner may include, for example, providing and / or controlling impedance adjustment of the provided RF therapy based on impedance matching measured across patient tissue and / or RF electrodes. Actively modified electrical signals may be interpreted such that the electrical signal may have different parameters, such as frequency, symmetry, amplitude, voltage, phase, intensity, etc. The parameters of the electrical signal may be based on the requirements of the treatment, including patient type, treatment parameters. In addition, the parameters of the electrical signal may be modified based on feedback information, such as measured standing wave ratio of RF energy, tissue temperature, temperature of the RF electrodes, temperature inside the applicator, temperature of the applicator surface, current and voltage of independent elements of the treatment device, and the like.

[0128] Figure 2The schematic diagram of shows a security element 203, which prevents any unauthorized intrusion into the communication of the treatment device and protects personal user data and / or accounts. The security element 203 can protect the treatment device from computer viruses, unauthorized access, and / or can protect the communication between the independent parts of the treatment device from being read or changed by unauthorized media or individuals. The security element 203 can provide encoding and / or anti-virus services for information used in communication, which prevent unwanted binary codes from intruding into the treatment device and / or communication. The security element 203 can correct errors generated during communication. The security element 203 can prevent unauthorized / unwanted external devices from connecting to the treatment device.

[0129] Figure 2 The safety element 203 in the communication diagram may be located between the host unit 202 and the communication interface 204. The safety element 203 may also be a part of the user unit 208, the service department 207, and / or the sales department 206. The safety element 203 may also be located between the communication interface 204 and the communication medium 205, the therapy generator 201, and / or may be a part of them.

[0130] The communication interface 204 may include hardware and / or software components that allow electrical, electromagnetic, infrared, and / or other signals to be converted into a readable form to allow communication between at least two parts of the treatment device and / or other communication sides or media. The communication interface 204 may provide for communication and / or encoding of information and / or data. The communication interface 204 may be, for example, a modem or GSM module that provides communication between the treatment device and an online network or server. The communication interface 204 may be part of the host unit 202, the therapy generator 201, and / or other parts of the treatment device.

[0131] The communication medium 205 may be a medium for transmitting communication data. The communication medium 205 may be used for communication between the treatment device and the user 208, the service department 207, and / or the sales department 206. The communication medium 205 may be a wire, an SD card, a flash memory, a coaxial wire, any conductive connection, a server, some kinds of networks in principle, such as RF waves, sound waves, light waves, GSM, 3G, 4G, 5G, a HUB switch, Bluetooth, Wi-Fi, and / or other media that may include one or more servers.

[0132] The communication data / information may be redirected to separate parts of the treatment device and / or may be redirected to separate users or services, such as user 208, service 207, and / or sales 206. The communication data / information may be redirected through host unit 202, communication medium 205, and / or therapy generator 201. For example, the server may filter data for user 208 and may filter other communication information that will be redirected to service 207, control unit, and / or other parts of the treatment device.

[0133] Figure 2 The element referred to as "user 208" in the example may be a representation of an HMI controlled by a user. Alternatively, Figure 2 The element referred to as "user 208" in the figure may be a representation of another communication device (personal computer, laptop, mobile phone, tablet) controlled by the user, wherein the communication device can send information to at least a portion of the treatment device and / or receive information from at least a portion of the treatment device. The information provided through this communication channel may be the type of treatment plan, information about the treatment effect, the actual value and / or predetermined value of one or more treatment parameters, feedback information, the selection of the body part to be treated, behavioral suggestions before and after treatment, and / or other information. At least a portion of the information may be sent to the user controlling the treatment device and may also be sent to the patient, such as through a software application for a mobile phone, tablet or laptop.

[0134] Figure 2 The service department 207 in the figure may represent a service department that has authorized access to information about the treatment device. The service department 207 may be a service department of a company that provides or manufactures the treatment device, wherein the communication between the company's service department and the user may be provided through the HMI, the communication device and / or automatically provided through a pre-programmed software interface. The information provided through this communication channel may include wear of independent electrical components of the treatment device, durability of any RF electrodes and / or magnetic field generating devices, failure of independent electrical components, possible software optimization and / or implementation of the device, thereby providing an application for connecting another additional treatment device, etc. The optimization and / or implementation of the treatment device may include, for example, remote access to the treatment device software and / or correction of errors.

[0135] Figure 2The sales department 206 in the embodiment can be a sales department that has authorized access to the treatment device information. The sales department 206 can inform the user of the type of accessories that can be added to the treatment device. In addition, the sales department 206 can facilitate the sale of plug-in modules and / or facilitate the sale of accessories for the treatment device. In addition, the sales department 206 can provide quotes related to billing and rental systems. The information exchanged to or from the sales department 206 through communication can be, for example, the number of treatments, the duration of the treatments, and / or the type of treatment applied, information about the applicator, and the like.

[0136] The treatment device may include a black box for storing data about treatment history, operation history, communication between independent parts of the treatment device, data from or about billing and rental systems, operating errors, and / or other information. Via a communication medium (e.g., a storage cloud and / or server), the data may be accessible to the sales department 206, the service department 207, and / or the user 208. The treatment device may include a billing and rental system to manage the cost of using the treatment device and / or the corresponding additional treatment device. The billing and rental system may send such information to the provider to prepare a billing invoice. The data of the black box may be downloaded by a verified authorized individual, such as a service technician, an accountant, and / or other individuals with administrator access rights. The verification of the authorized individual may be provided by a specific key, a password, a software code of several digits, and / or provided by a specific interconnecting cable.

[0137] The billing and leasing system can be based on the points deducted from the user account. The points can be predefined by the provider of the treatment device, such as the manufacturer of the treatment device. The points can be recharged during the operation time of the treatment device, and / or can be recharged to an online account related to one or more treatment devices of the user and / or provider. The points can be deducted according to the selected treatment plan or body part. The points value of a single one or more treatments and / or treatment parts can be displayed to the user before the treatment begins, during the treatment and / or after the treatment. If the points of the user account are used up, the treatment device may not allow any further treatment until the points are recharged. Points can be used as currency for independent treatments, wherein different treatments can cost different amounts of points based on the type of treatment, the duration of the treatment, the number of applicators used and / or other factors. Points can also be used to rent or purchase independent parts of the treatment device, complete treatment devices, hardware or software expansions of the treatment device, and / or other consumables and spare parts subordinate to the treatment device. The interface where the points system can be recharged can be a part of the treatment device, HMI, and / or can be accessible online through a website interface.

[0138] One or more software extensions (e.g., software applications) may be associated with the treatment device and treatment methods. One or more software extensions may be downloaded to any communication device, such as a smartphone, tablet, computer, and / or other electronic device. The software extension may communicate with the main unit and / or other parts of the treatment device. The communication device with the software extension installed may be used to display or adjust one or more treatment parameters or information associated with the treatment. Such information that can display treatment parameters and treatment-associated information may include, for example, the time schedule of the treatment, the measured size of the treatment body part before and / or after the independent treatment, the schematic diagram of the applied burst or sequence, the remaining time of the treatment, the patient's heart rate, the temperature of the patient's body (e.g., the temperature of the body surface), the type of treatment provided, the type of treatment regimen, the comparison results of the patient's body parameters with the previous treatment (e.g., body fat percentage), and / or the actual treatment effect of the treatment (e.g., muscle contraction or muscle relaxation). The software extension may also be provided to the patient to inform them of the schedule of treatment, the mapping progress between independent treatments, the percentage of treatment results compared to others, and / or behavioral suggestions before and / or after treatment. Behavioral recommendations may include, for example, recommendations on the amount of water the patient should drink during the day, recommendations on how much water the patient should drink during the day, what the patient's diet should be, the type and amount of exercise the patient should provide before and / or after treatment, and / or other information that may improve treatment outcomes.

[0139] Communications between the independent elements of the communication graph, such as therapy generator 201, host unit 202, security 203, communication interface 204, communication medium 205, user 208, service 207, and / or sales 206, may be bidirectional or multidirectional.

[0140] The connection between the user 208, the service department 207, the sales department 206, the communication medium 205, and / or the connection between the therapy generator 201 and the host unit 202 can be ensured by the security part 203 to provide secure communication and eliminate errors. The security part 203 can be located between the host unit 202 and the communication interface 204 and / or between the communication medium 205 and the communication interface 204.

[0141] like Figure 3 As shown, another option for remote access communication between the user 208, the service department 207 and / or the sales department 206 and the treatment device can be provided by the server 301. The server 301 may include a security department 203. The security department 203 can achieve independent access to the user 208, the service department 207 and / or the sales department 206.

[0142] like Figure 4As shown, communication medium 205 may communicate with one or more therapy generators 201. One or more therapy generators 201 may communicate with host unit 202. Before therapy generator 201 sends information to host unit 202, the information on communication medium 205 may be verified by security 203.

[0143] Figure 5 A schematic communication diagram between a communication medium 205 and one or more therapy generators 201A-201D is shown. Therapy generator A 201A may communicate with at least one or more therapy generators 201B-201D. Another therapy generator B 201B may also communicate with one or more therapy generators 201A, 201C, 201D. Therapy generator C 201C may not communicate directly with therapy generator A 201A, and may communicate through therapy generator B 201B. The security unit 203 may be in the communication path between each therapy generator 201A-201D and / or between therapy generator 201A and the communication medium 205.

[0144] Figure 6 A main unit 11 of a treatment device is shown. The main unit 11 may include an HMI 61, a ventilator grill 62, at least one applicator holder 63a and 63b, at least one device control 64, applicator connectors 65a and 65b, at least one main power source input 66, a curved cover 67 of the main unit 11, wheels 68, a main unit cover opening 69, a main unit handle 70, and / or a labeling area 71. The main power source input 66 may provide a connection or connection to a power grid or network.

[0145] The ventilator grid 62 of the treatment device can be designed as a single piece, and / or can be divided into multiple ventilator grids 62 to provide heat dissipation. The ventilator grid 62 can face the individual operating the main unit 11, face the ground and be invisible, and / or the ventilator grid 62 can be on the side of the main unit 11. The ground-facing position of the ventilator grid can be used to minimize disturbing noise to the patient, because the cooling process of the main unit 11 and / or electrical components powered by electrical energy can generate noise. The surface area of ​​all ventilator grids 62 on the surface of the main unit 11 can be 100cm 2 Up to 15000cm 2 , or 200cm 2 Up to 1000cm 2 , or 300cm 2 Up to 800cm 2 within the range.

[0146] Manipulation of the main unit 11 may be provided by a rotating wheel 68 on the bottom of the main unit 11 and / or by a main unit handle 70. A logo area 71 of the company providing the treatment device may be located below the main unit handle 70 and / or may be located anywhere on the curved cover 67 and HMI 61.

[0147] like Figure 6 As shown, the front side of the main unit 11 facing the patient may be designed as a curved cover 67 of the main unit. Depending on the ground projection of the main unit 11, the front side of the main unit 11 facing the patient may not have a right angle. The front side of the main unit 11 facing the patient may be designed as one, two or more pieces covering the inner side of the main unit 11. The main unit 11 with a curved facing side can improve the manipulation of the main unit 11 itself near the patient support, wherein the risk of collision between the main unit 11 and various sensitive body parts (e.g., fingers) of the patient is minimized. The facing side of the main unit 11 may also include a main unit cover opening 69. The main unit cover opening 69 may include a thermal camera for monitoring the temperature of the patient or target body part; may include a camera for monitoring the position of one or more applicators, the movement of the patient, and the like. The main unit cover opening 69 may be represented by an opening in the curved cover 67 of the main unit. The main unit cover opening 69 may include one or more connectors for connecting additional treatment devices. In addition, the main unit cover opening 69 may include one or more sensors (such as cameras, infrared sensors) to scan the movement of the patient, the heating of the treated body part and / or biological structure. Based on information from such sensors, actual and / or predetermined values ​​of one or more treatment parameters may be optimized as the patient moves, the skin surface reaches temperature threshold limits, the treated body part is determined, etc. The front side of main unit 11 may also include one or more applicator connectors 65a and / or 65b.

[0148] The applicator connectors 65a and 65b facing the patient may be closer to the patient's body than the applicator connected to the side facing the operator (e.g., a doctor or technician). Therefore, the length of the connecting tube 814 connecting the applicator to the main unit 11 can be minimized. The manipulation of the applicator and / or multiple applicators connected by the shorter connecting tube 814 may be easier than the applicator connected to the longer connecting tube 814. The front side of the main unit 11 may not have corners and / or angles, and may include at least a partial elliptical and / or circular curvature. The curvature may have a radius of curvature in the range of 20cm to 150cm, 30cm to 100cm, 30cm to 70cm or 40cm to 60cm. The angle of the curvature of the front side of the main unit 11 may be in the range of 30° to 200°, or 50° to 180°, or 90° to 180°. The angle of curvature can be defined by the same principle, as defined in Fig.23 The angle 30 of the mid-section 26 is discussed in further detail below.

[0149] The main unit 11 may include one or more applicator holders, such as 63a and 63b. Alternatively, one or more applicator holders may be connected to the main unit 11. Each applicator holder 63a and 63b may have a specific design for different types of applicators. Applicator holders 63a and 63b may each hold a single applicator 12a or 12b. Each applicator holder 63a, 63b may have several functions. For example, applicator holders 63a and 63b may be used for preheating or precooling of at least a portion of the applicator. In addition, applicator holders 63a and 63b may include another HMI and may be used to display information about the selected treatment, actual values ​​and / or predetermined values ​​of one or more treatment parameters. In addition, applicator holders 63a and / or 63b may provide an indication of whether the applicator is ready for use. In addition, applicator holders 63a and / or 63b may indicate the current value temperature of at least a portion of the applicator. The indication may be provided by color flashing or vibration. Applicator holders 63a and / or 63b may be used to set actual and / or predetermined values ​​for one or more treatment parameters and / or applicator parameters, such as the temperature of the portion of the applicator that contacts the patient.

[0150] The main unit 11 may include a device control 64 for turning the main unit 11 on and off, manual setting of power input parameters, and / or other functions. Applicator connectors 65a and 65b may be used for the transmission of electrical and / or electromagnetic signals from the main unit 11 and the applicator. Applicator connectors 65a and 65b may be used to connect one or more applicators (via a connecting tube 814), a communication device, an additional treatment device, and / or a memory storage device; the memory storage device is such as a USB, an SSD disk, a diagnostic device, and / or other memory storage devices known in the art. The applicator connector 65 (e.g., 65a and / or 65b) for connecting one, two or more applicators may be located in the main unit 11 or on the side of the main unit 11. The length of the coaxial cable may be related to the frequency of the transmitted electrical signal. To provide easier manipulation of one or more applicators 12a and / or 12b, the connection length from the main unit 11 to, for example, the applicator 12a (and therefore the connecting tube 814) should be as long as possible. However, the length of at least one coaxial cable between the electrical components of the main unit 11 may be related to the frequency of the transmitted electrical signal (e.g., RF signal) that is sent to at least one therapeutic energy source (e.g., an RF electrode for providing RF energy). Therefore, the length of at least one coaxial cable inside the main unit (e.g., between the power source and the applicator connectors 65a and / or 65b) may be as short as possible. The length of the coaxial cable located in the main unit 11 may be in the range of 3 cm to 40 cm, or 7 cm to 30 cm, or 10 cm to 20 cm. To optimize the manipulation of one or more applicators 12a or 12b connected to the main unit 11, the applicator connectors 65a and 65b may be located on the curved front side of the main unit 11.

[0151] The HMI 61 may include a touch screen display that shows actual values ​​and / or predetermined values ​​of one or more treatment parameters. The touch screen may provide options to select displayed treatment parameters and / or to adjust these parameters. The HMI 61 may be divided into two display sections 61a and a selection section 61b. The display section 61a may display actual values ​​and / or predetermined values ​​of one or more treatment parameters, and other information for the user. The selection section 61b of the HMI 61 may be used for selection of treatment parameters and / or other adjustments to the treatment. The HMI may be included in or connected to one or more applicators 12, the main unit 11, an additional treatment device 14 and / or other one or more communication devices 15, or may be a part thereof.

[0152] The HMI may be included in the main unit 11. The HMI may be fixed to the main unit 11 in a horizontal orientation, or the HMI 61 may be oriented or tilted between 0° and 90° relative to the ground or other horizontal support surface. The angle between the plane of the HMI 61 and the ground may be adjusted by at least one joint, or may be rotated around at least one Cartesian coordinate. The HMI 61 may be in the form of a detachable HMI (e.g., a tablet). The HMI 61 may be telescopically and / or rotationally adjusted according to one, two or three Cartesian coordinates by a holder, which may adjust the distance of the HMI 61 from the main unit 11 and / or the orientation of the HMI 61 relative to the main unit 11 and the user. The holder may include at least one, two or three implemented joint members.

[0153] One HMI 61 may be used for more than one type of treatment device provided by the provider. The HMI software interface may be part of the main unit software, or part of the software included in one or more additional treatment devices and / or communication devices. The software interface may be downloaded and / or implemented by connecting to the communication device, additional treatment device, flash memory device, remotely connected to sales, service and / or the Internet.

[0154] Fig.26An exemplary layout of the interior of the main unit 11 is shown. The interior of the main unit 11 may include a plurality of electrical component control systems, one or more control RF circuits, magnetic circuits, and / or other components required for the correct function of the treatment device. The positions of the individual components in the main unit 11 may be described by Cartesian coordinates, where the zero value is at the bottom edge of the front side facing the patient. The main unit 11 may include one or more pillars 74. At least two pillars 74 may form an X shape, which may be fixed to other vertical pillars 74 at their ends to form the structure of the main unit 11. The main unit 11 may include at least one cooling system 78, which is configured to cool electrical components, such as one or more control units, PCBs, power sources, switches, energy storage devices, and / or other electrical components of the treatment device. The cooling system 78 may be used to provide and / or cool the cooling fluid provided to the applicator. The SYM element 79 may be located at the upper third of the Z coordinate and the first third of the X coordinate, regardless of the Y coordinate. The function of the SYM is explained below. The main element 11 may also include one or more housings 72 formed of aluminum or other metal materials. One or more housings 72 may provide electrical, electromagnetic and / or radiation insulation (the latter only as insulation) of one or more internal portions of the main unit 11 from other portions of the main unit 11. For example, at least a portion of the RF circuit 73 may be located in one of the housings at the rear third of the X and Z coordinates. A power source 75 (powering at least a portion of the RF circuit and / or magnetic circuit) may be located at the rear third of the X coordinate and the front third of the Z coordinate. An energy storage device 76 may be at least partially insulated from one or more RF circuits. When multiple magnetic circuits are used, the multiple magnetic circuits may be at least partially insulated from each other. To ensure the short length of the coaxial cable from the energy storage device 76 to the applicator connector 65 as described earlier, the elements (energy storage device 76 and applicator connector 65, such as 65a) may all be located in the same half of the X and Z coordinates, such as in the front half of the X and Z coordinates. Other electrical components of the magnetic circuit, represented by box 77, may be located in the front half of the X coordinate and two-thirds of the Z coordinate.

[0155] Figure 7An exemplary display interface 700 of the HMI 61 is shown. The HMI 61 may display one or more applicator symbols 701. One or more applicator symbols 701 and their colors may represent the connected treatment, quantity and / or type of available or connected applicators, additional treatment devices (connected to the main unit 11 and / or participating in the treatment). List 702 may be redirected to a page or a different display layout, wherein a list of treatment plans may be recorded or adjusted. List 702 of treatment plans may include at least one or more treatment parameters (e.g., magnetic field strength, RF field strength, magnetic pulse strength, magnetic pulse rate strength, pulse rate duration, burst duration, composition of independent bursts, duty cycle, envelope shape, treatment time, composition of treatment parts, threshold temperature of biological structures during treatment, and / or other parameters) One or more predetermined values. The list of treatment parameters may include one or more saved treatment plans optimized for independent patients or body parts. After selecting a treatment plan, the treatment parameters may be additionally optimized by the user. Additionally, treatment parameters can be adjusted by selecting additional patient parameters, such as patient size (e.g., thin, slim, average weight, overweight, or obese), or patient BMI, gender, age group (e.g., under 30, 30 to 39, 40 to 49, 50 to 59, 60 and older). Additionally, treatment parameters can be additionally optimized by selecting only a portion of the treatment regimen.

[0156] HMI 61 may include one or more sliders that may have several functions. For example, slider 703 may be used as a navigator to select the interface page being used, such as list 702, treatment icon 704, or record 707. In addition, slider 703 may be used to indicate the remaining time until the end of treatment.

[0157] Treatment icon 704 may represent Figure 7The interface shown. The timer 705 may indicate the duration of treatment, the remaining time of treatment, and / or the elapsed time of treatment. The "Scheme 1" icon 706 may show the type and quantity of the selected and / or currently applied and / or ready to be applied scheme. "Record" 707 may redirect to another page of the interface, which has a record history of treatment, information about the treated patient, information about the billing and rental system, information about billing information, and / or the point cost of treatment. "Record" 707 may show how many points are left on the point account, how many points have been spent, the length of time the treatment device is used, and / or other billing information. The icon shown by the symbol "Settings" 708 may redirect the user to the settings of the treatment device, including, for example, the melody and / or intensity of the sound produced by the device and / or the brightness of the display. The sound produced by the treatment device and / or the brightness of the display may be different before and / or during treatment. The "Settings" 708 interface may also allow the date, time, language, type and / or parameters of the connection between the main unit and the applicator, additional treatment devices, and / or communication devices to be changed. The "Settings" 708 interface may include icons for initiating calibration and functional scans of the treatment device and its connected parts. The "Settings" 708 interface may provide software information, software history and / or software implementation, buttons for contacting service and / or sending error protocols, the type of operating mode (e.g., "Basic" or "Expert" with additional settings allowed for the treatment device), the possibility to top up treatment credits, restore to factory settings, and / or other settings.

[0158] As shown, the intensity mark 709 may be in the form of a percentage, a number, a power and / or other formats. The intensity mark 709 may be positioned adjacent to an icon of the intensity of the adjustable therapeutic energy source. The intensity mark 709 may be located below, above and / or in the icon (e.g., as a number in the intensity bar 710), and / or may be another visualization of the intensity of the adjustable therapeutic energy source. Each intensity bar 710 of a therapeutic energy source that identifies the energy provided (e.g., an RF field or a magnetic field) may have its own intensity mark 709. The treatment device may include a plurality of applicators 714, such as a first applicator A and a second applicator B that may be connected to the main unit of the treatment device. In this way, applicators A and B may be applicable to different muscles in the same muscle group or to paired muscles, such as left and right buttocks, left and right sides of the abdomen, left and right thighs, and other paired muscles or cooperative muscles. The number of connected applicators and / or additional treatment devices that provide therapeutic energy may be less than or greater than two.

[0159] like Figure 7 As shown, each applicator can provide magnetic treatment 718 (left HMI portion is Figure 7The purpose is labeled HIFEM A and HIFEM B, and is shown as an exemplary interface human machine interface) and / or RF treatment 712 (right HMI portion for Figure 7 The destinations are labeled RF A and RF B and are shown as an exemplary HMI).

[0160] The strength of each RF field and / or magnetic field can be adjusted independently, for example, by an independent magnetic strength scroller 719 and / or by a strength bar 710 to scroll an RF strength scroller 711. One or more scrollers or strength bars can be moved individually, or can be moved together with another scroller or strength bar to adjust multiple magnetic fields, multiple RF fields, and / or multiple RF fields and magnetic fields provided by one applicator together. In addition, one or more scrollers or strength bars can be controlled individually, or can be moved together with another scroller or strength bar to adjust multiple magnetic fields, multiple RF fields, and / or multiple RF fields and magnetic fields provided by two applicators together. One or more strength bars 710 can be distinguished by color and can be adjusted by the strength scroller 719 or 711 and / or by the strength button 720. The strength button 720 can change (e.g., increase or decrease) the RF field and / or magnetic field strength by fixed increments, such as 1% or 2% or 5% or 10% of the maximum possible field strength, or in the range of 1% to 10%, or in the range of 1% to 5%. The strength of the magnetic field and / or RF field can be adjusted individually for each treatment energy source. In addition, the strength of the magnetic field and / or RF field can be adjusted by the selection and / or connection of one or more applicators, additional treatment devices and / or treatment energy sources.

[0161] The operation of one or more RF electrodes and / or magnetic field generating devices can be synchronized and can be controlled by one, two or more intensity scrollers 719 and / or intensity buttons 720. Treatment can be started by button start 713, which can automatically (e.g., after starting treatment) change to button pause. During treatment, treatment can be restarted and / or stopped by button stop 716. The interface can also show an indicator of an uncomfortable button 717; when the treatment is uncomfortable, the uncomfortable button 717 can be activated by the patient through a remote control. When the uncomfortable button 717 is activated, the treatment can be automatically and immediately interrupted (e.g., paused or stopped). When the uncomfortable button 717 is activated, the treatment device can provide a human-perceptible signal, including an auditory alarm (including a sound signal). In addition, the human-perceptible signal may include a visual alarm, including, for example, a flashing color. Based on the patient's discomfort, the user can adjust, for example, treatment parameters or treatment regimens, attachment or connection of the applicator. The interface can also include a software power switch 715 to turn the treatment device on or off.

[0162] like Figure 7As shown, the HMI may include two intensity bars (e.g., 710) for RF therapy and two intensity bars (e.g., 719) for magnetic therapy. In addition, the HMI may include two intensity scrollers (e.g., 711) for RF therapy and two intensity bars (e.g., 719) for magnetic therapy. In addition, the HMI may include four intensity buttons for RF therapy and four intensity buttons for magnetic therapy (e.g., 720). One intensity scroller, one intensity bar, and / or two intensity buttons may be provided for one therapy circuit. Thus, Figure 7 An HMI of a treatment device may be shown, the HMI comprising two treatment circuits for RF treatment and two treatment circuits for magnetic treatment.

[0163] The treatment device may include one or more applicators. The treatment device may include two, three, four, five or more applicators. Each applicator may include at least one, two or more different treatment energy sources, such as one or more RF electrodes providing RF treatment and one or more magnetic field generating devices providing magnetic treatment. For example, a first applicator may include an RF electrode and a magnetic field generating device, while a second applicator may include another RF electrode and another magnetic field generating device. An applicator may be connected to the main unit via a connecting tube. The connecting tubes of different applicators may be interconnected or separated for each applicator. Alternatively, multiple applicators may be connected to the main unit via a common connecting tube. At least one treatment parameter of at least one applicator may be individually changed relative to one or more other applicators and / or additional treatment devices.

[0164] One or more applicators, additional treatment devices and / or communication devices can be mechanically connected to the main unit through one or more wires and / or through a fluid conduit. One or more wires and / or fluid conduits can be positioned and guided by a connecting tube. One or more wires connected between the main unit and the applicator can be used for the transmission of electrical signals (representing, for example, RF signals) to the RF electrodes located in the applicator to generate RF energy. One or more wires can be used to provide current to the magnetic field generating device located in the applicator to generate pulses of the magnetic field. The same wire and / or different wires connecting the applicator and the main unit 11 can be used for communication between the main unit 11 and the applicator 12 and / or for collecting feedback information. Feedback applications may include, for example, measured signal parameters and / or impedance characteristics of the wire before and / or during treatment. The fluid conduit between the main unit 11 and the applicator 12 can guide liquids, oils, water, steam, gases, and / or other temperature regulating cooling fluids.

[0165] One or more applicators may be coupled to the patient's body and / or body part by one or more strips, one or more ribbons, or by forming a vacuum under the applicator. In addition, the applicator may be coupled to the body part by a support matrix or by an adhesive layer, which is located on at least a portion of the applicator surface and contacts the patient's body or clothing. The applicator may be coupled to the body part by pushing the applicator to the patient's body part or clothing via an adjustable mechanical positioning arm; wherein the applicator is detachably coupled to the positioning arm, which includes at least one, two or more joints. The ribbon may be at least partially elastic and may form a closed loop, such as by hook-and-loop fasteners (via Velcro); buckles, studs, and / or other fastening mechanisms may be used to adjust the length. The ribbon may be coupled to the body part and may include a fastening mechanism for coupling the applicator to the ribbon and / or the patient's skin or clothing. Such a fastening mechanism may be, for example, a ribbon with a pit for the applicator. Coupling the applicator to the body part may include attaching or positioning the applicator near or in contact with the body part. One or more applicators may be coupled to a body part before or during application of one or more types of treatment (e.g., RF treatment or magnetic treatment). Additionally, the applicator may be coupled to a body part, skin, or clothing via a cover of soft material that may be folded around the applicator and / or around a portion of the body part. Additionally, the applicator may provide a soft material cover for other connection points for attachment of a strap, folding of the soft material, or any other connection options described herein.

[0166] The ribbon can be a length-adjustable ribbon, which can be at least partially flexible. One or more ribbons can couple or fix and / or attach one, two or more applicators to the patient's body or body part. The ribbon can be coupled to an applicator 800, or a ribbon can couple two or more applicators to the patient's body. When using multiple applicators (e.g., two, three or more), an applicator can be coupled to the patient's body part through a ribbon, and another applicator can be coupled to the body part through different ribbons. Alternatively, multiple applicators (e.g., two, three or more) can be coupled to the patient's body part through a same ribbon. At least one applicator coupled by a ribbon can be statically fixed relative to the patient's body for at least a portion of treatment. At least one applicator coupled to the patient's body by a ribbon can be manually or automatically repositioned by an operator one or more times during treatment to ensure optimal treatment effect and patient's treatment comfort.

[0167] Connecting the applicator and / or additional treatment device to the patient's body may include placing the applicator near the patient's body and / or body part. In the case of proximal connection, the shortest distance between the applicator and the patient's skin may be in the range of 0.01cm to 10cm, or 0.01cm to 5cm, or 0.01cm to 2cm, or 0.01cm to 1cm, or 0.01cm to 5mm, or 0.01cm to 2mm. However, the applicator may also be placed in direct contact with the patient's skin. In the case of direct contact, there may be a meaningless distance between the applied treatment and the patient's skin. In the case of proximal or direct contact, an intervening material may be located between the applicator and the patient's skin or clothing or body part. The intervening material may be an air gap, a filler, a support matrix, a portion of a band, a textile, other clothing, a gel, a liquid absorbing material, or a metal.

[0168] Fig. 22 An exemplary attachment of an applicator and / or additional treatment device 21 to a patient's body using a support matrix 22 is shown. Fig. 22 As shown, the support matrix 22 can be shaped as a grid and / or a bracket. The grid and / or bracket is at least partially flexible and attached to the patient's body. The support matrix can be used to connect the applicator and / or additional treatment device 21 to a defined position near the patient's body, referred to as the applicator site 24, via a fastening member 23. The support matrix can be Fig. 22 A polymer stent-like substrate, such as a textile / polymer sheet, etc. The fastening member may be one or more elements (such as a locking mechanism, a hinge, a bayonet-like system, Velcro) for fastening the applicator and / or the additional treatment device 21.

[0169] like Fig.25As shown, the applicator 800 may include one or more parts defining the housing of the applicator, which can be connected to the main unit by a connecting tube 814. In addition, the applicator may include one or more parts hidden in the applicator, which further define the function and functionality of the applicator. The housing of the applicator may include different parts, such as a handle cover 512, a handle 514, a top cover 516, and a second side portion 802, which forms the bottom cover of the applicator. The handle cover 512 may include a mark 813 and / or an HMI 508 for, for example, displaying and / or adjusting the actual value and / or predetermined value of one or more treatment parameters. The handle 514 can be used for the manipulation of the applicator 800 and / or for connecting the applicator 800 to the body part of the patient. The top cover 516 can define the interior of the applicator. The top cover 516 may include an air opening 504, which allows air to flow to or from the interior of the applicator to cool the electrical components located inside the applicator. The electrical components located on the interior inner side of the applicator may include, for example, RF electrodes, magnetic field generating devices and / or temperature sensors 510. The second side portion 802 forms a bottom cover of the applicator. The second side portion 802 may include one or more protruding shapes, grooves, etc. Power, energy, one or more electromagnetic signals and / or cooling fluid may be delivered to the applicator via a connecting tube 814. In addition, cooling of one or more electrical components in the applicator (e.g., the magnetic field generating device 900 and / or the substrate 113a having at least one RF electrode) may be provided by a fan 524, which is fixed to the top cover 516 and / or the second side portion 802. The RF electrode pad 113a may include a temperature sensor 510, which is configured to determine the temperature of the applicator, at least a portion of the bottom cover 526, a body part and / or a patient's biological structure. The RF electrode located on the substrate can be connected to a mating element 136, which reconnects the coaxial cable. The mating element 136 refers to Fig.24 To further describe. Fig.25 Also shown is a frame 506 that can be used to secure the magnetic field generating device to the top cover 516 and / or the second side portion 802. The frame 506 can be configured to eliminate noise and vibration during magnetic therapy.

[0170] The applicator can be Figures 8a to 8d Design as shown in the example. Figures 8a to 8d As shown, applicator 800 may be used to treat a body part.

[0171] One or more RF electrodes in the applicator 800 may be located between the magnetic field generating device and the patient's body part. The shape of the RF electrode may be set to at least partially match the curvature of the first side portion 801, the second side portion 802, and / or the curvature of the patient's body part. The magnetic field generating device may at least partially match the curvature of the first side portion 801, the second side portion 802, and / or the curvature of the patient's body part. The RF electrode and / or the magnetic field generating device may be curved to focus and / or provide better targeting of RF treatment and / or magnetic treatment. The first side portion 801 may be configured to maintain the position of the limb within the first side portion 801 during treatment. The first side portion 801 may provide a stable position and / or balance for the treated body part. The position of the patient's limb may be maintained in the first side portion 801, even if the limb is movable by muscle contraction. The lateral movement and / or rotation of the limb may be limited in such a manner due to the first side portion 801 and / or the belt 817: the limb may be in a stable position. Rotational movement relative to the applicator 800 can be limited by coupling the applicator 800 to a body part (at least a portion of the treated body limb) via a strap. In addition, when a portion of the arm is treated by magnetic and / or RF therapy, at least a portion of the limb can also be attached to the patient's torso to minimize movement of the limb.

[0172] The second side portion 802 can be located on an opposite side of the applicator 800 relative to the first side portion 801. The second side portion 802 can be generally planar, or the second side portion 802 can be at least partially concave and / or convex. The applicator 800 can be coupled to the patient via a positioning mechanism, such as a strap 817, such as Figure 8a and Figure 8b shown.

[0173] Figure 8aAn applicator including a positioning mechanism is described, which can be fixed in a recess 803 at a first end 804 of a first side portion 801 and a recess 806 at a second end 805 of the first side portion 801. The positioning mechanism (such as a band or strip) can be fastened, or its length can be adjusted by a clamp 807. The clamp 807 can move around a pin 808 in a clockwise or counterclockwise direction. The clamp 807 can be biased by a spring. Alternatively, the clamp 807 can be locked by a suitable locking mechanism or by any other movement constraint. The clamp 807 can include a fastener 809 on the lower side of the clamp 807 for fixing the correct length of the positioning mechanism. The fastener 809 can be a hook and loop fastener, a Velcro fastener, a pin-type fastener, and other mechanical fasteners. When the patient's body part is attached to the first side portion 801 of the applicator 800, the applicator 800 can be mainly used as described above to connect to the patient's body. The RF electrodes and / or the magnetic field generating means may be shaped to at least partially match the curvature of the first side portion 801. The RF electrodes and / or the magnetic field generating means may be curved to focus and / or provide better targeting of the RF therapy and / or magnetic therapy.

[0174] Figure 8b and Figure 8c An applicator including a positioning mechanism is shown, which can be directed vertically to the curvature of the first side portion 801 and / or vertically to the axis 810 of the applicator. The positioning mechanism can be positioned or guided by a concave surface 815 below, through or on the handle 812. A ribbon 817 can also be guided through the applicator 800 in any direction and / or guided on it to hold the applicator 800 to the patient's skin. When the patient's body part is attached to the second side portion 802 of the applicator 800, the applicator 800 can be mainly used as described above to connect to the patient's body. The shape of the RF electrode and / or magnetic field generating device can be set to at least partially match the first side portion 801. The RF electrode and / or magnetic field generating device can be flat or curved to focus and / or provide better targeting of RF treatment and / or magnetic treatment.

[0175] Figure 8bA top view of an applicator 800 is shown. The applicator 800 may include a marking 813 corresponding to the position of the magnetic field generating device within the applicator 800. The marking 813 may be located above the center of the magnetic field generating device. The marking 813 allows the user to easily and comfortably position the applicator 800. A recessed portion in the surface of the applicator 800 may be used as the marking 813. Alternatively, the marking 813 may be a different surface variation of a portion of the applicator cover, such as a different color, a different roughness, a pressure of one or more light sources (e.g., a light emitting diode LED), a specific curvature of the housing of the applicator, a logo of a manufacturing or distribution company, and the like. The housing of the applicator may include at least two colors. A first color may be on the applicator housing above the magnetic field generating device to allow correct positioning of the applicator, and the rest of the applicator may have a second color different from the first color. The color may be interpreted as a coating that reflects and / or absorbs light of a specific wavelength. Similar to the marking 813, the applicator may include a second marking to show the position of at least one RF electrode.

[0176] like Figure 8b and Figure 8c As shown, the applicator may include an outlet 811. The outlet 811 may allow for the circulation of air in the applicator 800 and the thermal dissipation of heat generated by at least one or more magnetic field generating devices and / or RF electrodes located in the applicator and supplied with energy through one or more wires inside the connecting tube 814. The connecting tube 813 may also include a fluid conduit that may provide or direct a cooling fluid from the main unit 11 to the applicator 800.

[0177] The applicator 800 may also include one or more temperature sensors 816, such as Figure 8c The temperature sensor 816 can protrude from the housing of the applicator 800, such as, for example, protruding from the surface of the second side portion 802 and / or protruding from the first side portion 801. The temperature sensor 816 can protrude from the housing of the applicator 800 to create a higher pressure on a portion of the body part being treated by the applicator 800 and to provide a better measurement of the temperature of the biological structure, body part and / or patient's body.

[0178] The second side portion 802 and / or the first side portion 801 can be heated and / or cooled. The second side portion 802 and / or the first side portion 801 can be heated (e.g., at the beginning of treatment) to reach the treatment temperature faster. The treatment temperature may include the temperature of the body part and / or biological structure increased by applying RF waves, which may be suitable for applying a magnetic field. Cooling or heating of multiple parts of the applicator can be used to maintain a constant temperature on the patient's skin. In addition, cooling or heating of multiple parts of the applicator can be used to achieve a higher treatment temperature of the patient's biological structure (deeper than 0.5 cm below the patient's skin). Cooling a portion of the applicator that contacts the patient (e.g., the second side portion 802 and / or the first side portion 801 of the applicator) can be used to minimize sweating in the patient. The patient's skin can be cooled by a cooling fluid (e.g., air) that flows and / or blows in from the applicator and / or other parts of the treatment device. Cooling of the patient's skin can be provided by heat dissipation between the cooling portion of the applicator that contacts the patient's skin and the patient's skin. The cooling portion of the applicator may be cooled by a cooling fluid flowing in the applicator and / or by a Peltier element utilizing the Peltier effect.

[0179] Patient sweating can be uncomfortable for the patient and adversely affect feedback information collection, can contact the applicator and the patient's skin, and / or can result in lower adhesion of the applicator to the patient's skin. To prevent sweating of the patient's skin, cooling of the applicator contact area (e.g., first side portion 801 and / or second side portion 802) can be utilized. Second side portion 802 and / or first side portion 801 can include grooves 819 that can be supplied with cooling fluid through applicator slit 820, wherein liquid and / or gas (e.g., gas, oil, or water) can be provided as Figure 8d Flow as shown. The first side portion or the second side portion of the applicator may include an applicator hole or applicator slit 820, wherein the air of the applicator 800 can be directed to remove heat, moisture and / or sweat from the patient's skin. The hole or slit may be present in the groove 819. The hole can be used to provide active substances to the patient. The contact portion of the applicator that contacts the body part may include a fluid-absorbing material, such as a sponge, a hydrophilic material, a non-woven organic and / or polymer textile; the fluid-absorbing material can at least partially remove sweat from the patient's skin and / or can improve the conductivity between the patient and the applicator 800. The reduction of sweating in the patient in at least a portion of the treated body part can be provided by a reduction in sweat gland activity. The reduction in sweat gland activity can be provided by applying a pulsed magnetic field, an intense light, a thermal shock, by applying an active substance (such as ethylene terephthalate) to the patient and / or to the patient, and / or by other mechanisms, and the thermal shock is provided by periodic cooling of the patient's skin.

[0180] Fig.23An exemplary applicator including a concave surface is shown. The applicator can be designed with a first side portion 801 that is at least partially convex. The first side portion 801 can alternatively be V-shaped or U-shaped. The radius of curvature can correspond to the size of the patient's limb. The second side portion 802 can alternatively or additionally be at least partially convex.

[0181] The patient can lie in a supine position, or sit on a patient support, such as a bed, sofa, or chair. The patient's arm can be set on the first side portion 801 of the applicator 800. The first side portion 801 can directly contact the patient, and RF treatment can be applied in combination with magnetic treatment. In addition, a strip or ribbon can be guided through the concave surface 815 to attach the applicator to the patient's body.

[0182] According to the vertical cross section, the first side portion 801 may have an at least partially oval or circular shape, wherein according to Fig.23 The curvature 25 in the first side portion 801 can be defined as a portion of an ellipse or circle that is adapted to the curvature of at least a portion of the first side portion 801. The section in which the curvature of the first side portion 801 matches the adapted ellipse or circle can be referred to as section 26. Section 26 is defined as the angle 30 between line 28 and line 29. According to the adapted portion of the ellipse or circle of the curvature of the replica applicator 800, lines 28 and 29 cross the symmetry center 27 and points 31 and 32, and points 31 and 32 are located in the section 26 with the longest distance. The symmetry center 27 is the center of the adapted ellipse and / or the adapted circle. The angle 30 of the section 26 defining the first side portion 801 can be at least 5°, or can be in the range of 10° to 270°, 30° to 235°, 45° to 180°, or 60° to 135°. The radius of curvature of at least a portion of the adapted circular shape for the first side portion 801 may be in the range of 50 mm to 1250 mm, or in the range of 10 mm to 750 mm, or in the range of 50 mm to 500 mm, or in the range of 60 mm to 250 mm. The second side portion 802 may be curved on at least a portion of its surface, wherein the segment 26 of the second side portion 802 may be at least 5°, or in the range of 10° to 270°, 30° to 235°, 45° to 180°, or 60° to 135°. In addition, the radius of curvature of at least a portion of the adapted circular shape for the second side portion 802 may be in the range of 50 mm to 1250 mm, 10 mm to 750 mm, 50 mm to 500 mm, or 60 mm to 250 mm.

[0183] One or more applicators and / or additional treatment devices may include a packing 32, such as Fig.23As shown. The packing 32 may refer to a material layer between an applicator or RF electrode (located on the surface of the applicator) and a patient's body part or skin (including the epidermis or clothing of the patient's skin). The packing 32 may refer to a material layer between an RF electrode (located on the surface of the applicator) and a patient's body part or skin. In addition, the packing 32 may be a component independent of the applicator 800. The packing 32 may be attached to the first side portion 801 and / or the second side portion 802 of the applicator 800. The packing 32 may be removed and disassembled from the applicator 800. The packing 32 may be mechanically coupled to the first side portion 801 and / or the second side portion 802 of the applicator 800. The packing 32 may be made of a solid flexible material, and / or a combination of a solid and flexible material may be used as a packing. The packing 32 may include a fluid material, such as water, a gel or a fluid solution, which includes ceramics, metals, polymers and / or other particles encapsulated in a flexible capsule made of a biocompatible material. The packing 32 can be profiled, wherein the thickness of the packing 32 as a layer between the RF electrode and the patient's skin can be different. In the position where the energy flux density of the RF treatment (including the RF field) is high enough to form an uncomfortable thermal site and / or a non-uniform temperature distribution, the thickness of the packing 32 can be higher. The packing 32 allows more uniform heating of the biological structure and minimizes the edge effect. The edge effect can also be minimized by the different dielectric properties of the packing in terms of the packing volume and / or the packing area. The packing 32 may have a larger thickness under at least a portion of the edge of the RF electrode. The thickness of the packing under at least a portion of the edge of the RF electrode may be greater than at least 5%, 10%, 15% or 20% of the thickness of the packing 32 under at least a portion of the center of the RF electrode, without considering gaps, incisions and / or protrusions. Under at least a portion of the bipolar RF electrode and / or under at least a portion of the distance between at least two bipolar RF electrodes, the packing 32 may have a larger thickness. The packing 32 may exceed the thickness of the packing 32 at such a location by about at least 5%, 10%, 15%, or 20% compared to the thickness of the packing 32 (where the distance between the two closest points of two different bipolar RF electrodes is at least 5%, 10%, 15%, or 20% or more). The packing 32 may also improve the delivery of therapeutic energy (e.g., magnetic field and / or RF field) to at least one biological structure, and may minimize energy reflection by providing a dielectric property of a gradual transition between two different interfaces of the applicator and the biological structure. The packing 32 may dissect or focus the RF field and / or magnetic field to enhance the therapeutic effect, and / or to provide deeper tissue penetration of the treatment.

[0184] The padding 32 may also be a liquid absorbing material (such as a foam material, a textile material, or a gel material) to provide better environmental conductivity between the applicator and the patient's body. The better conductivity of the contact portion of the applicator can be used for better adjustment of the RF signal for the RF treatment applied to the patient's body and / or better collection of feedback information. The padding 32 can facilitate conductive contact between the RF electrode and the patient's skin or body part. In addition, the padding 32 can be used as a non-conductive or dielectric material that modifies the energy transfer to the patient's body, provides cooling of the patient's skin, removes sweat from the patient's skin, and / or provides heating, such as capacitive heating of the patient's body. The fluid absorbing material used as the padding 32 can also provide better thermal conductivity, so that the temperature of the biological structure and / or the applicator can be adjusted faster, easier, and more accurately. The padding 32 may also include additional RF electrodes to provide RF treatment.

[0185] As previously described, the treatment device may include one, two, three, four, six or more applicators and / or additional treatment devices for providing magnetic therapy and / or RF therapy. Each applicator, additional treatment device and / or treatment energy source (e.g., magnetic field generating device and / or RF electrode) may have its own treatment circuit for energy delivery, wherein each treatment circuit may be individually adjusted by the control system for each parameter of providing treatment energy. Each applicator, treatment device or treatment energy source may be adjusted and provide treatment individually; and / or two or more applicators, treatment energy sources and / or additional treatment devices may be adjusted as a group, and may be adjusted simultaneously and synchronously, and / or may cooperate with each other.

[0186] When the treatment device includes two or more applicators, they may be coupled to the contact portion or close to different parts of the body. In one example, the first applicator may be coupled to the contact portion or close to the left buttocks, and the second applicator may be coupled to the contact portion or close to the right buttocks. In another example, the first applicator may be coupled to the contact portion or close to the left side of the abdominal area, and the second applicator may be coupled to the contact portion or close to the right side of the abdominal area. In yet another example, the first applicator may be coupled to the contact portion or close to the left thigh, and the second applicator may be coupled to the contact portion or close to the right thigh. In yet another example, the first applicator may be coupled to the contact portion or close to the left calf, and the second applicator may be coupled to the contact portion or close to the right calf. Multiple applicators may be beneficial for the treatment of collaborative muscles and / or paired muscles.

[0187] One or more applicators and / or additional treatment devices may include a magnetic field generating device (e.g., a magnetic coil) that generates a magnetic field for magnetic therapy. The magnetic field generating device may generate an RF field for RF therapy. The essence is that the generated frequencies of the electromagnetic field have very different values. The magnetic field generating device may generate a dominant magnetic field vector during the lower frequencies of the generated electromagnetic field for magnetic therapy. However, the magnetic field generating device may generate a dominant electromagnetic field vector during the higher frequencies of the electromagnetic field for magnetic therapy, which may be used for RF therapy. The magnetic field generating device in the high frequency electromagnetic field domain may provide an RF field similar to the RF field provided by the RF electrode. When one magnetic field generating device may be used to provide both RF therapy and magnetic therapy, the difference between the frequencies generated for RF therapy and magnetic therapy may be in the range of 500kHz to 5GHz, or 500kHz to 2.5GHz, or 400kHz to 800kHz, or 2GHz to 2.5GHz. Additionally, when one magnetic field generating device is used to provide both RF therapy and magnetic therapy, the frequency used for the RF therapy may correspond to a frequency within the range of 100 kHz to 3 GHz, 400 kHz to 900 MHz, or 500 kHz to 3 GHz.

[0188] One or more applicators and / or additional treatment devices may include one or more RF electrodes and one or more magnetic field generating devices, wherein the RF electrodes have properties, structures, and / or designs that are different from the magnetic field generating devices. The RF electrodes may be operable as monopolar electrodes, monopolar electrodes, bipolar electrodes, and / or multipolar electrodes. One or more RF electrodes may be used for capacitive and / or inductive heating of a biological structure or body part.

[0189] The applicator may include two bipolar RF electrodes. The bipolar electrodes may transmit an RF field between two bipolar RF electrodes located in at least one applicator. The bipolar electrodes may increase the safety and targeting of the provided RF treatment compared to monopolar electrodes. The bipolar electrodes may provide an electromagnetic field that passes through patient tissue that is located around and between the RF electrodes; wherein due to impedance matching, it is possible to prevent the formation of electromagnetic standing waves in the patient tissue and prevent undesired thermal damage to non-targeted tissue. In addition, the distance between the bipolar electrodes affects the depth of RF wave penetration, which allows enhanced targeting of RF treatment.

[0190] The applicator may include a monopolar RF electrode or multiple monopolar electrodes. The monopolar electrode may transfer radiofrequency energy between an active electrode and a passive electrode, wherein the active electrode may be part of the applicator and the passive electrode having a larger surface area may be located at least 5 cm, 10 cm, or 20 cm from the applicator. A ground electrode may be used as the passive electrode. The ground electrode may be on the opposite side of the patient's body to which the applicator is attached.

[0191] Magnetic therapy can be provided by a magnetic field generating device, which can be made of a conductive material, such as a metal, including, for example, copper. The magnetic field generating device can be formed into coils of different sizes and shapes. The magnetic field generating device can be a coil of multiple windings, wherein one loop of the coil can include one or more wires. An independent loop of one or more wires can be insulated from other turns or loops of one or more wires. With respect to magnetic coils, each loop of wiring can be referred to as a turn. In addition, the independent wires in a turn or loop can be insulated from each other. The shape of the magnetic field generating device can be optimized with reference to the size and design of the applicator. The coil can be wound to match at least a portion of the shape of the applicator according to the ground projection of the applicator. The coil windings can be at least partially circular, elliptical, and / or can have any other shape that matches the shape of the applicator or a portion thereof. The loops of the windings can be stacked on top of each other, can be arranged side by side; or the stacks of the windings can be combined side by side and can be on top of other windings. The coil can be flat.

[0192] 9 shows a ground projection of an exemplary circular planar magnetic field generating device 900. Magnetic field generating device 900 is characterized by dimensions including an outer diameter D, an inner diameter d, an inner radius r, and an outer radius R. Magnetic field generating device 900 may also be characterized by areas A1 and A2. Area A2 may represent a winding area of ​​a coil, while A1 may represent a magnetic core or an area without any magnetic core or windings.

[0193] Area A1 is associated with dimensions r and d. Area A1 may not include the windings of the coil and may be filled with air, oil, polymer material. Area A1 may represent a magnetic core, wherein the magnetic core may be an air core. Alternatively, the magnetic core may be a magnetically conductive material with high field saturation, such as a solid core made of soft iron, iron alloy, laminated silicon steel, silicon alloy, glassy metal, iron-cobalt alloy, iron-nickel alloy, powdered metal or ceramic and / or other materials.

[0194] Area A2 is associated with the dimensions of the outer radius R and the outer diameter D.

[0195] The size of the inner radius r may be in the range of 1% to 90% of the size of the outer radius R, or in the range of 2% to 80%, or 3% to 60%, or 4% to 50%, or 8% to 30%, or 20% to 40%, or 30% to 50% of the outer radius R. The sizes of the inner radius r and the outer radius R may be used to achieve a convenient shape for the generated magnetic field.

[0196] The outer diameter D of the magnetic device may be in the range of 30 mm to 250 mm, or 40 mm to 150 mm, or 50 mm to 135 mm, or 90 mm to 125 mm, and the size of the inner radius r may be in the range of 1% to 70%, or 1% to 50%, or 30% to 50%, or 5% to 25%, or 8% to 16% of the size of the outer radius R. For example, the size of the outer radius R may be 50 mm and the dimension r may be 5 mm. The region A1 may be omitted, and the magnetic field generating device may only include the region A2 with the coil windings.

[0197] As discussed, area A2 may include multiple windings. A winding may include one or more wires. The windings may be arranged closely, and one winding may contact an adjacent winding to provide a magnetic field with a high magnetic flux density. Winding area A2 may be 4 cm 2 Up to 790cm 2 、15cm 2 Up to 600cm 2 、45cm 2 Up to 450cm 2 or 80cm 2 Up to 300cm 2 、80cm 2 Up to 150cm 2 or 80cm 2 Up to 130cm 2 within the range.

[0198] Alternatively, the windings may include gaps between individual windings. The gaps may be between 0.01% and 50, or 0.1% and 25%, or 0.1% and 10%, or 0.1% and 5%, or 0.001% and 1% of the dimension Rr. Such a configuration may facilitate cooling and insulation of the individual windings of the magnetic field generating device. In addition, the shape of the generated magnetic field may be modified by such a configuration of the magnetic field generating device.

[0199] The wires of the coil windings may have different cross-sectional areas. The cross-sectional area of ​​the winding wire may be larger at the center of the winding, where the coil winding radius is smaller. Such cross-sectional area of ​​the wire may be 2% to 50%, 5% to 30% or 10% to 20% larger than the cross-sectional area of ​​the same wire (measured on the outer winding turns of the magnetic field generating device), where the coil winding radius is larger. The cross-sectional area of ​​the winding wire of the magnetic field generating device may be larger on the outer coil winding turns of the magnetic field generating device, where the coil winding radius is larger. Such cross-sectional area of ​​the wire may be 2% to 50%, 5% to 30% or 10% to 20% larger than the cross-sectional area of ​​the same wire (measured on the inner turns of the magnetic field generating device), where the coil winding radius is smaller.

[0200] The principles and parameters described above can be used to modify the shape of the provided magnetic field relative to the patient's body, provide more uniform and / or more targeted muscle stimulation (e.g., muscle contraction), reduce the stretching of the magnetic field generating device during treatment, and / or increase the durability of the magnetic field generating device. The magnetic field generating device can stretch and shrink during the generation of the time-varying magnetic field, and this can cause damage to the magnetic field generating device. The different cross-sectional areas of the conductive material used (e.g., the wire, metal strip, or forming windings of the magnetic field generating device) can minimize the destructive effects of expanding and shrinking the magnetic field generating device.

[0201] As discussed above, the cross-sectional area of ​​the conductive material used (e.g., wires, metal strips, and / or forming windings of the magnetic field generating device) may be varied within a range of 2% to 50%, or 5% to 30%, or 10% to 20% between individual loops of the wiring to improve the focusing of the magnetic therapy provided, to increase the durability of the magnetic field generating device, to minimize heating of the magnetic field generating device, and the like.

[0202] Additionally, the stack of wiring and / or insulation and / or expansion layers between the individual conductive windings of the magnetic field generating device may be non-constant and may vary based on wire cross-sectional area, winding radius, shape required to provide a magnetic field and / or other parameters.

[0203] According to the side view of the applicator, Figure 9b The thickness 901 of the illustrated magnetic field generating device 900 may be in the range of 0.3 cm to 6 cm, or 0.5 cm to 5 cm, or 1 cm to 3 cm.

[0204] The total surface area of ​​the surface of the magnetic field generating device (i.e., area A1+A2) can be within 5 cm according to the ground projection of the applicator. 2 Up to 800cm 2 , 10cm 2 Up to 400cm 2 , 20cm 2 Up to 300cm 2 or 50cm 2 Up to 150cm 2 within the range.

[0205] Depending on the ground projection of the applicator, the ratio of area A1 to winding area A2 may be in the range of 0.001 to 0.8, or 0.02 to 0.5, or 0.1 to 0.3. Depending on the ground projection of the applicator, the ratio between the winding area A2 of the magnetic field generating device and the area of ​​the RF electrode located in the same applicator may be in the range of 0.01 to 4, or 0.5 to 3, or 0.5 to 2, or 0.3 to 1, or 0.2 to 0.5, or 0.6 to 1.7, or 0.8 to 1.5, or 0.9 to 1.2.

[0206] Figure 10a to Figure 10g The position of one or more RF electrodes 101 relative to at least one magnetic field generating device 900 in the applicator 800 is shown. The position of the RF electrodes 101, 102 and / or the magnetic field generating device 900 can critically affect the efficiency and targeting of the therapeutic energy source. The RF electrodes and magnetic field generating device can be located within the applicator.

[0207] One or more RF electrodes 101, 102 may be located on the inner side of the applicator 800 (eg, Fig.10a , Fig.10b , Fig.10d , Fig.10e , Fig.10f , Figure 10g ) and / or the outside of the applicator 800 (as shown Fig.10c shown).

[0208] like Figures 10a to 10e and Figure 10g As shown, at least one RF electrode may at least partially overlap with an area A2 or A1 of at least one magnetic field generating device, depending on the ground projection of the applicator. Such an arrangement may allow for optimal synergistic effects of magnetic and RF treatments, may improve the uniformity of tissue heating by RF treatment, may improve the targeting of magnetic and RF treatments, and may also minimize health risks.

[0209] Fig.10a A side view of an applicator is shown, the applicator comprising at least one RF electrode and a magnetic field generating device. The applicator shown may comprise at least one RF electrode 101 which may be located below the magnetic field generating device 900 in the applicator 800 . Fig.10b FIG. 4 shows an upper view of an applicator of the same type, comprising RF electrodes and a magnetic field generating device. Fig.10a and Fig.10b As shown, at least one RF electrode 101 may be extremely thin to reduce undesirable physical effects caused by the time-varying magnetic field. Fig.10b As shown, the at least one RF electrode 101 may almost completely overlap the magnetic field generating device 900 .

[0210] Fig.10c Another exemplary applicator is shown, which includes at least one RF electrode and a magnetic field generating device. Fig.10c , at least one RF electrode 101 may be located outside the applicator 800, such as on or adjacent to an outer surface of the applicator 800. The insulation of the RF electrode outside the applicator is better than the insulation from the magnetic field generating device and / or from other conductive elements of the radiated electromagnetic field of the applicator. Better insulation can reduce the impact of undesirable physical effects induced by the at least one RF electrode 101 through the radiated electromagnetic field and / or the time-varying magnetic field. Fig.10cAs shown, one or more RF electrodes 101 located outside the applicator may also have better contact with the patient's body and thus may improve the operation of the tuned electrical components of the RF circuit. Additionally, delivery of RF therapy to at least one target biological structure of the patient may be enhanced.

[0211] Fig.10d Another exemplary applicator is shown, which includes at least one RF electrode and a magnetic field generating device. At least one RF electrode 101 may be located below the magnetic field generating device 900. The applicator 800 may also include at least one additional RF electrode 102 located above the magnetic field generating device 900, wherein both the RF electrode and the magnetic field generating device may be located in one applicator 800. The first side portion 801 (having at least one curved RF electrode 102 near or on its surface) can be used to treat curved body parts (e.g., at least a portion of the thigh, hip, neck and / or arm). The second side portion 802 (having at least one flat RF electrode 101 near or on its surface) can be used to treat body parts where a flat or nearly flat side of the applicator would be more appropriate, such as the abdominal area or buttocks.

[0212] Fig.10e Shown with Fig.10d A front view of a similar applicator 800 . Fig.10e As shown, the RF electrode 101 may actually be two electrodes 101a and 101b. The electrodes 101a and 101b may be bipolar electrodes. Thus, the applicator may include two bipolar electrodes 101a and 101b below the magnetic field generating device 900.

[0213] Fig.10f Another exemplary applicator 800 is shown, which includes an RF electrode and a magnetic field generating device. The applicator may include one or more RF electrodes 101; depending on the ground projection of the applicator, the RF electrode may have minimal overlap or no overlap with at least one magnetic field generating device 900. The applicator may include two RF electrodes 101, which have no overlap or minimal overlap with the magnetic field generating device.

[0214] Figure 10g Another exemplary applicator 800 is shown, which includes an RF electrode and a magnetic field generating device. The applicator may include at least one RF electrode 101, which may be located above the magnetic field generating device 900. The heating provided by the RF electrode located above the magnetic field generating device may also be provided to the magnetic field generating device itself.

[0215] One or more RF electrodes located on one or more applicators 800 may be placed in contact with the patient. In addition, one or more RF electrodes and / or applicators may be separated from the patient by an air gap, a packing, a dielectric material, an insulating material, a gel, and / or other material.

[0216] One or more RF electrodes 101, 102 and / or magnetic field generating devices 900 within an applicator may be separated from each other by air gaps, printed circuit board materials, insulators, cooling fluids and / or other materials. The distance between the nearest conductive portion of the magnetic field generating device and the nearest RF electrode may be in the range of 0.1 mm to 100 mm, or 0.5 mm to 50 mm, or 1 mm to 50 mm, or 2 mm to 30 mm, or 0.5 mm to 15 mm, or 0.5 mm to 5 mm. The spacing between the magnetic field generating device and the RF electrode may also be provided in the form of an insulating barrier that separates the RF circuit from the magnetic circuit and prevents another therapeutic circuit or another therapeutic energy source from affecting one therapeutic circuit or therapeutic energy source. A magnetic field generating device positioned closer to the patient's body may be able to more effectively and more permeably stimulate and provide a therapeutic effect to at least a portion of at least one target biological structure than a magnetic field generating device at a greater distance from the patient's body.

[0217] The magnetic field generating device and / or one or more RF electrodes included in or on the applicator can be cooled during treatment. The cooling of the magnetic field generating device and / or one or more RF electrodes can be provided by elements based on the Peltier effect and / or by the flow of a cooling fluid (such as air, water, oil and / or fluid) in or near the applicator. The cooling fluid can flow or guide around one or more magnetic field generating devices, one or more RF electrodes, and can flow or guide between at least a portion of the magnetic field generating device and at least one RF electrode. The cooling fluid can flow only on the top and / or bottom of the magnetic field generating device. The cooling fluid can be a fluid, such as a gas, oil, water and / or liquid. The cooling fluid can be delivered to the applicator from the main unit, where the cooling fluid can be thermostated. The cooling fluid can be delivered to the applicator and can be delivered to the vicinity of the magnetic field generating device and / or the RF electrode. The cooling fluid can be delivered to the applicator through a connecting tube connected to the main unit. The connecting tube can include a fluid conduit, which can be used as a path for the cooling fluid between the applicator and the main unit.

[0218] The main unit may include one or more cooling tanks, wherein the cooling fluid may be stored in the cooling tank and / or cooled. Each cooling tank may include one or more pumps, wherein one pump may provide the flow of cooling fluid to an applicator. Alternatively, a pump may provide the flow of cooling fluid to multiple applicators (e.g., two applicators). In addition, the main unit may include a cooling tank that stores and / or cools the cooling fluid for a corresponding applicator or multiple applicators. For example, when the therapeutic device includes two applicators, the main unit may include a cooling tank that provides cooling fluid to the two applicators. In another example, when the therapeutic device includes two applicators, the main unit may include two cooling tanks that provide cooling of the cooling fluid. Each cooling tank may provide the cooling of the cooling fluid to a specific applicator synchronously or individually. The cooling tank or cooling conduit may include a temperature sensor for measuring the temperature of the cooling fluid.

[0219] The fluid conduit may be a plastic tube. The plastic tube may lead from the cooling tank to the applicator and then back to the cooling tank. When the treatment device includes, for example, two applicators, the fluid conduit may lead from the cooling tank to one applicator and then back to the cooling tank, while the second fluid conduit may lead from the same or different cooling tank to the second applicator and then back to the cooling tank. However, the fluid conduit may lead from the cooling tank to the first applicator, then to the second applicator and finally to the cooling tank.

[0220] When the RF electrode is located in the vicinity of the magnetic field generating device, the time-varying magnetic field generated by the magnetic field generating device may induce undesirable physical effects of the RF electrode. Undesirable physical effects induced by the time-varying magnetic field may include, for example, induction of eddy currents, overheating of the RF electrode, skin effects, and / or causing other electronic and / or electromagnetic effects, such as phase shifts of the RF electrode. Such undesirable physical effects may lead to malfunction of the treatment device, loss of energy, reduced treatment effectiveness, increased energy consumption, overheating of at least applicator parts (e.g., RF electrode), collection of erroneous feedback information, signal regulation failure provided to the RF electrode, and / or other undesirable effects.

[0221] The described invention provides options, methods or designs for how to prevent and / or minimize one or more undesirable physical effects induced by a magnetic field in an RF electrode. The same options, methods or designs can help minimize the shielding of the magnetic field by the RF electrode. One option may include the arrangement of the RF electrode; the RF electrode has a minimal overlap or no overlap with the magnetic field generating device according to the ground projection of the applicator. Another option may include a specially designed RF electrode as described below. Another option may include a reduced thickness of the RF electrode. Yet another option may include providing an RF electrode of conductive material that reduces the undesirable physical effects of the RF electrode and the induction of heating. One or more RF electrodes that provide RF energy during treatment by the described treatment device may utilize at least one of these options, at least two options and / or a combination of these options, and its features as described below.

[0222] One option to minimize or eliminate undesirable physical effects induced by the magnetic field in the RF electrodes may include an arrangement of the RF electrodes having minimal or no overlap with the magnetic field generating means depending on the topographical projection of the applicator.

[0223] Fig.11 An example is shown in which the RF electrode 101a can be located below, near and / or above the magnetic field generating device 900 and has no overlap or minimal overlap with the magnetic field generating device 900 according to the ground projection of the applicator. Fig.11 As shown, the electrode 101a may be located outside the area A2.

[0224] Fig.12 Another exemplary applicator is shown, which includes a magnetic field generating device and one or more RF electrodes. The applicator 800 may include two RF electrodes 101a and 101b separated by a gap 113. According to the ground projection of the applicator, the two RF electrodes 101a and / or 101b may at least partially overlap 112 with the winding area A2 and / or area A1 of the magnetic field generating device 900. The partial overlap 112 is achieved by Fig.12 100 %. The ground projection may be represented by a picture of the applicator 800, which is obtained by X-ray from the bottom of the applicator. Such partial overlap 112 may be in the range of 1% to 100%, or 1% to 99%, or 1% to 70%, or 5% to 50%, or 5% to 40%, or 10% to 30%, or 25% to 100%, or 10% to 100%, or 30% to 95%, or 40% to 100%, or 70% to 100%, or 80% to 95%, or 30% to 70% of one RF electrode area, depending on the ground projection of the applicator. The overlap of two areas may refer to the ratio between the two different areas.

[0225] One or more temperature sensors 816a may be located between the bipolar RF electrodes 101a, 101b, such as Fig.12 According to the ground projection of the applicator, one or more temperature sensors 816a may be at least partially surrounded by at least one RF electrode 101a and 101b, as shown. Fig.12 As shown by temperature sensor 816a. The highest amount of RF energy may flow between bipolar electrodes 101a and 101b. Therefore, the body part or portion of the treated tissue between or directly below the bipolar electrodes may have the highest temperature and should be measured as a temperature reference for the actual temperature or the predetermined temperature. However, the temperature sensor may be placed inside the applicator or on the surface of the applicator.

[0226] The characteristic shape of the RF electrode can form a non-uniform temperature distribution of heat during treatment. It is useful to place the temperature sensor 816b in a manner that the temperature sensor is not surrounded by the bipolar electrodes 101a, 101b, so that the temperature sensor 816b is located between the RF bipolar temperature sensor 816b electrodes 101a, 101b. The temperature sensor can be placed inside the applicator or on the surface of the applicator. In addition, the temperature sensor 816c can be located below the RF electrode. The material covering at least a portion of the temperature sensor 816 (e.g., 816a, 816b or 816c) and contacting the patient's body can be made of the same material as the first side portion 801 and / or the second side portion 802. However, the material covering the first side portion 801 or the second side portion 802 of the temperature sensor 816 can be a material different from the rest of the first side portion 801 or the second side portion 802, such as a material with higher thermal conductivity, such as ceramic, titanium, aluminum, or other metal materials or alloys. The temperature sensor 816 may be a thermistor. The temperature sensor 816 (e.g., 816a, 816b, or 816c) may be secured or coupled to the first side portion 801 and / or the second side portion 802 by a thermally conductive material having good thermal conductivity, such as a layer of thermal epoxy. The wire connection between the temperature sensor 816 and the rest of the treatment device may be represented by one, two, or more conductive wires having a diameter in the range of 0.05 mm to 3 mm, or 0.01 mm to 1 mm, or 0.1 mm to 0.5 mm. The wire connection comprising a conductive wire having the described diameter is advantageous due to minimizing heat transfer between the wire and the temperature sensor 816. The thermal conductivity of the wire connection of the temperature sensor 816 is in the range of: 5 W·m -1 ·K -1 Up to 320W·m -1 ·K -1 , or 6W·m -1 ·K -1 Up to 230W·m -1 ·K-1 , or 6W·m -1 ·K -1 Up to 160W·m -1 ·K -1 , or 20W·m -1 ·K -1 Up to 110W·m -1 ·K -1 , or 45W·m -1 ·K -1 Up to 100W·m -1 ·K -1 , or 50W·m -1 ·K -1 Up to 95W·m -1 ·K -1 . The material of the wire connection may be, for example: nickel, monel, platinum, osmium, niobium, potassium, steel, germanium, aluminum, cobalt, magnesium copper, and / or alloys thereof. At least a portion of the wire connection connected to the temperature sensor 816 may be thermally insulated by a sheath or shield (such as by rubber tubing). The temperature sensor 816 may be an optical temperature sensor, such as an infrared IR heat sensor, which may be part of the applicator and / or the main unit. During treatment, the optical temperature sensor may be positioned to contact the patient's skin, or may be within a range of 0.1 cm to 3 cm, or 0.2 cm to 2 cm from the patient's skin. The optical temperature sensor may collect information from the patient's skin via an optical cable.

[0227] One or more RF electrodes positioned below the magnetic field generating device with at least partial overlap can provide a synergistic effect of magnetic therapy and RF therapy. Stronger or more intense treatment results can be provided by RF electrodes that are positioned below the magnetic field generating device with at least partial overlap. The RF field and magnetic field generated from the therapeutic energy source in such a configuration can target the same body part and / or target biological structure. This can result in better heating of the stimulated muscle and adjacent tissue, better suppression of discomfort caused by muscle stimulation (e.g., muscle contraction), better regeneration after treatment, and / or better prevention of over-acidification and other tissue damage.

[0228] Another option for minimizing or eliminating undesirable physical effects induced by the magnetic field in the RF electrodes may include a special design of the RF electrodes.

[0229] As part of the present invention, undesirable physical effects induced by the magnetic field in an RF electrode (which is located near or at least partially overlaps with a magnetic field generating device) can be further minimized or eliminated using a segmented RF electrode. The segmented RF electrode may include gaps, cutouts and / or protrusions. The area of ​​the gaps and / or cutouts may be formed by air, dielectric and / or other electrically insulating materials. The electrode may include various protrusions. Multiple gaps and / or cutouts may be visible from the ground projection of such an electrode. Another parameter that minimizes or eliminates the presence of undesirable physical effects may be the thickness of the RF electrode. If the conductive material of the RF electrode is thin, and the areas of the RF electrode are at least partially separated by an insulator, the eddy current loops induced by the magnetic field may be minimal, and because the induction in such areas is minimized.

[0230] The RF electrode may include one or more slits or cutouts that can segment the conductive area of ​​the RF electrode and / or the periphery of the RF electrode. Thus, compared to a conventional electrode, the RF electrode is segmented by interruptions in the surface area (i.e., an electrode without slits or cutouts). Two or more slits or cutouts of an RF electrode may be asymmetric. One or more slits and cutouts may have, for example, a rectangular or circular shape. The slit may be any hole and / or opening in the electrode area of ​​the RF electrode according to the ground projection of the applicator. The slit and / or cutout may have a regular, irregular, symmetrical and / or asymmetrical shape. The slit and / or cutout may be filled with, for example, air, dielectric and / or other electrically insulating materials (e.g., dielectric materials of a printed circuit board). When the RF electrode includes two or more slits or cutouts, the apertures or cutouts may have the same symmetry points and / or symmetry lines. The distance between two closest points on the borders of two different slits and cutouts of the RF electrode may be in the range of 0.1 mm to 50 mm, or 0.1 mm to 15 mm, or 0.1 mm to 10 mm, or 0.1 mm to 8 mm. When the RF electrode at least partially overlaps the magnetic field generating device, the RF electrode may comprise larger slits and cutouts in a portion of the conductive surface which is closer to the center of the magnetic field generating device.

[0231] Fig.13a An exemplary RF electrode is shown, wherein the RF electrode 101 comprises an electrode region 119a and defines one or more slits 117 in the conductive region of the RF electrode. The slits 117 may be elongated slots having a rectangular shape. One slit 117 may be parallel to the other slits.

[0232] Fig.13b Another exemplary RF electrode is shown, wherein the RF electrode 101 comprises an electrode region 119a and one or more slits 117a and 117b in the conductive region of the RF electrode. The slit 117a is not parallel to the slit 117b.

[0233] Fig.13c Another exemplary RF electrode is shown, wherein the RF electrode 101 comprises an electrode region 119a, and a combination of one or more slits 117 in the conductive region, cutouts 115 in the conductive region, and protrusions 114 of the RF electrode.

[0234] Fig.13d Another exemplary RF electrode is shown, where the RF electrode 101 includes a combination of one or more slits 117 at the conductive region and cutouts 115 in the electrode region. The lines represent thin wires (e.g., a single wire) of the electrode 101 and 119a of the RF electrode. The RF electrode may be a grid of conductive wires or a mesh of conductive wires. The protrusions 114 may define one or more cutouts 115 at the periphery of the electrode.

[0235] Fig.13e Another exemplary RF electrode including protrusions and cutouts is shown. The RF electrode 101 has an electrode area 119a, a boundary length 119b, and a length N shown as # The RF electrode 101 may include at least two, three or five protrusions 114 (e.g., 114a, 114b) or more. The protrusions 114 may be separated from each other by the cutouts 115. Similarly, the RF electrode 101 may include one, two, three or more protrusion cutouts. The first protrusion 114a and the second protrusion 114b of the plurality of protrusions may be arranged substantially parallel to each other. The protrusions 114 may be spaced apart at fixed intervals and may be arranged regularly. The shapes of the protrusions 114a, 114b may be set as rods or pins having a substantially linear shape. The protrusions 114a and 114b may be made of a conductive material. The cutout 115 may be filled with air, a dielectric or other electrically insulating material. The distance between the protrusions is such a distance that at least one circle 118a may be imaginarily inscribed in the cutout 115 and between the two protrusions 114a and 114b. At least one circle 118a may have a diameter in the range of 0.001mm to 30mm, or 0.005mm to 15mm, or 0.01mm to 10mm, or 0.01mm to 8mm, or 0.01mm to 7mm, or 0.01mm to 5mm, or 0.01mm to 3mm, or 0.01mm to 2mm, wherein each circle may have at least one tangent point located on the first protrusion 114a and at least one tangent point located on the second protrusion 114b. Each circle 118a may have different tangent points. The cutout 115 may be symmetrical and / or asymmetrical along its length. The cutout 115 may form a constant distance between protrusions 114a and 114b. The distance between the protrusions 114a and 114b may be non-constant along the length of the protrusions. The minimum distance between the two nearest protrusions 114a, 114b may increase as the protrusion length increases and / or decreases.

[0236] The protrusions 114 or cutouts 115 may have symmetrical, asymmetrical, irregular and / or regular shapes. The size, shape and / or symmetry of the individual protrusions 114 may be the same and / or different across the RF electrode 101. For example, each protrusion 114 may have the same shape, the same size, and / or symmetry.

[0237] The protrusion 114 is characterized by an imaginary inscribed circle 118b directly into the protrusion. The diameter of the imaginary inscribed circle 118b to the protrusion 114 ranges from 0.001 mm to 30 mm, or 0.01 mm to 15 mm, or 0.2 mm to 10 mm, or 0.2 mm to 7 mm, or 0.1 mm to 3 mm006D. The imaginary inscribed circle may not cross the boundary of the inscribed protrusion. The magnetic flux density B measured on at least a portion of the RF electrode surface area may be in the range of 0.1 T to 5 T, or in the range of 0.2 T to 4 T, or in the range of 0.3 T to 3 T, or in the range of 0.5 T to 5 T, or in the range of 0.7 T to 4 T, or in the range of 1 T to 3 T. The magnetic flux density B measured on at least a portion of the RF electrode surface area may be measured during treatment. The RF electrode surface area may include the surface area of ​​the conductive surface of the RF electrode.

[0238] The number of protrusions included in one RF electrode is N # It means the highest possible number of conductive areas electrically insulated from each other, which can be formed between and / or by two parallel slices 111 traversing the surface of the RF electrode. The distance between two parallel slices 111 can be in the range of 1 mm to 50 mm, or 2 mm to 35 mm, or 5 mm to 20 mm. Number of protrusions N # It may be in the range of 5 to 1000, or 10 to 600, or 20 to 400, or 50 to 400, or 100 to 400, or 15 to 200, or 30 to 100, or 40 to 150, or 25 to 75.

[0239] Irrespective of parallel slices 111 , the total number of protrusions in one RF electrode may range from 5 to 1000, or 10 to 600, or 20 to 400, or 50 to 400, or 100 to 400, or 15 to 200, or 30 to 100, or 40 to 150, or 25 to 140.

[0240] Irrespective of parallel slices 111 , the total number of slits or cuts in one RF electrode may range from 5 to 1000, or 10 to 600, or 20 to 400, or 50 to 400, or 100 to 400, or 15 to 200, or 30 to 100, or 40 to 150, or 25 to 140.

[0241] The number of slits, cutouts and / or protrusions in one RF electrode located below the coil comprising the core may be in the range of 5 to 1000, or 10 to 600, or 20 to 400, or 50 to 400, or 100 to 400, or 15 to 200, or 30 to 100, or 40 to 150, or 25 to 140.

[0242] In an area of ​​size 2 cm×1 cm, the number of independent protrusions included in one RF electrode may range from 1 to 8000, or 2 to 8000, or 5 to 8000, or 3 to 5000, or 5 to 1000, or 5 to 500, or 10 to 500, or 5 to 220, or 10 to 100.

[0243] During treatment, the magnetic flux density B and / or the magnitude of the magnetic flux density measured on at least a portion of the RF electrode 101 may be in the range of 0.1T to 5T, 0.2T to 4T, 0.3T to 3T, 0.7T to 5T, 1T to 4T, or 1.5T to 3T. The electrode may be provided with a bump density p according to Equation 1. p To limit,

[0244] Formula 1:

[0245] Where n represents the number of protrusions intersecting the magnetic field lines of magnetic flux density B [T], and l [cm] represents the length of the intersecting magnetic field lines of these protrusions. The length l may be at least 1 cm long, and the magnetic field lines may have a magnetic flux density B [T] of at least 0.3 T or 0.7 T. In at least a portion of the RF electrode, the density of the protrusions may be between 0.3 cm and 1 cm depending on the treatment device. -1 ·T -1 Up to 72cm -1 ·T -1 , or 0.4cm -1 ·T -1 Up to 10cm -1 ·T -1 , or 0.4cm -1 ·T -1 Up to 7cm -1 ·T -1 , or 0.5cm -1 ·T -1 Up to 6cm -1 ·T -1 , or 0.8cm -1 ·T -1 Up to 5.2cm -1 ·T -1 within the range.

[0246] The protrusions can be wider (ie, they can have a greater thickness), where the magnetic flux density is lower, and can be thinner, where the magnetic flux density is higher. In addition, the protrusion density p p Can be higher, where the magnetic flux density is higher.

[0247] Depending on the ground projection of the applicator, the electrode area of ​​one or more RF electrodes in an applicator or an additional treatment device can be within 1 cm 2 Up to 2500cm 2 , or 25cm 2 Up to 800cm 2 , or 30cm 2 Up to 600cm 2 , or 30cm 2 Up to 400cm 2 , or 50cm 2 Up to 300cm 2 , or 40cm 2 Up to 200cm 2 within the range.

[0248] The RF electrode may have a boundary ratio. The boundary ratio may be defined as the ratio between the perimeter and the area of ​​the electrode. Examples of boundary ratios are shown in Fig.13e In the embodiment of the present invention, the perimeter can be described as the border length 119b, and the area of ​​the RF electrode is described by the electrode area 119a of the RF electrode according to the ground projection of the applicator. The electrode area 119a is the area of ​​the RF electrode in the absence of a wire to power the RF electrode and in the absence of the sum of the perimeters of all gaps and / or cuts. The border length 119b is the sum of the perimeter of the electrode and all perimeters of the orifices inscribed inside the electrode, if any. The border ratio of the RF electrode can be 150m -1 Up to 20000m -1 , or 200m -1 Up to 10000m -1 , or 200m -1 Up to 4000m -1 , or 300m -1 Up to 10000m -1 , or 300m -1 Up to 4000m -1 , or 500m -1 Up to 4000m -1 , or 10m -1 Up to 20000m -1 , or 20m -1 Up to 10000m -1 , or 30m -1 Up to 5000m -1 within the range.

[0249] At least one RF electrode may have a magnetic flux density B at a position within 150 m, at least one RF electrode may have a magnetic flux density B at least one portion of the RF electrode surface ... -1 Up to 20000m -1 , or 250m -1 Up to 10000m -1 , or 200m -1 Up to 4000m -1 , or 300m -1 Up to 1000m -1 , or 400m -1 Up to 4000m -1 , or 400m -1 Up to 1200m -1 , or 500m -1 Up to 2000m -1 , or 10m -1 Up to 20000m -1 , or 20m -1 Up to 10000m -1 , or 30m -1 Up to 5000m -1 The ratio of boundaries within the range.

[0250] The ratio between the boundary ratio and the magnetic flux density B on the surface area of ​​the RF electrode may be referred to as the charging ratio. The charging ratio may involve at least 1.5 cm 2 The square surface area of ​​the RF electrode and the magnetic flux density are in the range of 0.1 T to 7 T, or 0.3 T to 5 T, or 0.5 T to 3 T, or 1 T to 5 T, or 1.2 T to 5 T. The charging rate of at least a portion of the RF electrode can be 70 m -1 ·B -1 Up to 30000m -1 ·B -1 , or 100m -1 ·B -1 Up to 5000m -1 ·B -1 , or 100m -1 ·B -1 Up to 2000m -1 ·B -1 , or 120m -1 ·B -1 Up to 1200m -1 ·B -1 , or 120m -1 ·B -1 Up to 600m-1 ·B -1 , or 230m -1 ·B -1 Up to 600m -1 ·B -1 The square surface area of ​​the RF electrode may include a surface area having a square shape.

[0251] Due to the higher boundary ratio and / or charging rate, the induced undesirable physical effects in the RF electrode may be lower, because the RF electrode may include protrusions that are partially insulated from each other. Due to the higher boundary ratio and / or charging rate, the possible imaginary inscribed circle in the protrusion must also be smaller, and thus the loop of the induced eddy current must be smaller. Therefore, the induced eddy current is smaller, and the undesirable physical effects induced in the RF electrode are lower or minimal.

[0252] In one applicator and according to its ground projection, the area on one side of all RF electrodes (ground projection) and the area on one side of all windings of all magnetic field generating devices (such as Figure 9a The ratio between the areas A2) shown may be in the range of 0.1 to 15, or 0.5 to 8, or 0.5 to 4, or 0.5 to 2.

[0253] like Fig.16 As shown, if a protrusion 114 intersects magnetic field lines B1 and B2, where the absolute value of |B1| is higher than the absolute value of |B2| and |B1|-|B2<|0.05T, then the protrusion can be divided into three regions by force lines B1 and B2. In other words, Fig.16 As shown, the protrusion 114 can be divided into three regions S1, S2, S3 having the same length according to the direction of the magnetic field gradient, and S1 is exposed to a magnetic flux density higher than S3. Region S1 can be placed in the highest magnetic flux density, S2 can be placed in the middle magnetic flux density, and S3 can be placed in the lowest magnetic flux density. Compared to the largest inscribed circle k2 having a diameter d2 inscribed in the region S3, the largest imaginary inscribed circle k1 having a diameter d1 inscribed in the region S1 can have a smaller diameter. Compared to the diameter d1, the diameter d2 can be 2% to 1500%, or 5% to 500%, or 10% to 300%, or 10% to 200%, or 10% to 100%, or 5% to 90%, or 20% to 70%, or 5% to 20%. In such a case, the protrusion is thinner, and the magnetic flux density is higher, so as to form a protrusion that is at least partially cone-shaped. Furthermore, the protrusions can be thinner, while the magnetic flux density is higher.

[0254] The RF electrodes may be of different sizes and shapes. According to the present invention, the bipolar electrodes may be parallel electrodes (such as Figures 14a to 14e ), or concentric electrodes (as Figures 15a to 15c shown). Figures 14a to 14e and Figures 15a to 15c The same type of RF electrode 101 shown may be used as RF electrode 102 and / or any other RF electrode or electrodes; RF electrode 101 may be positioned proximate to the second side portion of the applicator and RF electrode 102 positioned proximate to the first side portion.

[0255] The shape and arrangement of the RF electrodes of at least one applicator may be based on the size, shape and symmetry of the body location (anatomy) to which the at least one applicator is attached. The positioning and different shapes of the RF electrodes are beneficial to avoid the formation of hot spots, provide uniform heating of the largest possible treatment body area, and avoid the need to move with one or more applicators.

[0256] Fig.14a An example of a symmetrical positioning of the RF electrodes is shown. Fig.14b Another example of symmetrical positioning of the RF electrodes is shown. Fig.14c A further example of symmetrical positioning of the RF electrodes is shown. Fig.14d A view of an applicator is shown, which includes symmetrical positioning of the RF electrodes. Fig.14e A side view of an applicator is shown, the applicator including an example of symmetrical positioning of the RF electrodes.

[0257] according to Figures 14a to 14e As shown in the example of RF electrodes, the applicator may include at least a pair of parallel bipolar RF electrodes 101a and 101b separated by a gap 113. The RF electrodes are powered by wiring 100a and 100b. Fig.14a , Fig.14b and Fig.14d As shown, the RF electrodes 101a, 101b may be symmetrical and may be mirror images. The shapes of the independent RF electrodes 101a and 101b may be irregular, asymmetrical, and the lengths and / or areas of all protrusions of at least 40%, 50%, 70%, 90% or 99% of one RF electrode may be different. Body anatomy and testing may confirm that this type of RF electrode may provide the most comfortable and effective treatment of body parts, such as the abdominal area, buttocks, arms and / or thighs.

[0258] like Fig.14cAs shown, the RF electrodes 101a, 101b may be at least partially symmetrical according to at least one axis or point of symmetry (such as according to linear symmetry, point symmetry and rotational symmetry). For example, each electrode may be semicircular or C-shaped. In addition, the gap 113 between the RF electrodes 101a and 101b may be irregular and / or may be designed according to at least one axis of symmetry, such as a linear axis of symmetry with mirror symmetry. Therefore, in the case where the electrodes 101a and 101b may be semicircular, the gap 113 may be circular. The use of such symmetrical electrodes may be beneficial for treating a body part, where such symmetry may be necessary to emphasize the symmetry of a body part (e.g., a buttock or thigh).

[0259] The gap 113 between the RF electrodes 101a and 101b may include air, cooling fluid, oil, water, dielectric material, fluid, and / or any other electrical insulator, such as a substrate made of a composite material used for printed circuit boards. The RF electrodes 101a and 101b may be formed of copper foil and / or layers deposited on such a substrate. The gap 113 may affect the shape of the electromagnetic field (e.g., RF field) generated by the RF electrodes, and the penetration depth of the electromagnetic field into the patient's body tissue. In addition, the distance between at least two RF electrodes 101a and 101b may form the gap 113, and the gap 113 may have at least a partially circular, elliptical and / or parabolic shape, such as Fig.14a The gap 113 may have a regular shape for separating the RF electrodes at a constant distance, such as Fig.14b shown.

[0260] The gap 113 between the RF electrodes 101a and 101b may be designed to pass through an amount in the range of 2% to 70%, or 5% to 50%, or 15% to 40% of the magnetic field generated by the magnetic field generating device. The distance between the nearest parts of at least two different RF electrodes in one applicator may be in the range of 0.1 cm to 25 cm, or 0.2 cm to 15 cm, or 2 cm to 10 cm, or 2 cm to 5 cm.

[0261] The gap 113 between the two RF electrodes can be designed in the plane of the RF bipolar electrode, wherein the gap 113 can at least partially overlap the position where the magnetic flux density generated by the magnetic field generating device has the maximum absolute value. The gap 113 can be located at such a position to optimize treatment efficiency and minimize energy loss.

[0262] It should be noted that a strong magnetic field with a high derivative of the magnetic flux density dB / dt can induce undesirable physical effects even in RF electrodes having protrusions, gaps and / or cutouts. The gap 113 can be positioned or located at a location where the absolute value of the magnetic flux density is the largest. As a result, multiple RF electrodes located around the gap 113 can then be affected by a lower amount of magnetic flux density.

[0263] A plurality of RF electrodes (eg, two RF electrodes 101a and 101b) may be located on the substrate 113a, such as Fig.14d As shown. The substrate 113a can be used as a filler for the gap 113 between the RF electrodes and between one or more cutouts 115. Fig.14d and Fig.25 As shown, the base plate 113a and one or more RF electrodes can be bent into a desired shape and / or radius to fit the patient's body part. The RF electrode 101a or 101b can be bent along the lower cover 125 of the applicator 800, in particular along the curved portion 126 of the lower cover 125. Fig.14d As shown, the substrate 113a may define a substrate gap 113b for at least one sensor (such as a temperature sensor). The substrate gap 113b may also allow passage of one or more wires, cooling fluids, and / or for implementing another therapeutic energy source, such as a light therapy energy source (e.g., LED, laser diode) that provides illumination or additional heating of a biological structure and / or body part.

[0264] Fig.15a , Fig.15b and Fig.15c Two RF electrodes 101a and 101b are shown, wherein at least one RF electrode 101a may at least partially surround the other RF electrode 101b. The RF electrodes 101a and 101b may be separated by a gap 113, which may include, for example, a substrate 113a having the same insulating properties as described above with respect to Figures 14a to 14e The RF electrode 101b may include a hole 116 to minimize shielding of the magnetic field and minimize the induction of undesirable physical effects induced by the RF electrode 101b. The hole 116 may be located in the RF electrode plane, where the magnetic flux density of the magnetic field generated by the magnetic field generating device reaches a maximum value during treatment. The hole 116 may be circular, or may have other shapes, such as oval, square, triangle, or rectangle. The area range of the hole 116 may be: 0.05 cm 2 Up to 1000cm 2 , or 0.05cm 2 Up to 100cm 2 , or 3cm 2 Up to 71cm 2 , or 3cm 2 Up to 40cm 2 , or 3cm 2 Up to 20cm 2 , or 3cm 2 Up to 15cm 2 , or 0.5cm 2 Up to 2.5cm 2 The RF electrodes may be fully or partially concentric.

[0265] Fig.15a Two RF electrodes 101a and 101b are shown which may be non-circular and have at least one line and / or point symmetry, and the electrodes 101a and 101b may not have a center of symmetry. The RF electrode 101a may include a hole 116 at its center, where the magnetic flux density is maximum, to minimize the induction of undesirable physical effects of the RF electrode through the magnetic field.

[0266] Fig.15b Two RF electrodes 101a and 101b with rotational symmetry are shown which may have a circular shape. The RF electrodes 101a and 101b may have the same center of symmetry. The RF electrode 101a shown may include a hole 116 at its center, where the magnetic flux density is maximum, to minimize the induction of undesirable physical effects of the RF electrode by the magnetic field.

[0267] Fig.15c Two RF electrodes 101a and 101b are shown which may not have symmetry and have no center of symmetry.

[0268] Another option for minimizing or eliminating undesirable physical effects induced by the RF electrodes via the magnetic field may include reducing the thickness of the RF electrodes.

[0269] The thickness of the conductive layer of the RF electrode of the present invention may be in the range of 0.01 mm to 10 mm, or 0.01 mm to 5 mm, or 0.01 mm to 3 mm, or 0.01 mm to 1 mm, or 0.1 mm to 1 mm, or 0.005 mm to 0.1 mm, or 0.01 mm to 0.2 mm. One type of RF electrode may be designed by a method similar to the preparation of a printed circuit board (PCB), wherein a thin conductive layer may be deposited into a substrate having insulating properties and / or may be deposited on the substrate. The substrate may include one, two or more conductive layers of a material such as an alloy of copper, silver, aluminum, nickel and zinc, austenitic stainless steel and / or other materials to form an RF electrode. The thickness of the substrate material may be in the range of 0.01 mm to 10 mm, or 0.01 mm to 5 mm, or 0.01 mm to 3 mm, or 0.01 mm to 2 mm, or 0.1 mm to 2 mm, or 0.5 mm to 1.5 mm, or 0.05 mm to 1 mm. The substrate material may be a polymer, ceramic, copolymer sheet, phenolic resin layer, epoxy resin layer, fiberglass fabric, other woven fabric, polymer fabric, etc. The substrate may be at least partially flexible and / or rigid.

[0270] The RF electrodes may be a system of thin conductive wires, flat strips, sheets, and the like.

[0271] Yet another option for minimizing or eliminating unwanted physical effects induced by the RF electrodes via magnetic fields may include forming the RF electrodes from a conductive material that reduces unwanted physical effects of the RF electrodes and the induction of heating.

[0272] The RF electrode may be made of a specific conductive material that reduces the induction of unwanted physical effects in the RF electrode. Such materials may have a relative magnetic permeability in the range of 4 to 1,000,000, or 20 to 300,000, or 200 to 250,000, or 300 to 100,000, or 300 to 18,000, or 1,000 to 8,000. The material of the RF electrode may include carbon, aluminum, copper, nickel, cobalt, manganese, zinc, iron, titanium, silver, brass, platinum, palladium, etc., which may form alloys such as multiple alloys, permalloy, electrical steel, ferritic steel, ferrite, stainless steel thereof. In addition, the RF electrode may be made of a fixed powder of mixed metal oxides and / or metal oxides (metal of M metal element) to minimize the induction of eddy currents and heating of the RF electrode and also minimize the energy loss of the time-varying magnetic field.

[0273] The one or more RF electrodes that provide RF energy during treatment by the described treatment device can utilize at least one option, at least two options, or a combination of these options, regarding how to minimize or eliminate the undesirable physical effects induced by the magnetic field, as described above. In addition, one or more features of the options can be used in the manufacture, design, and operation of the treatment device of the present invention.

[0274] The treatment device combining RF treatment and magnetic treatment may include one or more treatment circuits. The treatment circuit for RF treatment may include a power source, an RF electrode and / or all the electrical components described herein for the RF cluster. The treatment circuit for magnetic treatment may include a power source, a magnetic field generating device, and all the electrical components described herein for the magnetic cluster HIFEM. Multiple treatment circuits providing the same or different treatments may include a common power source. Alternatively, each treatment circuit may include its own power source. The operation of all treatment circuits may be adjusted by a host unit or one or more control units. HMI, host voltage and / or one or more control units may be used for the selection, control and / or adjustment of one or more treatment parameters of each applicator and / or each treatment energy source (e.g., RF electrode or magnetic field generating device). The treatment parameters may be individually selected, controlled and / or adjusted by the HMI, host unit and / or one or more control units of each applicator.

[0275] Fig.17Exemplary electrical components of the magnetic circuit 400 are shown. The electrical signal passing through the magnetic circuit 400 may be converted into the form of one or more pulses of the electrical signal. The electrical pulses may be provided to the magnetic field generating device to generate pulses of a time-varying magnetic field. The independent electrical components of the magnetic circuit may be a power source (PS), an energy storage device (ESD), a switch (SW), a magnetic field generating device (MFGD), and a control unit (CUM) of the magnetic circuit. The magnetic circuit may include a treatment cluster for magnetic therapy, referred to as a HIFEM cluster. The HIFEM cluster may include, for example, an ESD, a SW, and / or a CUM. The control unit of the magnetic circuit CUM may be part of a control system. The control unit of the magnetic cluster CUM and / or other electrical components of the magnetic circuit may be slaves of a master unit. The HIFEM cluster, the control system, and / or the CUM may provide or control electrical energy storage in the ESD by controlling the amount of electrical energy stored. The HIFEM cluster, the control system, and / or the CUM may provide modification of electrical signals, adjustment of parameters of electrical signals transmitted through the HIFEM cluster, safe operation of the circuit, and / or charging or recharging of the ESD. For example, the HIFEM cluster or control system can provide adjustment of the magnetic flux density of the magnetic field provided by the MFGD through adjustment of the voltage and / or current of the electrical pulse rate delivered to the MFGD. Modification of the electrical signal can include distortion of the transmitted signal in the magnetic circuit; envelope distortion in the shape, amplitude and / or frequency domain; added noise to the transmitted electrical signal, and / or other degradation of the transmitted original signal entering the magnetic circuit.

[0276] The energy storage device ESD can accumulate electrical energy, which can be provided to the magnetic field generating device in the form of an electrical signal of energy (e.g., in the form of a high-power pulse). The ESD can include one, two, three or more capacitors. The ESD can also include one or more other electrical components, such as safety components, such as voltage sensors, high-voltage indicators and / or discharge resistors, such as Fig.18a As shown. The voltage sensor and the high voltage indicator may provide feedback information to the switch SW and / or to the control unit CUM. In a dangerous situation, a discharge resistor as part of the ESD may provide a discharge of at least one capacitor. The discharge of one or more ESDs may be controlled by the control unit CUM. The released electrical energy of the ESD may be delivered as a high power pulse and / or pulse rate to at least a part of the magnetic circuit, for example to the magnetic field generating device MFGD.

[0277] The capacitance of the energy storage device may be in the range of 5nF ​​to 100mF, or in the range of 25nF to 50mF, or in the range of 100nF to 10mF, or in the range of 1μF to 1mF, or in the range of 5μF to 500μF, or in the range of 10μF to 180μF, or in the range of 20μF to 80μF.

[0278] The energy storage device may be charged in a voltage range of 250V to 50kV, 700V to 5kV, 700V to 3kV, or 1kV to 1.8kV.

[0279] The energy storage device may provide a current pulse rate discharge in the range of 100 A to 5 kA, 200 A to 3 kA, 400 A to 3 kA or 700 A to 2.5 kA. The current may correspond to the value of the peak magnetic flux density generated by the magnetic field generating device.

[0280] By discharging the energy storage device, high power current pulses can be generated with energies in the range of 5 J to 300 J, 10 J to 200 J or 30 J to 150 J.

[0281] The switch SW may include any switching device, such as a diode, a pin diode, a MOSFET, a JFET, an IGBT, a BJT, a thyristor, and / or a combination thereof. The switch may include a pulse rate filter that provides modification of the electrical signal. The pulse rate filter may suppress the switching voltage ripple formed by the switch during ESD discharge.

[0282] The magnetic circuit may command the switch SW to be repeatedly turned on / off and discharge the energy storage device ESD to the magnetic field generating device, such as a coil, to generate a time-varying magnetic field.

[0283] The inductance of the magnetic field generating device may be at most 1 H, or in the range of 1 nH to 500 mH, 1 nH to 50 mH, 50 nH to 10 mH, 500 nH to 1 mH, or in the range of 1 μH to 500 μH or in the range of 10 μH to 60 μH.

[0284] The magnetic field generating device may not emit any radiation (eg gamma radiation).

[0285] The magnetic circuit may include a series connection of a switch SW and a magnetic field generating device. The switch SW and the magnetic field generating device together may be connected in parallel with an energy storage device ESD. The energy storage device ESD may be charged by the power source PS. Thereafter, the energy storage device ESD may be discharged to the magnetic field generating device MFGD by the switch SW. During the second half cycle of the LC resonance, the polarity of the energy storage device ESD may be reversed compared to the power source PS. Thus, twice the voltage of the power source may be present. Therefore, the power source and all parts to which the magnetic circuit is connected may be designed for high voltage loads, and a protection resistor may be placed between the power source and the energy storage device.

[0286] The magnetic field generating device MFGD and the energy storage device ESD may be connected in series. The magnetic field generating device MFGD may be arranged in parallel with the switch SW. The energy storage device ESD may be charged by the magnetic field generating device. To provide an energy pulse for generating a magnetic pulse (or a pulse rate for generating a magnetic pulse rate), a controlled short circuit of the power source occurs via the switch SW. In this way, a high voltage load at the terminals of the power source PS is avoided during the second half period of the LC resonance associated with the known device. During the second half period of the LC resonance, the voltage at the terminals of the power source PS may have a voltage equal to the voltage drop of the switch SW.

[0287] The switch may be any kind of switching device. Depending on the type of switch, the load on the power source may be reduced to a few volts, such as 1 volt to 10 volts. Thus, there is no need to protect the power source from high voltage loads, such as thousands of volts. Thus, the use of protection resistors and protection circuits may be reduced or eliminated.

[0288] Fig.18b Exemplary electrical components of the RF circuit 480 are shown. The RF circuit may provide an adjustment and / or modification of an electromagnetic signal (electrical signal) to an RF electrode (RFE). The RF circuit may include a power source (PS), a treatment cluster for RF treatment (area marked as RF), a control unit (CURF) of the RF cluster, a power amplifier (PA), a separator, a standing wave ratio of a combined power meter (SWR+power meter), a tuning element (tuning), a separator, an insulator, a symmetry element (SYM), a prematcher, and an RF electrode (RFE). The treatment cluster for RF treatment may include, for example, a control unit (CURF) of the RF cluster, a power amplifier (PA), a filter, a standing wave ratio of a combined power meter (SWR+power meter), and / or a tuning element (tuning). The control unit of the RF circuit CURF may be a part of a control system. The control unit of the RF circuit CURF and / or other electrical components of the RF circuit may be slaves of a host unit. One or more electrical components described as parts of the RF circuit may be eliminated, some electrical components may be combined into one with similar functions, and / or some electrical components may be added to improve the functionality of the circuit.

[0289] The power source of the RF circuit may provide an electrical signal with a voltage ranging from 1 V to 5 kV, or 5 V to 140 V, or 10 V to 120 V, or 15 V to 50 V, or 20 V to 50 V.

[0290] The CURF can control the operation of any electrical element of the RF circuit. The CURF can adjust or modify the parameters of the electrical signal transmitted through the RF circuit. The parameters of the signal (e.g., voltage, phase, frequency, envelope, current value, signal amplitude, etc.) can be affected by independent electrical elements of the RF circuit, which can be controlled by the CURF, the control system and / or the electrical properties of the independent electrical elements of the RF circuit. The electrical elements that affect the signal of the RF circuit can be, for example, a power source (PS), a power amplifier (PA), a filter, a SWR+ power meter, a tuning element, a separator, an insulator, a symmetric element (SYM) that changes an unbalanced signal into a balanced signal, a prematcher and / or an RF electrode that generates an RF wave. The modification of the electrical signal may include distortion of the signal transmitted in the RF circuit; envelope distortion in the shape, amplitude and / or frequency domain; increased noise of the transmitted electrical signal, and / or other degradation of the transmitted original signal entering the RF circuit.

[0291] The power amplifier PA may generate an RF signal of a corresponding frequency for generating RF waves through the RF electrode. The power amplifier may be a MOSFET, an LDMOS transistor, or a vacuum tube. The PA may be capable of increasing the amplitude of the provided signal and / or the modified signal for an electrical signal (e.g., an RF signal).

[0292] The filter may include one or more filters that can suppress undesirable frequencies of signals transmitted from the power amplifier. One or more filters can filter and provide treatment with a defined frequency band. According to the signal frequency domain, one or more filters can be used to filter electrical signals (such as electrical signals in RF circuits) to allow only desired frequency bands to pass through. Based on the internal software and / or hardware settings of the filter, the filter may be able to filter out inappropriate signal frequencies. The filter may operate based on communication with one or more other electrical components (e.g., CURF). One or more filters may be located between the power source and RFE of the RF signal PSRF.

[0293] The SWR+ power meter can measure the output power of the RF energy and evaluate multiple impedance matches between the power amplifier and the applicator. The SWR+ power meter may include a SWR meter that measures the standing wave ratio in the direction of wave transmission. The SWR+ power meter may include a power meter that measures the amplitude of such standing waves. The SWR+ power meter may communicate with the CURF and / or tuning elements. The SWR+ power meter can provide feedback information to prevent the formation of standing waves in the patient's body, to provide better signal adjustment through the tuning elements, and to provide safer treatment and energy delivery to biological structures more effectively in a more targeted manner.

[0294] The tuning element may provide an improvement in impedance matching. The tuning element may include, for example, a capacitor, an LC and / or an RLC circuit. The tuning element may provide controlled tuning of the capacitance of an RF circuit system, wherein the RF circuit system includes the independent electrical components of the RF circuit and also includes the patient's currently treated tissue under the influence of the provided RF waves. The tuning of the RF circuit may be provided before and / or during the treatment. The tuning element may also be referred to as an adapter.

[0295] The symmetry element SYM can convert a signal from an unbalanced input to a balanced output. The SYM can be a balancer and / or a balun, including winding a coaxial cable to balance the signal between the RF electrodes. The SYM element can provide signal symmetry between the first and second bipolar RF electrodes, for example, by forming a λ / 2 phase shift of the RF signal guided through the coaxial cable to the first and second bipolar RF electrodes.

[0296] The splitter can separate the RF signal transmitted / delivered by the coaxial cable in the RF circuit. The split signals can have the same phase of each split signal, and / or the split signals can have a constant phase shift from each other. For example, the splitter can provide a portion of the RF signal to a first RF electrode and a second portion of the RF signal to a second RF electrode of a bipolar electrode. The splitter can be shared for one, two or more independent RF circuits, or each RF circuit can have its own splitter.

[0297] The insulator may be combined with the separator and / or may be located before and / or after the separator relative to the transmission of the RF signal to the RF electrode. The insulator may electrically insulate at least a portion of the RF circuit from the magnetic circuit. The insulator may be used to minimize the effect of the magnetic circuit on the RF circuit.

[0298] Prematching devices can be used in devices using coaxial cables. Prematching devices can include small coils, condensers, and / or resistors.

[0299] The RF electrodes (RFE) (used as a source of therapeutic energy) may include one or more monopolar RF electrodes, one or more monopolar RF electrodes, and / or one or more pairs of bipolar RF electrodes.

[0300] The power source PS, power amplifier PA, filters, SWR+power meters, tuning elements, SYMs, separators, isolators and / or prematches of the RF circuit may be at least partially and / or completely replaced by an HF generator, which supplies a high frequency electrical signal to the rest of the circuit (including the RF electrodes).

[0301] Fig.24An example of a symmetric element SYM is shown. An input coaxial cable 130 provides an electrical signal (e.g., an RF signal) to a separator 131, which can separate the RF signal into two branches. The separator 131 can also include an insulating element, such as at least one, two, three or more capacitors connected in series, to form an insulating length in the range of 4mm to 100mm or 20mm to 50mm. The SYM can be established or represented by coaxial cables of different lengths leading to paired bipolar RF electrodes. The length difference between the coaxial cables 132 and 133 of position l1 can be in the range of λ of 0.4 to 0.6 or 0.46 to 0.55, where λ can be the wavelength of the guided RF signal in the coaxial cable 132 and / or the coaxial cable 133. The length of the coaxial cable 132 can be in the range of 1cm to 5m, 5cm to 90cm or 10cm to 50cm. The length of the coaxial cable 132+135b may be within the range of λ / 4±10% or ±5% or a positive integer multiple thereof. The length of the coaxial cable 133 may be within the range of 2m to 12m or 2.2m to 8m. The length of the coaxial cable 133 may be within the range of λ / 2±10% or ±5% plus the length of the cable 132. The length of the coaxial cable 133+135a may be within the range of 3λ / 4±10% or ±5%. In short, the coaxial cable 132+135b is offset from the coaxial cable 133+135a by λ / ±10% or ±5%. The SYM of this part may cause a 180° phase shift of the RF signal, which is delivered to one RF electrode 101a and 101b. The RF electrodes 101a and 101b may be parts of one applicator, or the RF electrode 101a may be a part of the first applicator and the RF electrode 101b may be a part of the second applicator. Connector 134 may be used to connect one or more applicators to the main unit. Item 12 may represent a connecting tube for the applicator. The length of the coaxial cables 135a and 135b in the connecting tube may be in the range of 1m to 6m, or 1.1m to 4m, or λ / 4±10% or ±5%. Mating element 136 may be a conductive connection of the conductive shielding portions of the coaxial cables 135a and 135b. Mating element 136 may have a conductive connection between 0.5cm and 1.5cm. 2 Up to 100cm 2 , 1cm 2 Up to 80cm 2 or 1.5cm 2 Up to 50cm 2 The mating element 136 may include a highly conductive material such as copper, silver, gold, nickel, or aluminum, wherein the impedance of the mating element 136 may be nearly zero. A capacitor, a resistor, and / or an inductor may be placed at the mating element 136 or between the mating element and the electrode.

[0302] The RF circuit and / or magnetic circuit may be at least partially located in one or more applicators. The wire connections between the applicators, additional treatment devices and / or the main unit may also be considered part of the RF circuit and / or magnetic circuit elements due to the impedance, resistivity and / or length of the wire connections. Fig.17 One or more electrical components of the magnetic circuit shown, Fig.18b and Fig.18a The RF circuit shown may be eliminated, may be stored in a different order, and / or two or more electrical components may form a single combined electrical component. Signal conditioning provided to the RF circuit may be provided at least in part by or in another different circuit of the treatment device (e.g., a magnetic circuit, etc.).

[0303] Fig.18a An exemplary schematic diagram of the electrical components of a treatment device is shown. The exemplary schematic diagram includes two independent power sources connected to a power network (PN), including a power source for RF treatment (PSRF) and a power source for magnetic treatment (PSM). PSRF can provide electromagnetic signals to two independent treatment clusters RFA and / or RF B for RF treatment. PSM can provide electromagnetic signals to one or more clusters HIFEMA and / or HIFEM B for magnetic treatment. One or more power sources can also power other parts of the treatment device, such as a human-machine interface (HMI) or a host unit. Each magnetic circuit and / or RF circuit may have its own control unit (CUM A, CUM B and CURF A and CURF B). CURF A and CURF B may be the control units of the RF treatment cluster for RF treatment A (RF A) and the treatment cluster for RF treatment B (RF B).

[0304] The control unit may include one or more PCBs or microprocessors. One or more control units may communicate with each other and / or with a host unit, which may be selected as a host unit for other control units in a master-slave communication. The host unit may be the first or only control unit communicating with the HMI. The host unit may control units CUMA and CUMB. The host unit may be a control unit including one or more PCBs and / or microprocessors. The host unit or control unit A (CUMA) or control unit B (CUM B) may be connected to a human-machine interface. In addition, the host unit may be a human-machine interface HMI, or may be connected to a human-machine interface HMI.

[0305] Fig.18aTwo parts of a treatment device are shown, wherein a first part can provide RF treatment and a second part can provide magnetic treatment. The two parts of the treatment device can be insulated from each other. The treatment device can include one or more electrical components and / or parts of the treatment device insulated from each other in a shielding voltage barrier, distance barrier and / or radiation barrier, and independent circuits. Examples of insulated parts can be found in Fig.18a It is also possible that the individual electrical components of the treatment device can be insulated from at least one part of the treatment device. The insulation of such parts and / or electrical components can be provided by materials with high dielectric constants, by the distance of the individual components and / or electrical components, by a system of capacitors or resistors. In addition, any shielding known from electronics, physics, by aluminum boxes and / or by other means can be used.

[0306] RF therapy and / or magnetic therapy may be provided by at least one, two, three, four or more therapy circuits (which may be located in the main unit) and / or applicators, wherein one therapy circuit may include an RF cluster or a magnetic cluster. Each applicator A and B (APA and APB) may include at least one electrical element of one, two or more therapy circuits. Each applicator may include at least one, two or more different therapy energy sources, such as one or more RF electrodes for providing RF therapy and one or more magnetic field generating devices for providing magnetic therapy. Fig.18a As shown, the treatment device may include a first applicator (AP A) and a second applicator (AP B). The first applicator (AP A) may include a first RF electrode (RFE A) of a first RF circuit and a first magnetic field generating device (MFGD A) of a first magnetic circuit. The second applicator (AP B) may include a second RF electrode (RFE B) of a second RF circuit and a second magnetic field generating device (MFGD B) of a second magnetic circuit. In different examples, the first applicator may include a first magnetic field generating device and a first pair of bipolar RF electrodes, and the second applicator may include a second magnetic field generating device and a second pair of bipolar RF electrodes. The two applicators may be separately connected to the main unit and may be independently positioned near the body part before or during treatment, at which time they are connected to the body part and contact the body part.

[0307] Fig.18aOther independent parts of the treatment device are also shown, such as a treatment cluster for RF treatment (RF A), a treatment cluster for RF treatment (RF B), a treatment cluster HIFEMA for magnetic treatment in a magnetic circuit, a treatment cluster HIFEM B for magnetic treatment, a power source for RF treatment (PSRF), a power source for magnetic treatment (PSM), an applicator A (APA), an applicator B (AP B). All parts (except the applicator) can be located in the main unit. The separator, symmetric element (SYMA) and symmetric element (SYM B) shown are parts of two RF circuits. Fig.18a The separator shown may be common to the RF circuit. The power source (PSRF) for RF therapy may include a steady-state power source (SPSRF) for the RF circuit, an auxiliary power source (APS RF) for the RF circuit, a power network filter PNFLT and / or a power unit (PU). Independent electrical components may not be included in the PSRF together with other electrical components. The power source for magnetic therapy (PSM) may include an auxiliary power source A (APS A), an auxiliary power source B (APS B), a steady-state power source (SPSM) for the magnetic circuit, a power pump (PP), a plate power source A (BPS A) and / or a plate power source B (BPS B). Independent electrical components may not be included in the PSM together with other electrical components. The treatment cluster HIFEMA for magnetic therapy of the magnetic circuit may include a control unit A (CUMA), an energy storage device A (ESDA), a switch A (SWA), a safety element (SE) and / or a pulse rate filter (PF). The therapy cluster HIFEM B of the magnetic circuit for magnetic therapy may include a control unit B (CUM B), an energy storage device B (ESDA) and / or a switch B (SWA). Fig.18a Not shown, but the treatment cluster HIFEM B for magnetic treatment may also include a pulse filter (PF) and / or a safety element (SE). Independent electrical components may be insulated from each other. However, independent electrical components and / or circuit parts may be merged and / or shared with other circuit parts. As an example, one control unit may be at least partially shared with two or more RF circuits and / or magnetic circuits, and one control unit may regulate the power or power network or power source (providing power to the RF circuits as well as the magnetic circuits). Another example may be at least one auxiliary power source and / or steady-state power source shared with at least two RF and / or magnetic circuits.

[0308] The treatment cluster HIFEM A for magnetic treatment may provide magnetic treatment independently of the treatment cluster HIFEM B for magnetic treatment. Alternatively, the treatment device may include only one treatment cluster HIFEM for magnetic treatment, or the treatment device may include two or more independent treatment clusters for magnetic treatment, wherein some treatment clusters HIFEM for magnetic treatment may share independent electrical components, such as control units, energy storage devices, pulse rate filters, etc.

[0309] like Fig.18a As shown, a treatment cluster HIFEM (e.g., HIFEMA) for magnetic treatment may include a control unit, such as CUMA. The control unit (e.g., CUMA) may control the charging and / or discharging of an energy storage device (e.g., ESD A), process feedback information, and / or adjust parameters of independent electrical components and / or treatment cluster HIFEM for magnetic treatment. In addition, the control unit (e.g., CUMA) may control: adjusting parameters or operations of electrical components (e.g., BPS A of circuit part PSM, switches, PF, ESDA of treatment cluster HIFEMA for magnetic treatment), and / or process information of sensors in applicator APA and / or AP B. The control unit (e.g., CUMA) may also communicate with one or more other magnetic and / or RF circuits, and / or include a host unit. The power source PSM, the energy storage device ESD, and / or the switch SW may be at least partially adjusted by the control unit of the magnetic circuit (e.g., CUMA). The control unit (e.g., CUMA) or the host unit and / or one or more independent electrical components of the circuit may be adjusted by any other electrical components based on mutual communication between them. Based on feedback information provided from the sensors and / or based on communication with other control units (e.g., a host unit), the host unit may be able to adjust treatment parameters for magnetic therapy and / or RF therapy. One control unit CUM or CURF may individually adjust one or more circuits that provide magnetic and / or RF therapy. At least one control unit may utilize peer-to-peer communication and / or master-slave communication with other control units (e.g., CUMA may be a slave control unit of the host unit).

[0310] The treatment device may include one, two, three or more ESDs, wherein each ESD may include one, two, three or more capacitors. One ESD may provide energy to one, two, three or more treatment energy sources, such as a magnetic field generating device that provides magnetic treatment. Each coil may be connected to its own corresponding ESD or more than one ESD. The ESD may include one or more other electrical components, such as safety elements SE, such as voltage sensors, high voltage indicators and / or discharge resistors, such as Fig.18aAs shown. The voltage sensor and the high voltage indicator may provide feedback information to the switch SW and / or a control unit, such as CUMA. In dangerous situations, a discharge resistor as part of the SE may provide discharge of at least one capacitor. The discharge of one or more ESDs may be controlled by a control unit (e.g., CUMA or CUMB). The signal provided from the energy storage device ESD to the magnetic field generating device via the switch SW may be modified by a pulse rate filter (PF). The PF may be part of the switch SW and / or may be located between the switch SW and the magnetic field generating device (e.g., MFGDA). The PF may suppress the switching voltage ripple formed by the switch during the discharge of the ESD. The proposed circuit may repeatedly turn on / off the switch SW and discharge the energy storage device ESD to the magnetic field generating device (e.g., MGFDA) to generate a time-varying magnetic field. As Fig.18a As shown, one or more electrical components of the magnetic circuit and / or RF circuit may be omitted and / or combined into one. For example, one or more independent electrical components of the PSRF and / or PSM may be combined into one, but the independence of the independent circuits may be reduced. In addition, the electrical components, PF, SE, etc. may be independent electrical components. In addition, the independent treatment circuits (e.g., RF circuits) may be different from each other, such as Fig.18a and Fig.18b It can be seen that electrical components (such as filters, SWR+power meters, tuning elements, separators, isolators, SYMs, and / or pre-matchers) can be eliminated and / or combined into one. The elimination and / or combination of independent electrical components can result in reduced efficiency of energy transfer to the patient's body (no tuning elements), higher energy losses (due to the absence of SYMs, pre-matchers, and / or tuning elements), signal adjustment failures in the circuit, and incorrect feedback information (no SWR+power meters, separators, and isolators); and / or in the absence of SWR+power meters, SYMs, and / or tuning elements, the therapeutic device can be dangerous to the patient.

[0311] The control units CUMA and CUM B can be used as slaves of the host unit, which can command both the control units CUMA and CUM B to discharge current to the corresponding magnetic field generating devices (e.g., MFGDA and MFGDB). Therefore, the control of each control unit CUMA and CUM B is independent. Alternatively, CUM B can be a slave of CUMA, and CUMA itself can be a slave of the host unit. Therefore, when the host unit commands CUMA to discharge current into the magnetic field generating device (e.g., MFGDA), CUMA can command CUM B to discharge current to another magnetic field generating device (e.g., MFGDB) located in a different applicator. In another alternative form, an additional control unit may be located between the host unit and the control units CUMA and CUM B, wherein such additional control unit can provide, for example, the timing of the discharge. By these two methods, the pulse rate of the magnetic field can be applied synchronously or simultaneously.

[0312] When the treatment device comprises more than one magnetic field generating device and the treatment method comprises utilizing more than one magnetic field generating device (e.g., coil), each coil may be connected to a respective magnetic circuit. However, one coil may be connected to multiple magnetic circuits. In addition, the power source PSM may be used for at least two magnetic field generating devices.

[0313] The power source (e.g., PSM and / or PSRF) can provide electrical energy to at least one of the RF circuit, the magnetic circuit, or at least one independent electrical component, and / or to another part of the treatment device, such as a host unit, an HMI, an energy storage device (e.g., ESD A and / or ESD B), a control unit (e.g., CUMA and / or CUMB), and / or a switch (e.g., SWA or SWB). The power source may include one or more components that convert electrical energy from a power network connection PN, such as Fig.18a Some of the individual electrical components of the power source, RF circuit and / or magnetic circuit may be constructed as a common electrical component and need not be constructed as Fig.18a Each RF and / or magnetic circuit may have its own power source and / or at least one electrical element of a power source, which powers only one of the RF and / or magnetic circuits. Additionally, at least a portion of one power source may power at least two different circuits before and / or during at least a portion of the treatment. A power source may include one or more portions shared with independent electrical circuits, which may be at least partially electrically isolated from each other.

[0314] One or more electrical components of a power source for RF therapy (e.g., a steady state power source (SPSM) for a magnetic circuit, an auxiliary power source APS A and / or APS B, a power pump PP, a board power supply BPS A and / or BPS B) may provide electrical energy directly and / or indirectly to independent electrical components of the RF circuit and / or the magnetic circuit. The directly provided electrical energy is provided by a conductive connection between two electrical components, wherein the other electrical components of the circuit are not connected in series to the directly powered electrical component. The insulation and / or other electrical components of the circuit (such as resistors, insulating capacitors, etc.) may not be considered electrical components. The indirectly powered electrical component may be powered by one or more other components, which provide electrical energy through any other component, and any other component may change the parameters of the provided electrical energy, such as current value, frequency, phase, amplitude, etc.

[0315] Fig.18a The power source PSM shown in more detail may include a connection to a power network PN. The PN may provide filtering and / or other adjustments of the input electrical signals to the power network, such as frequency and current value. The PN may also serve as an insulating element that forms a barrier between the treatment device and the power network. The PN may include one or more of a capacitor, a resistor and / or a filter that filters the signal returned from the treatment device. The PN may include a plug or a connection to a plug. The PN may be connected to a plug or a power grid. The PSM may include one or more steady-state power sources (e.g., a steady-state power source SPSM for a magnetic circuit), an auxiliary power source (e.g., APS A and / or APS B), one or more power pumps PP, and / or one or more plate power sources (e.g., BPS A and / or BPS B). As Fig.18a As shown, the treatment device may include at least two electrically isolated magnetic and / or RF circuits, which may be at least partially individually controllable, for example, the strength of the magnetic field generated by the magnetic field generating devices MFGDA and MFGDB connected to the treatment clusters HIFEMA and HIFEM B for magnetic treatment may be different. Under different power network conditions, the steady-state power source (SPSM) can provide a steady-state output voltage. The steady-state power source SPSM may be connected to an auxiliary power source (e.g., APSA and / or APS B). The two auxiliary power sources may be combined and form an electrical component. The steady-state output voltage generated by the steady-state power source and / or the auxiliary power source may be in the range of 1V to 1000V, or 20V to 140V, or 50V to 700V, or 120V to 500V, or 240V to 450V.

[0316] One or more auxiliary power sources can supply energy to one or more control units of the independent circuits. The APS can also supply energy to one or more plate power sources BPS (e.g., BPSA and / or BPS B). The APS can also supply energy to the host unit HMI and / or other components of the treatment device. Due to the APS, at least one control unit and / or the host unit can accurately and individually provide processing / adjustment of electrical signals in the RF and / or magnetic circuits, and / or the independent electrical components of the treatment device can also be protected from overload. The plate power source (e.g., element BPS A and / or BPS B) can be used as a source of electrical energy for at least one element of the magnetic circuit (e.g., energy storage device ESDA and / or B). Alternatively, one or more elements of the power source PSM can be combined and / or eliminated.

[0317] The power source can be used as a high voltage generator that provides voltage to the magnetic circuit and / or the RF circuit. The voltage provided by the power source can be in the range of 500V to 50kV, or 700V to 5kV, or 700V to 3kV, or 1kV to 1.8kV. The power source is capable of delivering sufficient amounts of electrical energy to each circuit, such as to any electrical element (e.g., energy storage device ESDA) and magnetic field generating device (e.g., MFGDA). The magnetic field generating device can repeatedly generate a time-varying magnetic field with parameters sufficient to cause muscle contraction.

[0318] according to Fig.18a , the RF circuit has its own power source PSRF, which may be at least partially different from the PSM. The PSRF may include an electrical element PNFLT, which suppresses electromagnetic radiation from internal parts of the PN and / or any parts of the RF circuit. The electrical element PNFLT may represent a power network filter. However, the PNFLT may also be a part of the PN. The PSRF may include an SPSRF, which provides a steady-state output voltage to an auxiliary power source APS RF of the RF circuit, a control unit of the RF circuit, a power unit PU, and / or other electrical elements using a DC source under different power network conditions. Fig.18a As further shown, the APS RF may include its own mechanism that converts AC into DC independently of the SPSRF. The APS RF may be capable of supplying power to the control unit and / or the host unit of the treatment cluster RF A for RF therapy, while the SPSRF may supply power to the control unit of the treatment cluster RF B for RF therapy alone. The power unit PU of the RF circuit may supply power to one or more RF circuits or at least one electrical element of the RF circuit, such as a power amplifier and / or other electrical elements of the treatment cluster RF A for RF therapy and / or the treatment cluster RF B for RF therapy, thereby forming and / or adjusting a high frequency signal.

[0319] At least one electrical element described as PSM, PSRF, APS, SPSM and / or SPSRF may be shared by at least one RF circuit and a magnetic circuit.

[0320] The control unit CURF can act as a slave of the host unit, which can command the CURF to provide an RF signal to the RF electrode through the RF circuit. In the case of two control units CURF, the control unit acts as a slave of the host unit, which can command the two control units CURF to provide RF signals to the corresponding RF electrodes. Therefore, each control unit is independent from the control of multiple CURFs. Alternatively, the first CURF can be a slave of the second CURF, and the first CURF itself can be a slave of the host unit. Therefore, when the host unit commands the first CURF to discharge current to the first RF electrode, the first CURF can command the second CURF to discharge current to the second RF electrode located in a different applicator. In another alternative form, an additional control unit may be located between the host unit and multiple control units CURF, wherein such additional control units can provide, for example, the timing of discharge. Through these two principles, the pulse rate of the RF field can be applied continuously or in a pulsed manner.

[0321] Fig.17 , Fig.18a and Fig.18b The treatment clusters HIFEM A and HIFEM B shown for magnetic treatment can be controlled by one or more sliders or scrollers associated with an HMI part labeled Figure 7 HIFEM A and HIFEM B are shown. The user may control or adjust the operating speed of one or more electrical elements of the treatment cluster HIFEM A and / or HIFEM B for magnetic treatment via the associated intensity scroller, intensity bar and / or intensity slider shown on the human machine interface HMI.

[0322] in addition, Fig.17 , Fig.18a and Fig.18b The treatment cluster RF A for RF treatment and the treatment cluster RF B for RF treatment shown can be controlled by a slider, bar or intensity scroller associated with an HMI part labeled Figure 7 RF A and RF B 712 are shown. By means of the associated intensity scrollers, intensity bars and / or intensity sliders shown on the human machine interface HMI, the user can control or adjust the speed of operation of one or more electrical elements of the treatment clusters RF A and / or RF B for RF treatment. In addition, by utilizing the associated intensity scrollers, intensity bars and / or intensity sliders, the user can control or adjust the speed of transmission of electrical signals through or between the treatment clusters RF A or RF B for RF treatment.

[0323] The treatment device may include two or more applicators, each of which may include a magnetic field generating device and one or two RF electrodes. The inductance of the first magnetic field generating device located in the first applicator may be equivalent to the inductance of the second magnetic field generating device located in the second applicator. In addition, the number of turns, winding area and / or winding-free area of ​​the first magnetic field generating device in the first applicator may be equivalent to the number of turns, winding area and / or winding-free area of ​​the second magnetic field generating device in the second applicator. The first magnetic field generating device in the first applicator can provide a magnetic field equivalent to the second magnetic field generating device in the second applicator. The equivalent magnetic field provided by multiple magnetic field generating devices during the same or other treatment phases may have the same treatment parameters, such as the number of sequence pulse rates, the number of burst pulse rates, the same amplitude of the magnetic flux density of the pulse, the same envelope shape, and the like. However, in the equivalent magnetic field, reasonable deviations in the amplitude of the magnetic flux seal, for example, may be tolerated. The amplitude deviation of the magnetic flux density or the average magnetic flux density as measured by a fluxmeter or oscilloscope may be in the range of 0.1% to 10% or 0.1% to 5%.

[0324] Alternatively, the inductance of the magnetic field generating devices in the two applicators may be different. Additionally, the magnetic fields provided by the multiple magnetic field generating devices during the same or other treatment phases may have different treatment parameters.

[0325] When the treatment device has two or more applicators, each applicator may include a magnetic field generating device and one or two RF electrodes. The size or area of ​​one RF electrode located in the first applicator may be equivalent to the other RF electrode position in the second applicator. The first applicator and the second applicator may provide an identical RF field provided during the same or other treatment phases, wherein the identical RF field may have the same treatment parameters, such as wavelength, phase, time period, and intensity of the RF field.

[0326] Alternatively, the area size of the RF electrodes in the two applicators may be different.In addition, the magnetic fields provided by the multiple magnetic field generating devices during the same or other treatment sessions may have different treatment parameters.

[0327] Fig.19 An exemplary composition of a magnetic field (eg, a time-varying magnetic field) provided by a magnetic field generating device is shown. In addition, Fig.19 The composition of the RF field can also be shown. Fig.19In the description of the present invention, the term "pulse" may refer to a "magnetic pulse" or an "RF pulse". Similarly, the term "pulse rate" may refer to a "magnetic pulse rate" or an "RF pulse rate". In addition, the term "sequence" may refer to a "magnetic sequence". The term "magnetic sequence" may include a sequence of magnetic pulses, wherein a sequence of magnetic pulses may be understood as a plurality of magnetic successive pulses, wherein one pulse follows another pulse rate. Since a magnetic pulse may include one magnetic pulse, the term "magnetic sequence" may also include a sequence of magnetic pulses. The term "burst" may refer to a "magnetic burst".

[0328] like Fig.19 As shown, a pulse may refer to a period of time during which therapeutic energy (e.g., a magnetic field) is applied with sufficient intensity to cause at least a partial therapeutic effect, such as at least partial muscle contraction, muscle contraction, temperature change of a biological structure, and / or neural stimulation. Magnetic pulses may include, for example, Fig.19 A bi-phase shape is shown. The magnetic pulse may include the magnitude of the magnetic flux density.

[0329] The magnetic pulse rate may refer to a time period that includes pulses and passive time periods of the pulse rate. The magnetic pulse rate may refer to the time period of one magnetic pulse and the passive time period, i.e., the duration between two pulses from a rising / falling edge to a consecutive rising / falling edge. The passive duration of the pulse rate may include no therapeutic energy being applied to the patient's body, and / or insufficient therapeutic energy being applied to cause at least a partial therapeutic effect due to insufficient therapeutic energy intensity (e.g., magnetic flux density) and / or frequency of the delivered therapeutic energy. Such time periods may be referred to as pulse rate durations. Fig.19 As shown, each pulse rate may include a biphasic duration period, referred to as the pulse duration. Alternatively, the pulse or pulse rate may be monophasic.

[0330] like Fig.19 As further shown, the plurality of pulse rates may form a sequence. A sequence may refer to a plurality of pulse rates, wherein a sequence may include at least two pulse rates, wherein the pulse rates follow each other. The sequence may be continuous Fig.19 The duration period T1 is shown.

[0331] The magnetic sequence may include a plurality of magnetic pulse rates ranging from 2 magnetic pulse rates to 200,000 magnetic pulse rates, or from 2 magnetic pulse rates to 150,000 pulse rates, or from 2 magnetic pulse rates to 100,000 magnetic pulse rates. The magnetic sequence may induce at least partial muscle contraction or muscle contraction, at least one incomplete tonic muscle contraction, at least one hypercontraction, or at least one complete tonic muscle contraction, one by one, multiple times. During the application of a sequence, the magnetic field may provide a muscle contraction followed by muscle relaxation. During the application of a sequence, muscle relaxation may be followed by another muscle contraction. During a sequence, a muscle work cycle (which may include muscle contraction followed by muscle relaxation) may be repeated at least two, three, four, or more times.

[0332] A burst may refer to a sequence provided during a time period T1 and a time period T2, and the time period T2 may represent a time period when no therapeutic effect is induced. The time period T2 may be a time period for providing passive treatment, wherein the therapeutic energy is not applied to the patient's body and / or the applied therapeutic energy is insufficient to induce a therapeutic effect. Fig.19 The illustrated time period T3 may represent continued application of the burst.

[0333] The magnetic sequence of time-varying magnetic fields may be followed by a static magnetic field, and / or the magnetic sequence may be followed by a time-varying magnetic field of a frequency and / or magnetic flux density that is insufficient to cause at least partial muscle contraction or muscle contraction. For example, a burst may provide at least one at least partial muscle contraction followed by no muscle contraction. In another example, a burst provides at least one muscle contraction followed by no muscle contraction. Treatment may include a number of magnetic bursts in the range of 15 to 25,000, or in the range of 40 to 10,000, or in the range of 75 to 2,500, or in the range of 150 to 1,500, or in the range of 300 to 750, or up to 100,000. The repetition rate of successive bursts may be incrementally increased / decreased in increments of 1 Hz to 200 Hz, or 2 Hz to 20 Hz, or 5 Hz to 15 Hz, or more than 5 Hz. Alternatively, the amplitude of the magnetic flux density may be varied in successive bursts, such as incrementally increased / decreased in increments of at least 1%, 2%, or 5% or more of the previous pulse rate frequency. During one burst of application, the magnetic field may provide one muscle contraction followed by muscle relaxation. During the same burst of application, muscle relaxation may be followed by another muscle contraction. During one burst, the muscle work cycle (which may include muscle contraction followed by muscle relaxation) may be repeated at least two, three, four or more times.

[0334] Additionally, the treatment duty cycle may be associated with the application of pulsed treatment energy of the magnetic field, such as Fig.19 The treatment duty cycle may refer to the ratio between the time of active treatment T1 and the sum of the time of active and passive treatment during a period T3.

[0335] An exemplary treatment duty cycle is shown in Fig.19 A duty cycle of 10% means that the active treatment T1 lasts 2 seconds and the passive treatment T2 lasts 18 seconds. In this exemplary treatment, the period T3 including active and passive treatment lasts 20 seconds. The treatment duty cycle can be defined as the ratio between T1 and T3. The therapeutic duty cycle may be in the range of 1:100 (which means 1%) to 24:25 (which means 96%), or 1:50 (which means 2%) to 4:6 (which means 67%), or 1:50 (which means 2%) to 1:2 (which means 50%), or 1:50 to 1:3 (which means 33%), or 1:50 (which means 2%) to 1:4 (which means 25%), or 1:20 (which means 5%) to 1:8 (which means 12.5%), or 1:100 (which means 1%) to 1:8 (which means 12.5%), or at least 1:4 (which means at least 25%).

[0336] An exemplary application of a burst repetition rate of 4 Hz may be a time-varying magnetic field applied to a patient with a repetition rate of 200 Hz and a therapeutic duty cycle of 50% in a sequence lasting 125 ms, i.e., each sequence includes 25 pulses. An alternative exemplary application of a burst repetition rate of 6 bursts per minute may be a time-varying magnetic field applied to a patient with a repetition rate of 1 Hz and a therapeutic duty cycle of 30% in a sequence lasting 3 s, i.e., each sequence includes 3 pulses.

[0337] Fig.19 An exemplary composition of the sequence components provided by the RF electrodes may also be shown.

[0338] When the treatment device utilizes multiple applicators (e.g., two), each applicator may include a magnetic field generating device. Since each magnetic field generating device can provide a corresponding magnetic field, the multiple applicators may include different magnetic fields. In this case, the magnitude of the magnetic flux density of the magnetic pulses or pulse rates may be the same or different, as specified by the user through the HMI and / or by one or more control units.

[0339] A pulse of one magnetic field provided by one magnetic field generating device (e.g., a magnetic coil) may be generated and applied synchronously with a pulse of another magnetic field provided by another magnetic field generating device. During a treatment phase with a treatment device including two magnetic field generating devices, a pulse of one magnetic field provided by one magnetic field generating device may be generated synchronously with a pulse of a second magnetic field provided by a second magnetic field generating device. Synchronous generation may include simultaneous generation.

[0340] The synchronized generation of magnetic pulses may be provided by synchronized operation of switches, energy storage devices, magnetic field generating devices, and / or other electrical components of the plurality of magnetic therapy circuits. However, the synchronized operation of the electrical components of the magnetic therapy circuits may be commanded, adjusted, or controlled by a user via an HMI, a host unit, and / or a plurality of control units.

[0341] Fig.27a The simultaneous type of synchronous generation of magnetic pulses of two exemplary magnetic field generating devices is shown. Magnetic field generating device A (MFGD A) can generate a first magnetic field, which includes a plurality of biphasic magnetic pulses 271a. Magnetic field generating device B (MFGD B) can generate a second magnetic field, which includes a plurality of magnetic pulses 271b. The magnetic pulses of the two magnetic fields are generated during the pulse duration 272 of the magnetic pulse 271a of the first magnetic field. In addition, the pulses of the two magnetic fields are generated within the pulse duration 273 of the first magnetic field. The simultaneous generation of magnetic fields means that the magnetic pulses 271a of the first time-varying magnetic field are generated at the same time as the magnetic pulses 271b of the second time-varying magnetic field.

[0342] The synchronous generation of the magnetic field may include generating a first pulse rate of the first time-varying magnetic field so that the first pulse rate lasts for a certain period of time, wherein the period of time lasts from the start of the first pulse of the first time-varying magnetic field to the start of the next consecutive pulse of the first time-varying magnetic field; and generating a second pulse rate of the second time-varying magnetic field by a second magnetic field generating device so that the second pulse rate lasts from the start of the first pulse of the second time-varying magnetic field to the start of the next consecutive pulse of the second time-varying magnetic field. The synchronous generation of the magnetic field means that the first pulse of the second time-varying magnetic field is generated during the period of the first pulse rate.

[0343] Figure 27b An example of synchronous generation of magnetic pulses is shown. Magnetic field generating device A (MFGDA) may generate a first magnetic field including a plurality of biphasic magnetic pulses 271a. Magnetic field generating device B (MFGD B) may generate a second magnetic field including a plurality of magnetic pulses 271b. Magnetic pulses 271b of the second magnetic field may be generated during a pulse duration 273 of the pulse rate of the first magnetic field, but outside of a pulse duration 272 of the pulses of the first magnetic field.

[0344] Fig.27cAnother example of synchronous generation of magnetic pulses is shown. Magnetic field generating device A (MFGD A) may generate a first magnetic field including a plurality of biphasic magnetic pulses 271a. Magnetic field generating device B (MFGD B) may generate a second magnetic field including a plurality of magnetic pulses 271b. Magnetic pulses 271b of the second magnetic field may be generated during a pulse duration 273 of the pulse rate of the first magnetic field. Additionally, magnetic pulses 271b of the second magnetic field may be generated during a pulse duration 272 of the pulse rate of the first magnetic field. The start of magnetic pulses 271b of the second magnetic field may be spaced from the start of pulses 271a of the first magnetic field by a period of time referred to as a pulse offset 274. The pulse offset may be in the range of 5μs to 10ms, or 5μs to 1000μs, or 1μs to 800μs.

[0345] Fig.27d Yet another example of synchronous generation of magnetic pulses is shown. Magnetic field generating device A (MFGDA) may generate a first magnetic field comprising a plurality of biphasic magnetic pulses 271a. Magnetic field generating device B (MFGDB) may generate a second magnetic field comprising a plurality of magnetic pulses 271b. Magnetic pulses 271b of the second magnetic field may be generated within a pulse duration 273 of the pulse rate of the first magnetic field. Magnetic pulses 271b of the second magnetic field may be generated outside of a pulse duration 272 of the pulses of the first magnetic field. The start of magnetic pulses 271b of the second magnetic field may be spaced from the end of magnetic pulses 271a of the first magnetic field by a time period referred to as a pulse distance period 275. The pulse distance period may last in the range of 5μs to 10ms, or 5μs to 1000μs, or 1μs to 800μs.

[0346] In addition to synchronous generation, magnetic pulses of multiple magnetic fields may also be generated individually. The individual generation of magnetic pulses of magnetic fields may include the generation of pulses of one magnetic field that are generated outside of the pulse rate duration of another magnetic field.

[0347] Fig.27eAn example of separate generation of magnetic pulses is shown. Magnetic field generating device A may generate a first magnetic field comprising a sequence of biphasic magnetic pulses 271a having a pulse duration 272a. Each magnetic pulse 271a is a portion of a pulse having a pulse duration 273a. The pulse duration 272a of the first magnetic field may be a portion of the pulse duration 273a of the first magnetic field. The sequence of the first magnetic field may have a sequence duration 276a. Magnetic field generating device B may generate another magnetic field comprising another sequence of multiple magnetic pulses 271b having a pulse duration 272b. Each magnetic pulse 271b is a portion of a pulse having a pulse duration 273b. The pulse duration 272b of the second magnetic field may be a portion of the pulse duration 273b of the second magnetic field. The sequence of the second magnetic field may have a sequence duration 276b. The sequence having a sequence duration 276a is generated by magnetic field generating device A at a different time than the sequence having a sequence duration 276b is generated by magnetic field generating device B. The two sequences may be separated by an independent period 277, which may be in the range of 1 ms to 30 s. During the independent period 277, the magnetic field generating means may be inactive, meaning that the energy storage means providing the current pulse rate may not store any energy.

[0348] All instances of synchronous or independent generation of magnetic pulses can be applied in one treatment phase. In addition, pulse offsets and / or pulse distance periods can be calculated for any magnetic pulse 271b of a second or another magnetic field, which can be positioned according to any of the examples given by Figures 27B to 27E. Pulse offsets and / or pulse distance periods can be measured and calculated based on oscilloscope measurements. Synchronous generation of magnetic pulses can lead to and infer synchronous generation of magnetic pulse rates and / or sequences by two or more magnetic field generating devices. Similarly, independent generation of magnetic pulses can lead to and infer synchronous generation of magnetic pulse rates and / or sequences by two or more magnetic field generating devices.

[0349] The adjustment or control provided by the host unit and / or one or more control units can be used to form or shape the magnetic envelope or RF envelope. For example, the magnetic pulse or RF pulse can be modulated for the amplitude of each pulse or multiple pulses to allow the assembly of various envelopes. Similarly, the amplitude of the RF energy can be modulated for the amplitude to assemble various envelopes. The host unit and / or one or more control units can be configured to provide the assembly of one or more envelopes described herein. The differentially shaped magnetic envelope and / or RF envelope (also referred to herein as envelope) can be differentially perceived by the patient. The envelope of the present application (or all envelopes shown in the drawings) can be fitted to a curve by the amplitude of the magnetic flux density of the pulse, pulse rate or sequence and / or amplitude of the power output of the RF pulses of the RF wave.

[0350] The envelope may be a magnetic envelope formed by magnetic pulses. The magnetic envelope formed by the pulses may include a plurality of pulses, for example at least two, three, four or more consecutive magnetic pulses. The consecutive magnetic pulses of such a magnetic envelope may follow each other. In the case of such an envelope, the envelope duration starts with the first pulse and ends with the last pulse of the plurality of pulses. The envelope may include a sequence of magnetic pulses. The envelope may be a fitted curve of the amplitude of the magnetic flux density through the pulses. Thus, the envelope formed by the magnetic pulses may define a sequence shape according to the modulation of the magnetic flux density, repetition rate and / or pulse duration of the magnetic pulses. Thus, the envelope may be an RF envelope formed by RF pulses and their envelope modulation, repetition rate or pulse duration of the RF pulses of the RF wave.

[0351] The envelope may be a magnetic envelope formed by magnetic pulses. The magnetic envelope formed by the pulses may include a plurality of pulses (e.g., at least two, three, four or more consecutive magnetic pulses), wherein the pulses follow each other without any missing pulses. In such a case, the envelope duration may start with a pulse of a first pulse and end with a passive duration of a last pulse of the plurality of pulses. Thus, the envelope formed by the magnetic pulses may define a sequence shape according to the modulation of the magnetic flux density, repetition rate and / or pulse duration. The envelope may include a sequence of magnetic pulses. The sequence includes magnetic pulses in a pattern that is repeated at least twice during the protocol. The magnetic envelope may be a fitted curve through the amplitude of the magnetic flux density of the pulses.

[0352] The envelope may be a magnetic envelope formed from a magnetic sequence. The magnetic envelope formed from a sequence may include a plurality of sequences (e.g., at least two, three, four or more consecutive magnetic sequences), wherein the sequences follow each other with a duration between the sequences. In such cases, the envelope duration may begin with a pulse of a first pulse rate of a first sequence and end with a passive duration of a plurality of pulse rates. Multiple sequences in one envelope may be separated by missing pulse rates including pulses. The number of missing pulse rates may be in the range of 1 to 20 or 1 to 10.

[0353] The envelope may be modulated for various offset values ​​of the magnetic flux density. The offset value may be in the range of 0.01 T to 1 T, or 0.1 T to 1 T, or 0.2 T to 0.9 T. The offset value may correspond to a non-zero value of the magnetic flux density.

[0354] During one treatment session, the treatment device may apply various numbers of envelopes. Two or more envelopes of magnetic fields may be combined to form possible resulting shapes.

[0355] In the examples described above, the envelope may begin with a first pulse. Further, the envelope continues to exist for a duration of a first corresponding pulse rate including the first pulse. Additionally, the envelope may end with a passive duration of a last pulse rate, wherein the last pulse rate may follow the first pulse rate. This option is illustrated in the following figure showing an exemplary shape of an envelope of a magnetic pulse rate. As shown in the following figure, the envelope shape may be provided by modulation of the magnetic flux density. The shape of the RF envelope may be provided by modulation of the power of the RF wave or the amplitude of the pulse.

[0356] Fig.28 281 is an exemplary illustration of an increasing envelope 281 formed by magnetic pulses 282, wherein one magnetic pulse 282 is followed by a passive period of a magnetic pulse rate. The amplitude of the magnetic flux density of successive pulses in the increasing envelope is increasing. The amplitude of the magnetic flux density of one pulse is higher than the amplitude of the magnetic flux density of the previous pulse. Similarly, the amplitude of the magnetic flux density of the second pulse is higher than the amplitude of the magnetic flux density of the first pulse. The increasing amplitude can be used for muscle preparation. The envelope duration 283 of the increasing envelope 281 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave can be modulated for amplitude to assemble the increasing envelope 281.

[0357] Fig.29 291 is an exemplary illustration of a reduction envelope 291 formed by magnetic pulses 292. The magnitude of the magnetic flux density of successive pulses in the reduction envelope is reduced. The magnitude of the magnetic flux density of one pulse is lower than the magnitude of the magnetic flux density of the previous pulse. Similarly, the magnitude of the magnetic flux density of the second pulse is lower than the magnitude of the magnetic flux density of the first pulse. The envelope duration 293 of the reduction envelope 291 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave can be modulated for amplitude to assemble the reduction envelope 291.

[0358] Fig.30 303 is an exemplary illustration of a rectangular envelope 302 formed by magnetic pulses 303. The amplitude of the magnetic flux density of the pulses in the rectangular envelope may be constant. However, the amplitude of the magnetic flux density of successive pulses may oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. The amplitude of the magnetic flux density of the first pulse may be equal to the amplitude of the magnetic flux density of the second pulse, where the second pulse follows the first pulse. The envelope duration 304 of the rectangular envelope 302 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. The rectangular envelope may be used for the induction of muscle contraction or muscle twitch. Similarly, the amplitude of the RF wave may be modulated for amplitude to assemble the rectangular envelope 302.

[0359] Fig.31is an exemplary illustration of a combined envelope 311, which can be hypothetically considered as a combination of an increasing envelope and a rectangular envelope. The combined envelope 311 includes magnetic pulses 312. The amplitude of the magnetic flux density of the pulses in the combined envelope can be increasing in the range of 1% to 95%, 5% to 90%, or 10% to 80% of the duration of the entire combined envelope. The amplitude of the magnetic flux density of successive pulses in the rectangular portion of the combined envelope can oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. The envelope duration 313 of the combined envelope 311 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. As shown in FIG. Fig.31 The combined envelope shown can be used for muscle preparation and induction of muscle contraction or muscle twitch. Similarly, the amplitude of the RF wave can be modulated for amplitude to assemble the envelope 311.

[0360] Fig.32 3 is an exemplary illustration of a combined envelope 321, which can be hypothetically considered as a combination of a rectangular envelope and a reducing envelope. The combined envelope 321 includes magnetic pulses 322. The amplitude of the magnetic flux density of the pulses in the combined envelope can be reduced in the range of 1% to 95% or 5% to 90% or 10% to 80% of the duration of the entire combined envelope. The amplitude of the magnetic flux density of consecutive pulses in the rectangular portion of the combined envelope can oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. The envelope duration 323 of the combined envelope 321 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. As shown in FIG. Fig.32 The combined envelope shown can be used for the induction of muscle contraction or muscle twitch, and the subsequent termination of muscle stimulation. Similarly, the amplitude of the RF wave can be modulated for amplitude to assemble the combined envelope 321.

[0361] Fig.33 331 is an exemplary illustration of a triangular envelope 331, which can be understood as a combination of an increasing envelope immediately preceding a decreasing envelope. The triangular envelope 331 can include a magnetic pulse 332. The triangular shape of the envelope can be asymmetrical. In addition, the straightness of one or more lines of the triangular shape can be interrupted by another type of envelope described herein, such as a rectangular envelope. One triangular envelope can closely follow another triangular envelope, or can be joined to another triangular envelope. By joining two triangular envelopes, the resulting envelope can have a sawtooth shape. The envelope duration 333 of the triangular envelope 331 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave can be modulated for amplitude to assemble the triangular envelope 331.

[0362] Fig.34is an exemplary illustration of a trapezoidal envelope 341. The trapezoidal envelope 341 may include a magnetic pulse 342. The trapezoidal envelope may include an increasing (rising) time period T R , keep time period T H and decrease (fall) time period T F . During the increase time period, the amplitude of the magnetic flux density of successive pulses is increased. In addition, during the increase time period, the amplitude of the magnetic flux density of one pulse is higher than the amplitude of the magnetic flux density of the previous pulse. During the holding time period, the amplitude of the magnetic flux density of successive pulses may oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. During the decrease time period, the amplitude of the magnetic flux density of successive pulses is decreased. In addition, during the decrease time period, the amplitude of the magnetic flux density of one pulse is lower than the amplitude of the magnetic flux density of the previous pulse. The holding period may be interrupted by another holding time period having a different predetermined value of the magnetic flux density. The envelope duration 343 of the trapezoidal envelope 341 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave may be modulated for amplitude to assemble the trapezoidal envelope 341.

[0363] The trapezoidal envelope may be perceived by the patient as the most comfortable for muscle tissue stimulation. The trapezoidal envelope respects the natural course of muscle contraction, i.e., muscle contraction may be time-varying. The intensity of a natural muscle contraction increases, remains at a maximum intensity, and decreases. The trapezoidal envelope corresponds to a natural muscle contraction, i.e., the intensity of a muscle contraction may correspond to the magnetic flux density. The magnetic flux density increases, remains, and decreases during the duration of the trapezoidal envelope. The same shaped envelope may have RF electrodes formed by RF pulses of appropriate amplitude.

[0364] The trapezoidal envelope may be interrupted at least once by one or more pulses, pulse rates, bursts and / or sequences that do not fit the trapezoidal envelope shape, but the trapezoidal envelope may continue to exist after this interruption.

[0365] In addition, the trapezoidal envelope may include multiple sequences, such as two, three, four or more sequences. In the case of a trapezoidal shape, the envelope may include three sequences. The first sequence may include pulses with increasing magnetic flux density. The magnetic flux density of one pulse may be higher than the magnetic flux density of a second pulse following the first pulse. The second sequence may include pulses with constant magnetic flux density. However, the operation of the treatment device may not provide a strictly constant magnetic flux density for each pulse, so the magnetic flux density may oscillate in the range of 0.1% to 5%. The third sequence may include pulses with decreasing magnetic flux density. The magnetic flux density of one pulse may be lower than the magnetic flux density of a second pulse following the first pulse.

[0366] In addition, the trapezoidal envelope may include multiple bursts, such as two, three, four or more bursts. In the case of a trapezoidal shape, the envelope may include three bursts. The first burst may include pulses with increasing magnetic flux density. The magnetic flux density of one pulse may be higher than the magnetic flux density of a second pulse following the first pulse. The second burst may include pulses with constant magnetic flux density. However, the operation of the treatment device may not provide a strictly constant magnetic flux density for each pulse, so the magnetic flux density may oscillate in the range of 0.1% to 5%. The third burst may include pulses with decreasing magnetic flux density. The magnetic flux density of one pulse may be lower than the magnetic flux density of a second pulse following the first pulse.

[0367] Fig. 20 Another exemplary trapezoidal envelope is shown. The vertical axis may represent magnetic flux density, and the horizontal axis may represent time. The trapezoidal envelope may be a fitted curve of the magnitude of the magnetic flux density of the applied pulses during the sequence, where T R The time period with increasing magnetic flux density is called the increasing transient time, that is, the magnitude of the magnetic flux density can increase. H T is the time period with the maximum magnetic flux density, that is, the magnitude of the magnetic flux density may be constant. F is a time period with a reduced magnetic flux density, that is, the magnitude of the magnetic flux density may decrease. R 、T H and T F The sum of may be a trapezoidal envelope duration that may correspond to a muscle contraction.

[0368] The trapezoidal envelope may reduce energy consumption. The trapezoidal shape may improve cooling of the magnetic field generating device due to lower energy consumption. Additionally, resistive losses may be reduced due to lower temperatures of the magnetic field generating device. Different repetition rates may induce different types of muscle contractions. Each type of muscle contraction may consume a different amount of energy.

[0369] Fig.353 is an exemplary illustration of a trapezoidal envelope 351, which includes an increasing time period T1, a first decreasing time period T2, and a second decreasing time period T3. The trapezoidal envelope 351 includes a magnetic pulse 352. The increasing time period includes a pulse with an increasing amplitude of magnetic flux density. The first decreasing time period and the second decreasing time period include pulses with a decreasing amplitude of magnetic flux density. In the illustrated example, the first decreasing time period follows the increasing time period and precedes the second decreasing time period. The amplitude of the magnetic flux density of successive pulses is shown to decrease more sharply during the second decreasing time period. Alternatively, the amplitude of the magnetic flux density of successive pulses may decrease more sharply during the first decreasing time period. The envelope duration 353 of the trapezoidal envelope 351 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Therefore, the envelope may be a magnetic envelope formed by an RF pulse. Similarly, the amplitude of the RF wave may be modulated for amplitude to assemble the trapezoidal envelope 351.

[0370] Fig.36 361 is an exemplary illustration of a trapezoidal envelope 361, which includes a first increase period, a second increase period, and a decrease period. The trapezoidal envelope 361 includes a magnetic pulse 362. The first increase period and the second increase period include pulses with an increase in amplitude of the magnetic flux density. The first increase period and the second increase period include pulses with an increase in amplitude of the magnetic flux density. In the illustrated example, the second increase period follows the first increase period and precedes the decrease period. The amplitude of the magnetic flux density of successive pulses is shown to increase more sharply during the first increase period. Alternatively, the amplitude of the magnetic flux density of successive pulses may increase more sharply during the second increase period. The envelope duration 363 of the trapezoidal envelope 361 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave may be modulated for amplitude to assemble the trapezoidal envelope 361.

[0371] Fig.37 371 is an exemplary illustration of a step envelope 371, which includes a first increase time period T1, a first hold time period T2, a second increase time period, a second hold time period, and a decrease time period. The step envelope 371 includes magnetic pulses 372. During the first and second increase time periods, the amplitude of the magnetic flux density of the successive pulses may increase. During the decrease time period, the amplitude of the magnetic flux density of the successive pulses may decrease. During the hold time period, the amplitude of the magnetic flux density of the successive pulses may be constant, or may oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. The envelope duration 373 of the step envelope 371 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave may be modulated for amplitude to assemble the step envelope 371.

[0372] Fig.38 381 is an exemplary illustration of a step envelope 381, which includes a first increase time period T1, a first hold time period T2, a first decrease time period T3, a second hold time period T4, and a second decrease time period T5. The step envelope 381 includes magnetic pulses 382. During the increase time period, the amplitude of the magnetic flux density of successive pulses may increase. During the first and second decrease time periods, the amplitude of the magnetic flux density of successive pulses may decrease. During the hold time period, the amplitude of the magnetic flux density of successive pulses may be constant, or may oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. The envelope duration 383 of the step envelope 381 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave may be modulated for amplitude to assemble the envelope 381.

[0373] Fig.39 391 is an exemplary illustration of another type of trapezoidal envelope 391, which includes a magnetic pulse 392. The trapezoidal envelope may include an increase period T1, a hold period T2, and a decrease period T3. During the increase period, the amplitude of the magnetic flux density of successive pulses increases. In addition, during the increase period, the amplitude of the magnetic flux density of one pulse is higher than the amplitude of the magnetic flux density of the previous pulse. During the hold period, the amplitude of the magnetic flux density of successive pulses may oscillate around a predetermined value of the amplitude of the magnetic flux density in the range of 0.01% to 5%. During the decrease period, the amplitude of the magnetic flux density of successive pulses decreases. In addition, during the decrease period, the amplitude of the magnetic flux density of one pulse is lower than the amplitude of the magnetic flux density of the previous pulse. The hold period may include another hold period T4 with a different predetermined value of the magnetic flux density. The envelope duration 393 of the envelope 391 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave and / or RF pulse may be modulated for amplitude to assemble the envelope 391 .

[0374] The envelope may include a combined modulation of the magnetic flux density and the repetition rate. Fig.40 An exemplary diagram of a rectangular envelope 401 with a constant magnitude of magnetic flux density is shown. The rectangular envelope 401 may include a magnetic pulse 402. The time period T RR2 and T RR3 shows the rectangular envelope shown in T RR1 The pulse has a higher repetition rate than the rest of the magnetic pulse. RR2 and T RR3A stronger muscle contraction can be provided compared to the rest of the rectangular envelope shown. However, all the envelopes shown may include modulation in the repetition rate domain. The envelope duration 403 of the rectangular envelope 401 starts from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Therefore, the envelope can be a magnetic envelope formed by the RF pulse. Its amplitude can also form an amplitude, called an RF envelope. Similarly, the amplitude and / or repetition rate of the RF pulse can be modulated for the amplitude to assemble the envelope 401.

[0375] As mentioned, the envelope may be formed from magnetic sequences separated by one or more missing pulses. Fig.41 An envelope formed by a magnetic sequence including magnetic pulses 412 is shown. As shown, a first sequence including a sequence of pulses with increasing magnetic flux density has a duration T1. A second sequence including pulses with constant or oscillating magnetic flux density has a duration T2. ​​A third sequence including pulses with decreasing magnetic flux density has a duration T3. Envelope 411 including multiple sequences has a trapezoidal shape. The duration between durations T1 and T2 or durations T2 and T3 may represent a time gap in which a missing pulse rate including a missing pulse will be located. An envelope duration 413 of envelope 411 begins from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate. Similarly, the amplitude of the RF wave or RF pulses may be modulated for amplitude to assemble envelope 411.

[0376] During treatment, the magnetic envelope can be combined. Fig.42 An example of a combination of magnetic envelopes is shown. An increasing envelope 422 having an increasing shape comprises a sequence of magnetic pulses 421. The increasing envelope 422 may have a duration T E1 The rectangular envelope 423 includes a sequence of magnetic pulses 421. The rectangular envelope may have a duration T E2 The reduction envelope 424 includes a sequence of magnetic pulses 421. The reduction envelope 424 may have a duration T E3 The resulting sub-cycles of the treatment regimen formed by the combination of the first, second and third envelopes may provide for example Fig.34 and Fig. 20 The resulting sub-cycle of the treatment regimen has a duration 425 from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate of the treatment sub-cycle. Similarly, the amplitude of the RF wave and / or RF pulse can be modulated for amplitude to assemble a combination of envelopes.

[0377] Fig.43Another example of a combination of magnetic envelopes is shown, where the decreasing period has a different magnetic flux density than the rectangular envelope. This example may show that a combination of magnetic envelopes may include envelopes with different magnetic flux densities. An increasing envelope 432 having an increasing shape includes a sequence of magnetic pulses 431. The increasing envelope may have a duration T E1 The rectangular envelope 433 includes a sequence of magnetic pulses 431. The rectangular envelope may have a duration T E2 The reduction envelope includes a sequence of magnetic pulses 431. The reduction envelope 434 may have a duration T E3 The resulting sub-cycles of the treatment regimen formed by the combination of the first, second and third envelopes may provide for example Fig.34 and Fig. 20 The resulting sub-cycle of the treatment regimen has a duration 435 from the first pulse of the first pulse rate to the end of the passive duration of the last pulse rate of the treatment sub-cycle. Similarly, the amplitude of the RF wave and / or RF pulse can be modulated for amplitude to assemble a combination of envelopes.

[0378] Fig.44 Two exemplary envelopes of a magnetic field are shown with examples of an inter-envelope period, i.e., a time period between envelopes. The time period between envelopes may include time without magnetic stimulation. However, the time period between envelopes may include magnetic pulses that provide insufficient or unrecognizable muscle stimulation (including, for example, muscle contraction and muscle relaxation). Magnetic pulses generated during the time period between envelopes may also form an envelope. Magnetic pulses that provide insufficient or unrecognizable muscle stimulation may be generated by discharging an energy storage device to a magnetic field generating coil to discharge the static capacity. The energy storage device may then be charged to a higher amount of current and / or voltage by a power source to provide a high power current pulse to the magnetic field generating device. A rectangular envelope 442 having a duration T1 may include a magnetic pulse 441. A trapezoidal envelope 444 having a duration T2 may include a magnetic pulse 441. A magnetic pulse having a duration T EP The inter-envelope time period may include an envelope 443 (e.g., having a decreasing shape), which is given by the magnetic flux density of the magnetic pulse 441 during the inter-envelope time period. Alternatively, the inter-envelope time period may include a single pulse that provides a muscle twitch. Thus, the envelope may be the magnetic envelope formed by the RF pulse. Its amplitude may also form an amplitude, called the RF envelope. The time period between the RF envelopes may include a time without heating.

[0379] RF therapy (RF field) can be generated by a therapy energy source (e.g., RF electrode) in continuous operation, pulsed operation, or operation including multiple cycles. Continuous operation is provided during continuous RF therapy. Pulsed operation is provided during pulsed RF therapy.

[0380] During continuous operation, the RF electrodes may generate an RF field for the entire treatment or for a duration during treatment, as commanded by the host unit and one or more control units. The RF electrodes may generate an RF wave having a sinusoidal shape. In other words, the RF electrodes may generate a radio frequency waveform having a sinusoidal shape. Other shapes are also possible, such as sawtooth, triangle or square, depending on the amplitude of the RF wave.

[0381] Continuous RF treatment can have one of the following effects, namely: due to continuous heating of the patient's target biological structure, the highest synergistic effect of the magnetic treatment provided, the highest effect of polarization of the patient's target biological structure to ensure deep magnetic field penetration into the patient's tissue and high effect of the generated magnetic field on the patient's tissue, such as promoting muscle contraction.

[0382] During pulsed generation, the RF electrode may generate an RF field of two or more treatment effective time periods, wherein the time periods may be separated by passive time periods. The effective time period of pulsed RF therapy may represent a time period during which the RF electrode is effective and generates an RF field. The effective time period may be in the range of 1 s to 15 minutes, or 30 s to 10 minutes, or 5 s to 900 s, or 30 s to 300 s, or 60 s to 360 s. The passive time period of RF pulsed therapy may represent a time period during which the RF electrode is ineffective and does not generate an RF field. The passive time period of RF pulsed therapy may be in the range of 1 s to 15 minutes, or 10 s to 10 minutes, or 5 s to 600 s, or 5 s to 300 s, or 10 s to 180 s. Pulsed generation and its parameters may vary during treatment.

[0383] Through the control unit or host unit of the treatment device, the user can select, control or adjust various treatment plans of the treatment device. In addition, the host unit and / or the control unit can select, control or adjust the treatment plan, body part or another option selected by the user. In addition, based on any of the sensors mentioned above, the host unit and / or the control unit can select, control or adjust various treatment parameters of the treatment.

[0384] The treatment regimen may include a selection of one or more treatment parameters and predetermined values ​​thereof assigned to the respective regimen. Further, the treatment regimen may include various types of combined treatments of magnetic therapy and RF therapy.

[0385] With respect to treatment parameters, the user may control or adjust various treatment parameters of the treatment device through a control system including a host unit or one or more control units of the treatment device. The host unit and / or control unit may control or adjust treatment parameters based on a treatment regimen, body part, or another option selected by the user. In addition, based on feedback provided by any of the sensors described above, the host unit and / or control unit may control or adjust various treatment parameters of the treatment. The host unit or one or more control units may provide adjustment of magnetic field treatment parameters, including magnetic flux density, magnetic flux density amplitude, pulse duration, pulse rate duration, pulse repetition rate, pulse rate repetition rate, sequence duration, number of pulses and / or pulses in a sequence, burst duration, composition of magnetic bursts, composition of magnetic sequences, number of envelopes, duty cycle, shape of envelopes, and / or maximum value of magnetic flux density derivative. The host unit or one or more control units may provide adjustment of treatment parameters of the RF field, including the frequency of the RF field, the duty cycle of the RF field, the intensity of the RF field, the energy flux provided by the RF field, the power of the RF field, the power amplitude of the RF field, and / or the power amplitude of the RF wave, where the RF wave may refer to the electrical component of the RF field. The treatment parameters may be controlled or adjusted within the following ranges.

[0386] In addition, treatment parameters may include, for example, treatment time, temperature of the magnetic field generating device, temperature of the RF electrodes, temperature of the applicator, temperature of the cooling tank, selection of the targeted body part, number of connected applicators, temperature of the cooling fluid (as measured by appropriate temperature sensors in the fluid conduit, connecting tube, applicator or cooling tank), selected body part, and the like.

[0387] Different magnetic flux densities, pulse durations, sequences and / or burst compositions may have different effects on muscle tissue. A portion of the magnetic treatment may cause, for example, muscle training to increase muscle strength, muscle volume, muscle conditioning; and other portions of the magnetic treatment may cause muscle relaxation. The signal provided to the RF electrodes may be modulated relative to the capacity of the circuit formed by the two bipolar RF electrodes and the patient's body, thereby preventing the formation of RF standing waves in the applicator and / or the patient, etc. The modulation of the RF field may be provided in the frequency domain, the intensity domain, the pulse duration and / or other parameters. The goal of independent RF treatment, magnetic treatment and / or a combination thereof is to achieve the most complex and / or effective treatment of the target biological structure. Modulation in the time domain may provide effective and passive stimulation cycles. Passive cycles may occur when the RF treatment and / or magnetic treatment includes a cycle without muscle stimulation and / or temperature changes or other therapeutic effects provided by the RF field of the target biological structure. During the passive cycle, a magnetic field and / or RF field may not be generated. In addition, during the passive cycle, a magnetic field and an RF field may be generated, but the intensity of the magnetic field and / or the RF field will not be sufficient to provide a therapeutic effect of at least one target biological structure.

[0388] The magnetic flux density of the magnetic field may be in the range of 0.1 T to 7 T, or in the range of 0.5 T to 7 T, or in the range of 0.5 T to 5 T, or in the range of 0.5 T to 4 T, or in the range of 0.5 T to 2 T. Such definitions may include the magnitude of the magnetic flux density of the magnetic field. The indicated ranges of magnetic flux density may be used to induce muscle contraction. The magnetic flux density and / or the magnitude of the magnetic flux density may be measured by a flux meter or an oscilloscope.

[0389] The repetition rate may refer to the frequency at which the magnetic pulses are fired. The repetition rate may be derived from the duration of the magnetic pulse. The repetition rate of the magnetic pulse may be in the range of 0.1 Hz to 700 Hz, or 1 Hz to 700 Hz, or 1 Hz to 500 Hz, or in the range of 1 Hz to 300 Hz, or 1 Hz to 150 Hz. Since each magnetic pulse comprises one magnetic pulse, the repetition rate of the magnetic pulse is equivalent to the repetition rate of the magnetic pulse. The duration of the magnetic pulse may be in the range of 1 μs to 10 ms, or 3 μs to 3 ms, or 3 μs to 2 ms, or 3 μs to 1 ms, or 10 μs to 2000 μs, or 50 μs to 1000 μs, or 100 μs to 800 μs. The repetition rate of the pulse may be measured from a record of oscilloscope measurements.

[0390] The sequence duration may be in the range of 1 ms to 300 s, or 1 ms to 80 s, or 2 ms to 60 s, or 4 ms to 30 s, or 8 ms to 10 s, or 25 ms to 3 s. The time between two consecutive sequences may be in the range of 5 ms to 100 s, or 10 ms to 50 s, or 200 ms to 25 s, or 500 ms to 10 s, or 750 ms to 5 s, or 300 ms to 20 s. The repetition rate may be measured from a record of oscilloscope measurements.

[0391] The burst duration may be in the range of 10 ms to 100 s, or 100 ms to 15 s, or 500 ms to 7 s, or 500 ms to 5 s. The repetition rate of the magnetic burst may be in the range of 0.01 Hz to 150 Hz, or 0.02 Hz to 100 Hz, or in the range of 0.05 Hz to 50 Hz, or 0.05 Hz to 10 Hz, or 0.05 Hz to 2 Hz. The repetition rate may be measured from a record of oscilloscope measurements.

[0392] Another parameter used to provide effective magnetic therapy and induce muscle contraction is the derivative of magnetic flux density defined by dB / dt, where: dB is the magnetic flux density derivative [T] and dt is the time derivative [s]. The magnetic flux density derivative is related to the magnetic field. The magnetic flux density derivative can be defined as the amount of induced current in the tissue and can therefore be used as one of the key parameters to provide muscle contraction. The higher the magnetic flux density derivative, the stronger the muscle contraction. The magnetic flux density derivative can be calculated according to the formula mentioned above.

[0393] The maximum value of the magnetic flux density derivative may be up to 5 MT / s, or in the range of 0.3 kT / s to 800 kT / s, 0.5 kT / s to 400 kT / s, 1 kT / s to 300 kT / s, 1.5 kT / s to 250 kT / s, 2 kT / s to 200 kT / s, 2.5 kT / s to 150 kT / s.

[0394] The frequency of the RF field (e.g., RF waves) may be in the range of hundreds of kHz to tens of GHz, for example in the range of 100 kHz to 3 GHz, or 500 kHz to 3 GHz, 400 kHz to 900 MHz, or 500 kHz to 900 MHz, or approximately 13.56 MHz, 40.68 MHz, 27.12 MHz, or 2.45 GHz.

[0395] The energy flux provided by the RF field (e.g., RF wave) may be 0.001 W / cm 2 Up to 1500W / cm 2 , or 0.001W / cm 2 Up to 15W / cm 2 , or 0.01W / cm 2 Up to 1000W / cm 2 , or 0.01W / cm 2 Up to 5W / cm 2 , or 0.08W / cm 2 Up to 1W / cm 2 or 0.1W / cm 2 Up to 0.7W / cm 2 The term "about" should be interpreted as within 5% of the recited value.

[0396] The voltage of the electromagnetic signal provided by the power source of the treatment circuit for RF treatment may be in the range of 1V to 5kV, or 5V to 140V, or 10V to 120V, or 15V to 50V, or 20V to 50V.

[0397] The temperature of the biological structure, the surface temperature of the treated body part, the temperature of the body part, the temperature inside the applicator, the temperature of the RF electrodes and / or the temperature of the magnetic field generating device can be measured by, for example, Figure 8c The temperature of the RF electrode and / or magnetic field generating device may be measured by a temperature sensor 816 implemented in the applicator shown. The temperature of the RF electrode and / or magnetic field generating device may be maintained in the range of 38°C to 150°C, 38°C to 100°C, or 40°C to 80°C, 40°C to 60°C, or 41°C to 60°C, or 42°C to 60°C. The surface temperature of the treated body part, the temperature in the treated body and / or biological structure may be increased to a temperature in the range of 38°C to 60°C, or 40°C to 52°C, or 41°C to 50°C, or 41°C to 48°C, or 42°C to 48°C, or 42°C to 45°C. The temperature values ​​described above may be achieved during 5s to 600s, 10s to 300s, or 30s to 180s after the start of the RF treatment and / or magnetic treatment. Thereafter, the temperature value may be maintained constant during the treatment, with the maximum temperature deviation being in the range of 5°C, 3°C, or 2°C, or 1°C.

[0398] At the beginning of the treatment, the starting temperature in the patient's skin and / or the biological structure may be increased to a starting temperature in the range of 42°C to 60°C, or 45°C to 54°C, or 48°C to 60°C, or 48°C to 52°C, and / or to a temperature that is 3°C, or 5°C, or 8°C higher than the temperature when the apoptotic process begins, but not more than 60°C. After 45s to 360s, or 60s to 300s, or 120s to 400s, or 300s to 500s when the starting temperature is reached, the intensity of the RF field may be reduced, and the temperature of the patient's skin and / or the temperature of the biological structure may be maintained at a temperature in the range of 41°C to 50°C, or 42°C to 48°C. According to another treatment method, the temperature of the biological structure may be reduced and increased at least twice during the treatment in the range of 2°C to 10°C, 2°C to 8°C, or 3°C to 6°C, while at least one applicator is attached to the same patient body part, such as the abdominal area, buttocks, arms, legs, and / or other body parts.

[0399] The temperature of the biological structure can be calculated based on a mathematical model, a correlation function, and in combination with at least one or more measured characteristics. Such measured characteristics can include the temperature of the patient's skin, the capacitance between the RF electrodes, the volt-ampere characteristics of the RF bipolar electrodes, and / or the volt-ampere characteristics of an electrical component connected to the RF electrodes.

[0400] The duration of treatment may be 5 minutes to 120 minutes, or 5 minutes to 60 minutes, or 15 minutes to 40 minutes. In a week, the same body part may be treated once, twice or three times. In addition, a break between two consecutive treatments may be one week, two weeks or three weeks.

[0401] The sum of the energy flux densities of RF therapy and magnetic therapy applied to the patient during treatment can be 0.03 mW / mm 2 Up to 1.2W / mm2 In the range of 0.05mW / mm 2 Up to 0.9W / mm 2 In the range of 0.01mW / mm 2 Up to 0.65W / mm 2 During simultaneous application of RF therapy and active magnetic therapy, a portion of the energy flux density of the magnetic therapy may be in the range of 1% to 70%, 3% to 50%, 5% to 30%, or 1% to 20% of the treatment time.

[0402] The power output of the RF energy (ie, RF field) provided by one RF electrode may be in the range of 0.005W to 350W, or 0.1W to 200W, or 0.1W to 150W.

[0403] Fig.21 Different types of muscle contractions are shown that may be provided by the treatment device and achieved by applying a magnetic field or a combination of a magnetic field and an RF field. The muscle contractions may differ in energy expenditure and muscle targeting, such as muscle strengthening, muscle volume increase / decrease, muscle endurance, muscle relaxation, muscle warming, and / or other effects. The vertical axis may represent the intensity of the muscle contraction, and the horizontal axis may represent time. The arrows may represent the magnetic pulses and / or pulse rate applied to the patient's muscles.

[0404] A low repetition rate (e.g., in the range of 1 Hz to 15 Hz) of the time-varying magnetic field pulse rate can induce twitching. The low repetition rate can be low enough to allow the treated muscle to relax completely. The energy consumption of the treated muscle can be low due to the low repetition rate. However, the low repetition rate can induce effective muscle relaxation, for example, between two contractions.

[0405] An intermediate repetition rate of the time-varying magnetic field pulse rate may cause an incomplete tonic muscle contraction, which may be in the range of 15 Hz to 29 Hz. An incomplete tonic muscle contraction may be defined by a repetition rate in the range of 10 Hz to 30 Hz. The muscle may not fully relax. The muscle may partially relax. The strength of the muscle contraction may increase with an applied constant magnetic flux density.

[0406] A higher repetition rate of the time-varying magnetic field pulse rate can cause a complete tonic muscle contraction. A higher repetition rate can be, for example, in the range of 30 Hz to 150 Hz, or 30 Hz to 90 Hz, or 30 Hz to 60 Hz. A complete tonic muscle contraction can cause the strongest excess muscle contraction. Excess muscle contraction can be stronger than voluntary muscle contraction. Energy consumption can be higher. Strengthening effects can be improved. In addition, it is believed that with a repetition rate of at least 30 Hz, the volume and / or number of fat cells can be reduced.

[0407] Even higher repetition rates of time-varying magnetic field pulse rates above 90 Hz can inhibit and / or prevent the nervous system and / or pain receptors from transmitting at different levels of pain excitation. The higher repetition rate can be at least 100 Hz, at least 120 Hz, or at least 140 Hz, or in the range of 100 Hz to 230 Hz, or 120 Hz to 200 Hz, or 140 Hz to 180 Hz. Applying a time-varying magnetic field to a patient's muscles can cause a pain relief effect.

[0408] A high repetition rate of the time-varying magnetic field pulse rate (in the range of 120 Hz to 300 Hz, or 150 Hz to 250 Hz, or 180 Hz to 350 Hz, or above 200 Hz) can induce a muscle relaxation effect.

[0409] The quality of a muscle contraction induced by a time-varying magnetic field can be characterized by parameters such as the contraction force of the muscle contraction, the muscle-tendon length, the relative shortening of the muscle, or the shortening velocity of the muscle.

[0410] The contraction force of muscle contraction can reach at least 0.1N / cm 2 and up to 250N / cm 2 The shrinkage force can be 0.5N / cm 2 Up to 200N / cm 2 In the range of 1N / cm 2 Up to 150N / cm 2 In the range of 2N / cm 2 Up to 100N / cm 2 within the range.

[0411] The muscle-tendon length may be up to 65% of the remaining muscle-tendon length. The muscle-tendon length may be in the range of 1% to 65% of the remaining muscle-tendon length, or in the range of 3% to 55% of the remaining muscle-tendon length, or in the range of 5% to 50% of the remaining muscle-tendon length.

[0412] During muscle contraction the muscle may shorten up to 60% of the resting muscle length. The muscle shortening may be in the range of 1% to 50% of the resting muscle length, or in the range of 0.5% to 40% of the resting muscle length, or in the range of 1% to 25% of the resting muscle length.

[0413] The muscle may shorten at a rate of up to 10 cm / s. The muscle shortening rate may be in the range of 0.1 cm / s to 7.5 cm / s, or in the range of 0.2 cm / s to 5 cm / s, or in the range of 0.5 cm / s to 3 cm / s.

[0414] A time-varying magnetic field may be applied to a patient to induce a muscle sculpting effect through muscle contraction. Muscles may gain increased tone and / or volume. Muscle strength may also increase.

[0415] Regarding the type of combined treatment of RF treatment and magnetic treatment, the treatment device can be configured to provide different treatment energies (e.g., RF fields and magnetic fields) at various time periods during a treatment phase. The user can control or adjust the treatment through the HMI. The HMI can be connected to the host unit and / or one or more control units. In addition, according to the treatment plan, body part or another option selected by the user, the host unit and / or the control unit can control or adjust the application of different treatment energies. In addition, according to the feedback provided by the above and any sensors, the host unit and / or the control unit can control or adjust the application of different treatment energies. Therefore, the host unit and / or one or more control units can control or adjust the treatment and treatment energy (e.g., RF treatment and magnetic treatment) at various time periods during a treatment phase. All the shown application types of magnetic treatment and RF treatment can be provided by the treatment device.

[0416] A type of combined application of magnetic therapy and RF therapy may be simultaneous application. During simultaneous application, both magnetic therapy and RF therapy may be applied at the same time during the entire or most of the treatment phase. In one example, simultaneous application may be achieved by applying a magnetic field of one or more segments and applying a continuous RF field. In another example, pulsed magnetic therapy may be applied during continuous RF therapy. In yet another example, simultaneous application may be achieved by continuously applying RF therapy and, for example, one or more long sequences of magnetic pulses. In such cases, the long sequence of magnetic pulses should include magnetic pulses with a repetition rate having a value in the range of 1 Hz to 15 Hz or 1 Hz to 10 Hz. When only one or two long magnetic sequences are used for the entire treatment phase, the sequence duration of such sequences may be in the range of 5 s to 90 minutes, or 10 s to 80 minutes, or 15 minutes to 45 minutes.

[0417] Muscle contraction caused by a time-varying magnetic field with or during simultaneous RF treatment may include more affected muscle fibers. In addition, the targeted biological structure (e.g., muscle) may contract more at a lower magnetic flux density of the applied magnetic field than without simultaneous RF treatment.

[0418] Simultaneous application of RF therapy and magnetic therapy to the same body part can improve the dissipation of heat created by the RF therapy. This effect is based on increased blood circulation in or near the treated body part. In addition, the induced muscle work can improve the homogeneity of heating and dissipation of heat induced and provided by the RF field.

[0419] Another type of combined application of magnetic therapy and RF therapy may be a separate application. During a separate application, both magnetic therapy and RF therapy may be applied at different times during a treatment session. RF therapy may be provided before, after, and / or between the magnetic envelope, burst, sequence, pulse rate, and / or pulses of the magnetic therapy.

[0420] The ratio between the time when magnetic therapy is applied and the time when RF therapy is applied may be in the range of 0.2% to 80%, or 2% to 60%, or 5% to 50%, or 20% to 60%. The time magnetic therapy is applied for this calculation is the sum of all pulse rate durations during the treatment.

[0421] Another type of combined application of magnetic therapy and RF therapy may be dependent application. The application of one therapeutic energy may be dependent on the start of another therapeutic energy or one or more treatment parameters. Dependent application may be started or adjusted based on feedback from one or more sensors. For example, the start of applying RF therapy may be dependent on the start of magnetic therapy, or the start of a sequence, burst and / or envelope. When heat dissipation provided by muscle work (including muscle contraction and / or relaxation) is not provided, health risks of unwanted tissue damage caused by overheating may occur. In another example, the start of applying magnetic therapy may be dependent on the start, duration or intensity of RF therapy. Magnetic therapy may preferably be started after the biological structure is sufficiently heated. Magnetic therapy that provides at least partial muscle contraction or muscle contraction can improve blood or lymph flow, provide massage of adjacent tissues, and provide better redistribution of heat induced by RF therapy in the patient's body.

[0422] The treatment regimen may be divided into two or more treatment phases. The number of treatment phases of a regimen may range from 2 to 50, or from 2 to 30, or from 2 to 15.

[0423] Each treatment phase of the treatment regimen may include different treatment parameters and / or types of combined treatments of magnetic therapy and RF therapy, as described above.

[0424] One treatment phase may last for a phase time, wherein the phase time may be in the range of 10s to 30 minutes, or 15s to 25 minutes, or 20s to 20 minutes. Different phases may have different therapeutic effects in one or more treated biological structures (e.g., muscle and fat tissue). For example, one treatment phase may provide high intensity muscle training, wherein muscle contractions are intense, and a large number of such contractions are provided; wherein a higher repetition rate of a magnetic pulse rate with a high magnetic flux density may be used during one treatment phase. Another treatment phase may have a muscle relaxation effect, wherein a low and / or high repetition rate of a magnetic pulse rate may be used, and / or a lower magnetic flux density of the magnetic field may also be used.

[0425] The treatment regimen may include different settings for the power output of the RF treatment, such as commanded or controlled by the control of the treatment device. One setting may be a constant power output, wherein the power output may be the same during the treatment regimen. Another setting may be an oscillating power output for the RF treatment. The power output of the RF treatment may oscillate around a predetermined value of the power output in the range of 0.1% to 5% of the predetermined power output. Yet another setting may be a variable power output of RF energy, wherein the power output of the RF treatment changes during the treatment regimen. The change in the power output of the RF treatment may be provided in one or more power output change steps, wherein one power output change step may include a change in the value of the power output of the RF treatment applied by one or more RF electrodes. During the power output change step, the change in the power output of the RF treatment from one value to another may be in the range of 0.1W to 50W, or 0.1W to 30W, or 0.1W to 20W. The power output change step may have a duration in the range of 0.1s to 10 minutes or 0.1s to 5 minutes.

[0426] With regard to the variation of the power output of the RF energy, the power output of the RF energy may have different values ​​during different time periods of the treatment protocol. Thus, the RF treatment may have different values ​​of power output during a first time period, followed by a power output variation step, followed by a second time period having different values ​​of the power output of the RF treatment. The first time period having one value of the power output of the RF treatment may be in the range of 1 s to 15 minutes or 10 s to 10 minutes. The second time period having another value of the power output of the RF treatment may be in the range of 1 s to 45 minutes or 4 s to 59 minutes or 5 s to 35 minutes. For example, the RF treatment may have a power output value of about 20 W during the first time period and may have a power output value of about 10 W during the second time period.

[0427] A first exemplary treatment regimen may include two treatment phases. The first treatment phase may include envelopes of magnetic pulse rates, wherein the envelopes may include pulse rates having a repetition rate in the range of 1 Hz to 10 Hz. The envelope of the first treatment phase may have a rectangular or trapezoidal shape. The duration of the first treatment phase may be 3 minutes to 15 minutes. The second treatment phase may include envelopes of magnetic pulse rates, wherein the envelopes may include pulse rates having a repetition rate in the range of 15 Hz to 45 Hz. The envelope of the second treatment phase may have a rectangular or trapezoidal shape. The duration of the first treatment phase may be 3 minutes to 15 minutes. The treatment phases may be repeated one after another. RF treatment may be applied continuously during the entire treatment regimen. RF treatment may include one or two power output variation steps.

[0428] A second exemplary treatment regimen may include three treatment phases. The first treatment phase may include envelopes of magnetic pulse rates, wherein the envelopes may include pulse rates having a repetition rate in the range of 5 Hz to 50 Hz. The envelope of the first treatment phase may have a rectangular or trapezoidal shape. The duration of the first treatment phase may be 3 minutes to 15 minutes. The second treatment phase may include envelopes of magnetic pulse rates, wherein the envelopes may include pulse rates having a repetition rate in the range of 15 Hz to 45 Hz. The envelope of the second treatment phase may have a rectangular or trapezoidal shape. The duration of the first treatment phase may be 3 minutes to 15 minutes. The third treatment phase may include envelopes of magnetic pulse rates, wherein the envelopes may include pulse rates having a repetition rate in the range of 10 Hz to 40 Hz. The envelope of the third treatment phase may have a rectangular or trapezoidal shape. The duration of the third treatment phase may be 3 minutes to 15 minutes. The treatment phases may be repeated one by one. RF treatment may be applied continuously during the entire treatment regimen. RF treatment may include one or two power output variation steps. One power output variation step may be initiated within 1 minute or 20 minutes after the start of the treatment regimen. In one example, a power output change step may be initiated within three minutes of the start of the treatment regimen.

[0429] All examples, embodiments and methods may be used alone or in any combination.

[0430] New systems and methods have been described. The invention should be interpreted in the broadest sense, and therefore, of course, various modifications and variations can be made without departing from the spirit and scope of the invention. Therefore, the invention should not be limite...

Claims

1. A therapeutic device for performing cosmetic treatment on a patient, comprising: A host unit, the host unit comprising: a therapy generator, the therapy generator comprising a high frequency generator configured to generate a high frequency electrical signal; an input interface, the input interface comprising a human-machine interface configured to receive input from a user of the therapeutic device; and a control unit configured to control the high frequency generator based on the input from the user; an applicator coupled to the primary unit and configured to be coupled to a body region of the patient via an adhesive layer, the applicator comprising: a therapeutic energy source comprising a radio frequency electrode configured to receive the high frequency electrical signal and provide radio frequency therapy in the form of a radio frequency field to cause heating of the body region of the patient; and the adhesive layer being located on at least a portion of a surface of the applicator and configured to contact the body area of ​​the patient; The RF electrode includes holes that divide a conductive region of the RF electrode.

2. The device according to claim 1, wherein: The distance between two closest points located on the boundaries of two different holes is in the range of 0.1 mm to 8 mm.

3. The apparatus of claim 1 , further comprising a billing system based on deducting points from an account of the user; in, The human-machine interface includes at least one of a display, a touch screen, a button, or a slide controller, wherein the human-machine interface includes a list of treatment options for the user to select; wherein the human-machine interface is configured to allow the user of the device to set and / or select and / or adjust treatment parameters of a treatment regimen from the treatment regimen list; and The points are deducted according to the treatment regimen selected.

4. The device according to claim 1, wherein: The frequency of the radio frequency field is in the range of 400 kHz to 900 MHz.

5. The device according to claim 4, wherein: The device also includes a passive electrode located outside the applicator, wherein the radio frequency electrode is in contact with the body region, and Wherein, the radio frequency field is a monopolar radio frequency field.

6. The device according to claim 4, wherein: The control unit is configured to generate the radio frequency field in at least one pulse sequence so as to cause heating of the body region in the range of 40° C. to 52° C.; Furthermore, the at least one pulse train lasts for a duration in the range of 25 ms to 3 s.

7. The device according to claim 6, wherein: The control unit is configured to provide the radio frequency field in bursts, Each outbreak includes an active time period and a passive time period. Wherein, the active time period includes the at least one pulse sequence, and the passive time period includes passive treatment when no physiological effect is induced.

8. The device according to any one of the preceding claims 1 to 7, wherein: The energy flux of the radio frequency energy is 0.01W / cm 2 Up to 1,000W / cm 2 within the range.

9. The device according to any one of claims 1 to 7, wherein: The output power of the radio frequency energy provided by the radio frequency electrode is in the range of 0.1W to 150W.

10. The apparatus according to any one of claims 1 to 7, wherein: The applicator also includes a flexible substrate, Wherein, the flexible substrate is insulating, Wherein, the radio frequency electrode is deposited on the flexible substrate, The flexible substrate comprises a polymer, a ceramic, a copolymer sheet, a phenolic resin layer, an epoxy resin layer, a glass fiber fabric, a textile fabric or a polymer fabric, and Wherein, the thickness of the substrate is in the range of 0.1 mm to 2 mm.